Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases

Abstract

Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and / or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.

Description

ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASESCROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 575,924, filed on October 23, 2017, and U.S. Provisional Application No. 62 / 667,200, filed on May 4, 2018, each of which is incorporated herein by reference in its entirety.BACKGROUND

[0002] Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and / or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.SUMMARY

[0003] Described herein, in certain embodiments, is a method of modulating expression of a target protein, by a cell having an mRNA that comprises a non-sense mediated RNA decay- inducing ex on (NMD exon) and encodes the target protein, the method comprising contacting a therapeutic agent to the cell, whereby the therapeutic agent modulates splicing of the NMD exon from the mRNA, thereby modulating level of processed mRNA encoding the target protein, and modulating the expression of the target protein in the cell, wherein the target protein is selected from the group consisting of: AKT3, CACNA1A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3, COL4A4, COL4A4, CR1, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERN1, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NFl, NF2, NIPBL, NR1H4, NSDl, NSDl, NSDl, NSDl, OPAl, OPAl, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAPl, TOPORS, and VCAN proteins.

[0004] Described herein, in certain embodiments, is a method of treating a disease or condition in a subject in need thereof by modulating expression of a target protein in a cell of the subject, comprising: contacting the cell of the subject with a therapeutic agent that modulates splicing of a non-sense mediated mRNA decay-inducing exon (NMD exon) from an mRNA in the cell, wherein the mRNA comprises the NMD exon and encodes the target protein, thereby modulating level of processed mRNA encoding the target protein, and modulating expression of the target protein in the cell of the subject, wherein the target protein is selected from the group consistingof: AKT3, CACNA1A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3, COL4A4, COL4A4, CR1, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERN1, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NFl, NF2, NIPBL, NR1H4, NSD1, NSD1, NSD1, NSD1, OPA1, OPA1, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAPl, TOPORS, and VCAN proteins.

[0005] In some embodiments, the therapeutic agent: (a) binds to a targeted portion of the mRNA encoding the target protein; (b) modulates binding of a factor involved in splicing of the NMD exon; or (c) a combination of (a) and (b).

[0006] In some embodiments, the therapeutic agent interferes with binding of the factor involved in splicing of the NMD exon to a region of the targeted portion. In some embodiments, the targeted portion is proximal to the NMD exon. In some embodiments, the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream of 5' end of the NMD exon. In some embodiments, the targeted portion is at least about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides, about 40 nucleotides, about 30 nucleotides, about 20 nucleotides, about 10 nucleotides, about 5 nucleotides, about 4 nucleotides, about 2 nucleotides, about 1 nucleotides upstream of 5' end of the NMD exon. In some embodiments, the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream of 3' end of the NMD exon. In some embodiments, the targeted portion is at least about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides, about 40 nucleotides, about 30 nucleotides, about 20 nucleotides, about 10 nucleotides, about 5 nucleotides, about 4 nucleotides, about 2 nucleotides, about 1 nucleotides downstream of 3' end of the NMD exon.

[0007] In some embodiments, the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564388; GRCh38 / hg38: chrl9 13236618; GRCh38 / hg38: chr21 43060012; GRCh38 / hg38: chrl 207775610; GRCh38 / hg38: chrl 196675450; GRCh38 / hg38: chrl5 92998149; GRCh38 / hg38: chrl6 28479765; GRCh38 / hg38: chr6 33183698; GRCh38 / hg38: chr2 227296487;GRCh38 / hg38: chr2 227144833; GRCh38 / hg38: chr2 227015360; GRCh38 / hg38: chrl 207637688; GRCh38 / hg38: chrl9 47835403; GRCh38 / hg38: chrl 59904516; GRCh38 / hg38: chrl 26442335; GRCh38 / hg38: chrl 28230252; GRCh38 / hg38: chr2 88582824; GRCh38 / hg38: chrl7 64102804; GRCh38 / hg38: chrl 23798484; GRCh38 / hg38: chrX 109383446; GRCh38 / hg38: chrX 109439175; GRCh38 / hg38: chrl5 72362466; GRCh38 / hg38: chrl5 72345776; GRCh38 / hg38: chrl6 30115645; GRCh38 / hg38: chr2 148460219; GRCh38 / hg38: chr2 148490695; GRCh38 / hg38: chr2 148505761; GRCh38 / hg38: chr6 49436597; GRCh38 / hg38: chrl9 50230825; GRCh38 / hg38: chr6 75867431; GRCh38 / hg38: chrl7 31249955;GRCh38 / hg38: chr22 29628658; GRCh38 / hg38: chr5 37048127; GRCh38 / hg38: chrl2 100499841; GRCh38 / hg38: chr5 177169394; GRCh38 / hg38: chr5 177200761; GRCh38 / hg38: chr5 177247924; GRCh38 / hg38: chr5 177275947; GRCh38 / hg38: chr3 193628509; GRCh38 / hg38: chr3 193603500; GRCh38 / hg38: chrl3 100305751; GRCh38 / hg38: chrl2 32894778; GRCh38 / hg38: chr22 46203575; GRCh38 / hg38: chrl 150327557; GRCh38 / hg38: chrl 150330401; GRCh38 / hg38: chr2 165327155; GRCh38 / hg38: chrl2 51688758; GRCh38 / hg38: chrl2 51780202; GRCh38 / hg38: chr2 166304329; GRCh38 / hg38: chr7 80794957; GRCh38 / hg38: chr7 85059541; GRCh38 / hg38: chrl l 226081; GRCh38 / hg38: chrl9 1216268; GRCh38 / hg38: chrl9 1221621; GRCh38 / hg38: chr6 33448789; GRCh38 / hg38: chr9 32551469; and GRCh38 / hg38: chr5 83544965.

[0008] In some embodiments, the targeted portion is about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564388; GRCh38 / hg38: chrl9 13236618; GRCh38 / hg38: chr21 43060012; GRCh38 / hg38: chrl 207775610; GRCh38 / hg38: chrl 196675450; GRCh38 / hg38: chrl5 92998149; GRCh38 / hg38: chrl6 28479765; GRCh38 / hg38: chr6 33183698; GRCh38 / hg38: chr2 227296487;GRCh38 / hg38: chr2 227144833; GRCh38 / hg38: chr2 227015360; GRCh38 / hg38: chrl 207637688; GRCh38 / hg38: chrl9 47835403; GRCh38 / hg38: chrl 59904516; GRCh38 / hg38: chrl 26442335; GRCh38 / hg38: chrl 28230252; GRCh38 / hg38: chr2 88582824; GRCh38 / hg38: chrl7 64102804; GRCh38 / hg38: chrl 23798484; GRCh38 / hg38: chrX 109383446;GRCh38 / hg38: chrX 109439175; GRCh38 / hg38: chrl5 72362466; GRCh38 / hg38: chrl5 72345776; GRCh38 / hg38: chrl6 30115645; GRCh38 / hg38: chr2 148460219; GRCh38 / hg38: chr2 148490695; GRCh38 / hg38: chr2 148505761; GRCh38 / hg38: chr6 49436597; GRCh38 / hg38: chrl9 50230825; GRCh38 / hg38: chr6 75867431; GRCh38 / hg38: chrl7 31249955;GRCh38 / hg38: chr22 29628658; GRCh38 / hg38: chr5 37048127; GRCh38 / hg38: chrl2 100499841; GRCh38 / hg38: chr5 177169394; GRCh38 / hg38: chr5 177200761; GRCh38 / hg38: chr5 177247924; GRCh38 / hg38: chr5 177275947; GRCh38 / hg38: chr3 193628509; GRCh38 / hg38: chr3 193603500; GRCh38 / hg38: chrl3 100305751; GRCh38 / hg38: chrl2 32894778; GRCh38 / hg38: chr22 46203575; GRCh38 / hg38: chrl 150327557; GRCh38 / hg38: chrl 150330401; GRCh38 / hg38: chr2 165327155; GRCh38 / hg38: chrl2 51688758; GRCh38 / hg38: chrl2 51780202; GRCh38 / hg38: chr2 166304329; GRCh38 / hg38: chr7 80794957; GRCh38 / hg38: chr7 85059541; GRCh38 / hg38: chrl l 226081; GRCh38 / hg38: chrl9 1216268; GRCh38 / hg38: chrl9 1221621; GRCh38 / hg38: chr6 33448789; GRCh38 / hg38: chr9 32551469; and GRCh38 / hg38: chr5 83544965.

[0009] In some embodiments, the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564285; GRCh38 / hg38: chrl9 13236449; GRCh38 / hg38: chr21 43059730; GRCh38 / hg38: chrl 207775745; GRCh38 / hg38: chrl 196675529; GRCh38 / hg38: chrl5 92998261; GRCh38 / hg38: chrl6 28479644; GRCh38 / hg38: chr6 33183634; GRCh38 / hg38: chr2227296526; GRCh38 / hg38: chr2 227144653; GRCh38 / hg38: chr2 227015283; GRCh38 / hg38: chrl 207637848; GRCh38 / hg38: chrl9 47835579; GRCh38 / hg38: chrl 59904366; GRCh38 / hg38: chrl 26442372; GRCh38 / hg38: chrl 28230131; GRCh38 / hg38: chr2 88582755;GRCh38 / hg38: chrl7 64102673; GRCh38 / hg38: chrl 23798311; GRCh38 / hg38: chrX109383365; GRCh38 / hg38: chrX 109439038; GRCh38 / hg38: chrl5 72362376; GRCh38 / hg38: chrl5 72345677; GRCh38 / hg38: chrl6 30115595; GRCh38 / hg38: chr2 148460304; GRCh38 / hg38: chr2 148490787; GRCh38 / hg38: chr2 148505830; GRCh38 / hg38: chr6 49436522;GRCh38 / hg38: chrl9 50230999; GRCh38 / hg38: chr6 75867523; GRCh38 / hg38: chrl731250125; GRCh38 / hg38: chr22 29628773; GRCh38 / hg38: chr5 37048354; GRCh38 / hg38: chrl2 100500024; GRCh38 / hg38: chr5 177169559; GRCh38 / hg38: chr5 177200783; GRCh38 / hg38: chr5 177248079; GRCh38 / hg38: chr5 177276101; GRCh38 / hg38: chr3 193628616; GRCh38 / hg38: chr3 193603557; GRCh38 / hg38: chrl3 100305834; GRCh38 / hg38: chrl2 32894516; GRCh38 / hg38: chr22 46203752; GRCh38 / hg38: chrl 150327652; GRCh38 / hg38: chrl 150330498; GRCh38 / hg38: chr2 165327202; GRCh38 / hg38: chrl2 51688849; GRCh38 / hg38: chrl2 51780271; GRCh38 / hg38: chr2 166304238; GRCh38 / hg38: chr7 80794854;GRCh38 / hg38: chr7 85059498; GRCh38 / hg38: chrl l 225673; GRCh38 / hg38: chrl9 1216398; GRCh38 / hg38: chrl9 1221846; GRCh38 / hg38: chr6 33448868; GRCh38 / hg38: chr932551365; and GRCh38 / hg38: chr5 83545070.

[0010] In some embodiments, the targeted portion is about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564285; GRCh38 / hg38: chrl9 13236449; GRCh38 / hg38: chr21 43059730; GRCh38 / hg38: chrl 207775745; GRCh38 / hg38: chrl 196675529; GRCh38 / hg38: chrl5 92998261; GRCh38 / hg38: chrl6 28479644; GRCh38 / hg38: chr6 33183634; GRCh38 / hg38: chr2227296526; GRCh38 / hg38: chr2 227144653; GRCh38 / hg38: chr2 227015283; GRCh38 / hg38: chrl 207637848; GRCh38 / hg38: chrl9 47835579; GRCh38 / hg38: chrl 59904366; GRCh38 / hg38: chrl 26442372; GRCh38 / hg38: chrl 28230131; GRCh38 / hg38: chr2 88582755;GRCh38 / hg38: chrl7 64102673; GRCh38 / hg38: chrl 23798311; GRCh38 / hg38: chrX109383365; GRCh38 / hg38: chrX 109439038; GRCh38 / hg38: chrl5 72362376; GRCh38 / hg38: chrl5 72345677; GRCh38 / hg38: chrl6 30115595; GRCh38 / hg38: chr2 148460304; GRCh38 / hg38: chr2 148490787; GRCh38 / hg38: chr2 148505830; GRCh38 / hg38: chr6 49436522;GRCh38 / hg38: chrl9 50230999; GRCh38 / hg38: chr6 75867523; GRCh38 / hg38: chrl7 31250125; GRCh38 / hg38: chr22 29628773; GRCh38 / hg38: chr5 37048354; GRCh38 / hg38: chrl2 100500024; GRCh38 / hg38: chr5 177169559; GRCh38 / hg38: chr5 177200783; GRCh38 / hg38: chr5 177248079; GRCh38 / hg38: chr5 177276101; GRCh38 / hg38: chr3 193628616; GRCh38 / hg38: chr3 193603557; GRCh38 / hg38: chrl3 100305834; GRCh38 / hg38: chrl2 32894516; GRCh38 / hg38: chr22 46203752; GRCh38 / hg38: chrl 150327652; GRCh38 / hg38: chrl 150330498; GRCh38 / hg38: chr2 165327202; GRCh38 / hg38: chrl2 51688849; GRCh38 / hg38: chrl2 51780271; GRCh38 / hg38: chr2 166304238; GRCh38 / hg38: chr7 80794854;GRCh38 / hg38: chr7 85059498; GRCh38 / hg38: chrl l 225673; GRCh38 / hg38: chrl9 1216398;GRCh38 / hg38: chrl9 1221846; GRCh38 / hg38: chr6 33448868; GRCh38 / hg38: chr932551365; and GRCh38 / hg38: chr5 83545070.

[0011] In some embodiments, the targeted portion is located in an intronic region between two canonical exonic regions of the mRNA encoding the target protein, and wherein the intronic region contains the NMD exon. In some embodiments, the targeted portion at least partially overlaps with the NMD exon. In some embodiments, the targeted portion at least partially overlaps with an intron upstream or downstream of the NMD exon. In some embodiments, the targeted portion comprises 5' NMD exon-intron junction or 3 ' NMD exon-intron junction. In some embodiments, the targeted portion is within the NMD exon. In some embodiments, the targeted portion comprises about 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more consecutive nucleotides of the NMD exon.

[0012] In some embodiments, the mRNA encoding the target protein comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 135-191. In some embodiments, the mRNA encoding the target protein is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%), 97%), or 100% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1-5, 12, 19-21, 25, 26, 28, 30, 33, 35, 38, 40, 41, 44, 45, 51, 53, 55-57, and 192-21 1. In some embodiments, the targeted portion of the mRNA comprises a sequence with at least 80%>, 85%), 90%), 95%), 97%o, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of a sequence selected from the group consisting of SEQ ID NOs: 135-191. In some embodiments, the agent is an antisense oligomer (ASO) and wherein the ASO comprises a sequence that is at least about 80%>, 85%>, 90%>, 95%>, 97%>, or 100%> complementary to at least 8 contiguous nucleic acids of a sequence selected from the group consisting of SEQ ID NOs: 135- 191.

[0013] In some embodiments, the targeted portion of the mRNA is within the non-sense mediated RNA decay-inducing exon selected from the group consisting of: GRCh38 / hg38: chrl 243564285 243564388 ; GRCh38 / hg38: chrl9 13236449 13236618; GRCh38 / hg38: chr21 43059730 43060012; GRCh38 / hg38: chrl 207775610 207775745; GRCh38 / hg38: chrl 196675450 196675529; GRCh38 / hg38: chrl 5 92998149 92998261 ; GRCh38 / hg38: chrl6 28479644 28479765; GRCh38 / hg38: chr6 33183634 33183698; GRCh38 / hg38: chr2227296487 227296526; GRCh38 / hg38: chr2 227144653 227144833; GRCh38 / hg38: chr2 227015283 227015360; GRCh38 / hg38: chrl 207637688 207637848; GRCh38 / hg38: chrl9 47835403 47835579; GRCh38 / hg38: chrl 59904366 59904516; GRCh38 / hg38: chrl 26442335 26442372; GRCh38 / hg38: chrl 28230131 28230252 ; GRCh38 / hg38: chr2 8858275588582824; GRCh38 / hg38: chrl7 64102673 64102804; GRCh38 / hg38: chrl 2379831123798484; GRCh38 / hg38: chrX 109383365 109383446; GRCh38 / hg38: chrX 109439038 109439175; GRCh38 / hg38: chrl5 72362376 72362466; GRCh38 / hg38: chrl5 72345677 72345776; GRCh38 / hg38: chrl6 30115595 30115645; GRCh38 / hg38: chr2 148460219 148460304; GRCh38 / hg38: chr2 148490695 148490787; GRCh38 / hg38: chr2 148505761 148505830; GRCh38 / hg38: chr6 49436522 49436597; GRCh38 / hg38: chrl9 50230825 50230999; GRCh38 / hg38: chr6 75867431 75867523; GRCh38 / hg38: chrl7 3124995531250125; GRCh38 / hg38: chr22 29628658 29628773; GRCh38 / hg38: chr5 3704812737048354; GRCh38 / hg38: chrl2 100499841 100500024; GRCh38 / hg38: chr5 177169394 177169559; GRCh38 / hg38: chr5 177200761 177200783; GRCh38 / hg38: chr5 177247924 177248079; GRCh38 / hg38: chr5 177275947 177276101; GRCh38 / hg38: chr3 193628509 193628616; GRCh38 / hg38: chr3 193603500 193603557; GRCh38 / hg38: chrl3 100305751 100305834; GRCh38 / hg38: chrl2 32894516 32894778; GRCh38 / hg38: chr22 46203575 46203752; GRCh38 / hg38: chrl 150327557 150327652; GRCh38 / hg38: chrl 150330401 150330498; GRCh38 / hg38: chr2 165327155 165327202; GRCh38 / hg38: chrl2 51688758 51688849; GRCh38 / hg38: chrl2 51780202 51780271; GRCh38 / hg38: chr2 166304238 166304329; GRCh38 / hg38: chr7 80794854 80794957; GRCh38 / hg38: chr7 8505949885059541; GRCh38 / hg38: chrl l 225673 226081; GRCh38 / hg38: chrl9 1216268 1216398; GRCh38 / hg38: chrl9 1221621 1221846; GRCh38 / hg38: chr6 33448789 33448868; GRCh38 / hg38: chr9 32551365 32551469; and GRCh38 / hg38: chr5 83544965 83545070.

[0014] In some embodiments, the targeted portion of the mRNA is upstream or downstream of the non-sense mediated RNA decay-inducing exon selected from the group consisting of:GRCh38 / hg38: chrl 243564285 243564388 ; GRCh38 / hg38: chrl9 13236449 13236618;GRCh38 / hg38: chr21 43059730 43060012; GRCh38 / hg38: chrl 207775610 207775745;GRCh38 / hg38: chrl 196675450 196675529; GRCh38 / hg38: chrl5 92998149 92998261;GRCh38 / hg38: chrl6 28479644 28479765; GRCh38 / hg38: chr6 33183634 33183698;GRCh38 / hg38: chr2 227296487 227296526; GRCh38 / hg38: chr2 227144653 227144833; GRCh38 / hg38: chr2 227015283 227015360; GRCh38 / hg38: chrl 207637688 207637848; GRCh38 / hg38: chrl9 47835403 47835579; GRCh38 / hg38: chrl 59904366 59904516;GRCh38 / hg38: chrl 26442335 26442372; GRCh38 / hg38: chrl 28230131 28230252 ; GRCh38 / hg38: chr2 88582755 88582824; GRCh38 / hg38: chrl7 64102673 64102804; GRCh38 / hg38: chrl 23798311 23798484; GRCh38 / hg38: chrX 109383365 109383446; GRCh38 / hg38: chrX 109439038 109439175; GRCh38 / hg38: chrl5 72362376 72362466; GRCh38 / hg38: chrl5 72345677 72345776; GRCh38 / hg38: chrl6 30115595 30115645; GRCh38 / hg38: chr2148460219 148460304; GRCh38 / hg38: chr2 148490695 148490787; GRCh38 / hg38: chr2 148505761 148505830; GRCh38 / hg38: chr6 49436522 49436597; GRCh38 / hg38: chrl9 50230825 50230999; GRCh38 / hg38: chr6 75867431 75867523; GRCh38 / hg38: chrl7 31249955 31250125; GRCh38 / hg38: chr22 29628658 29628773; GRCh38 / hg38: chr5 37048127 37048354; GRCh38 / hg38: chrl2 100499841 100500024; GRCh38 / hg38: chr5 177169394 177169559; GRCh38 / hg38: chr5 177200761 177200783; GRCh38 / hg38: chr5 177247924 177248079; GRCh38 / hg38: chr5 177275947 177276101; GRCh38 / hg38: chr3 193628509 193628616; GRCh38 / hg38: chr3 193603500 193603557; GRCh38 / hg38: chrl3 100305751 100305834; GRCh38 / hg38: chrl2 32894516 32894778; GRCh38 / hg38: chr22 46203575 46203752; GRCh38 / hg38: chrl 150327557 150327652; GRCh38 / hg38: chrl 150330401 150330498; GRCh38 / hg38: chr2 165327155 165327202; GRCh38 / hg38: chrl2 51688758 51688849; GRCh38 / hg38: chrl2 51780202 51780271; GRCh38 / hg38: chr2 166304238 166304329; GRCh38 / hg38: chr7 80794854 80794957; GRCh38 / hg38: chr7 85059498 85059541; GRCh38 / hg38: chrl l 225673 226081; GRCh38 / hg38: chrl9 1216268 1216398; GRCh38 / hg38: chrl9 1221621 1221846; GRCh38 / hg38: chr6 33448789 33448868; GRCh38 / hg38: chr9 32551365 32551469; and GRCh38 / hg38: chr5 83544965 83545070.

[0015] In some embodiments, the targeted portion of the mRNA comprises an exon-intron junction of exon selected from the group consisting of: GRCh38 / hg38: chrl 243564285 243564388; GRCh38 / hg38: chrl9 13236449 13236618; GRCh38 / hg38: chr21 43059730 43060012; GRCh38 / hg38: chrl 207775610 207775745; GRCh38 / hg38: chrl 196675450 196675529; GRCh38 / hg38: chrl5 92998149 92998261; GRCh38 / hg38: chrl6 28479644 28479765; GRCh38 / hg38: chr6 33183634 33183698; GRCh38 / hg38: chr2 227296487 227296526; GRCh38 / hg38: chr2 227144653 227144833; GRCh38 / hg38: chr2 227015283 227015360; GRCh38 / hg38: chrl 207637688 207637848; GRCh38 / hg38: chrl9 47835403 47835579; GRCh38 / hg38: chrl 59904366 59904516; GRCh38 / hg38: chrl 2644233526442372; GRCh38 / hg38: chrl 28230131 28230252 ; GRCh38 / hg38: chr2 88582755 88582824; GRCh38 / hg38: chrl7 64102673 64102804; GRCh38 / hg38: chrl 23798311 23798484; GRCh38 / hg38: chrX 109383365 109383446; GRCh38 / hg38: chrX 109439038 109439175; GRCh38 / hg38: chrl5 72362376 72362466; GRCh38 / hg38: chrl5 72345677 72345776; GRCh38 / hg38: chrl6 30115595 30115645; GRCh38 / hg38: chr2 148460219 148460304; GRCh38 / hg38: chr2 148490695 148490787; GRCh38 / hg38: chr2 148505761 148505830; GRCh38 / hg38: chr6 49436522 49436597; GRCh38 / hg38: chrl9 50230825 50230999; GRCh38 / hg38: chr6 75867431 75867523; GRCh38 / hg38: chrl7 31249955 31250125; GRCh38 / hg38: chr22 29628658 29628773; GRCh38 / hg38: chr5 3704812737048354; GRCh38 / hg38: chrl2 100499841 100500024; GRCh38 / hg38: chr5 177169394 177169559; GRCh38 / hg38: chr5 177200761 177200783; GRCh38 / hg38: chr5 177247924 177248079; GRCh38 / hg38: chr5 177275947 177276101; GRCh38 / hg38: chr3 193628509 193628616; GRCh38 / hg38: chr3 193603500 193603557; GRCh38 / hg38: chrl3 100305751 100305834; GRCh38 / hg38: chrl2 32894516 32894778; GRCh38 / hg38: chr22 46203575 46203752; GRCh38 / hg38: chrl 150327557 150327652; GRCh38 / hg38: chrl 150330401 150330498; GRCh38 / hg38: chr2 165327155 165327202; GRCh38 / hg38: chrl2 51688758 51688849; GRCh38 / hg38: chrl2 51780202 51780271; GRCh38 / hg38: chr2 166304238 166304329; GRCh38 / hg38: chr7 80794854 80794957; GRCh38 / hg38: chr7 8505949885059541; GRCh38 / hg38: chrl l 225673 226081; GRCh38 / hg38: chrl9 1216268 1216398; GRCh38 / hg38: chrl9 1221621 1221846; GRCh38 / hg38: chr6 33448789 33448868; GRCh38 / hg38: chr9 32551365 32551469; and GRCh38 / hg38: chr5 83544965 83545070.

[0016] In some embodiments, the target protein produced is a full-length protein or a wild-type protein.

[0017] In some embodiments, the therapeutic agent promotes exclusion of the NMD exon from the processed mRNA encoding the target protein. In some embodiments, exclusion of the NMD exon from the processed mRNA encoding the target protein in the cell contacted with the therapeutic agent is increased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about8- fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about9- fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to exclusion of the NMD exon from the processed mRNA encoding the target protein in a control cell. In some embodiments, the therapeutic agent increases the level of the processed mRNA encoding the target protein in the cell. In some embodiments, the level of the processed mRNA encoding the target protein produced in the cell contacted with the therapeutic agent is increased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about8- fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about9- fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to a level of the processed mRNA encoding the target protein in a control cell. In some embodiments, the therapeutic agent increases the expression of the target protein in the cell. In some embodiments, a level of the target protein produced in the cell contacted with the therapeutic agent is increased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7- fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7- fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8- fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to a level of the target protein produced in a control cell.

[0018] In some embodiments, the disease or condition is induced by a loss-of-function mutation in the target protein.

[0019] In some embodiments, the disease or condition is associated with haploinsufficiency of a gene encoding the target protein, and wherein the subject has a first allele encoding a functional target protein, and a second allele from which the target protein is not produced or produced at a reduced level, or a second allele encoding a nonfunctional target protein or a partially functional target protein. In some embodiments, the disease or condition is selected from the group consisting of: Sotos syndrome 1; Beckwith-Wiedemann syndrome; Migraine, familial hemiplegic, 1; Episodic ataxia, type 2; Epileptic encephalopathy, childhood-onset; Wagner syndrome 1; Optic atrophy type 1; Alport syndrome; Arrhythmogenic right ventricular dysplasia 9; Neurofibromatosis type 1; Epileptic encephalopathy, early infantile, 11; Seizures, benign familial infantile, 3; Cognitive impairment with or without cerebellar ataxia; Epileptic encephalopathy, early infantile, 13; Seizures, benign familial infantile, 5; Pathway (CNS);16pl 1.2 deletion syndrome?; Mental retardation, autosomal dominant 1; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss ; Deafness, autosomal dominant 22; Neurofibromatosis type 2; Mental retardation,autosomal dominant 5; Epilepsy, generalized, with febrile seizures plus, type 7; and Febrile seizures, familial, 3B.

[0020] In some embodiments,the disease or condition is associated with an autosomal recessive mutation of a gene encoding the target protein, wherein the subject has a first allele encoding from which: (i) the target protein is not produced or produced at a reduced level compared to a wild-type allele; or (ii) the target protein produced is nonfunctional or partially functional compared to a wild-type allele, and a second allele from which: (iii) the target protein is produced at a reduced level compared to a wild-type allele and the target protein produced is at least partially functional compared to a wild-type allele; or (iv) the target protein produced is partially functional compared to a wild-type allele. In some embodiments, the disease or condition is selected from the group consisting of: Alport syndrome; Ceroid lipofuscinosis, neuronal, 3; Galactose epimerase deficiency; Homocystinuria, B6-responsive and nonresponsive types; Methyl Malonic Aciduria; Propionic acidemia; Retinitis pigmentosa 59; Tay-Sachs disease; Insensitivity to pain, congenital; and HSAN2D, autosomal recessive.

[0021] In some embodiments, the therapeutic agent promotes exclusion of the NMD exon from the processed mRNA encoding the target protein and increases the expression of the target protein in the cell. In some embodiments, the therapeutic agent inhibits exclusion of the NMD exon from the processed mRNA encoding the target protein. In some embodiments, exclusion of the NMD exon from the processed mRNA encoding the target protein in the cell contacted with the therapeutic agent is decreased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5- fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to exclusion of the NMD exon from the processed mRNA encoding the target protein in a control cell. In some embodiments, the therapeutic agent decreases the level of the processed mRNA encoding the target protein in the cell. In some embodiments, the level of the processed mRNA encoding the target protein in the cell contacted with the therapeutic agent is decreased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5- fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 toabout 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to a level of the processed mRNA encoding the target protein in a control cell.

[0022] In some embodiments, the therapeutic agent decreases the expression of the target protein in the cell. In some embodiments, a level of the target protein produced in the cell contacted with the therapeutic agent is decreased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5- fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to a level of the target protein produced in a control cell.

[0023] In some embodiments, the disease or condition is induced by a gain-of-function mutation in the target protein. In some embodiments, the subject has an allele from which the target protein is produced at an increased level, or an allele encoding a mutant target protein that exhibits increased activity in the cell.

[0024] In some embodiments, the therapeutic agent inhibits exclusion of the NMD exon from the processed mRNA encoding the target protein and decreases the expression of the target protein in the cell. In some embodiments, the target protein comprises SCN8A. In some embodiments, the disease or condition comprises a central nervous system disease. In some embodiments, the disease or condition comprises epilepsy. In some embodiments, the disease or condition comprises Dravet syndrome.

[0025] In some embodiments, the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage. In some embodiments, the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer comprises a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-0-methyl, a 2'-Fluoro, or a 2'-0- methoxyethyl moiety.

[0026] In some embodiments, the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer comprises at least one modified sugar moiety. In some embodiments, each sugar moiety is a modified sugar moiety.

[0027] In some embodiments, the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer consists of from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, or 12 to 15 nucleobases.

[0028] In some embodiments, the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%), or 100%, complementary to the targeted portion of the mRNA.

[0029] In some embodiments, the method further comprises assessing mRNA level or expression level of the target protein.

[0030] In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a fetus, an embryo, or a child. In some embodiments, the cells are ex vivo. In some embodiments, the therapeutic agent is administered by intrathecal injection, intracerebroventricular injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, intravitreal, or intravenous injection of the subject. In some embodiments, the method further comprises administering a second therapeutic agent to the subject.

[0031] In some embodiments, the second therapeutic agent is a small molecule. In some embodiments, the second therapeutic agent is an antisense oligomer. In some embodiments, the second therapeutic agent corrects intron retention.

[0032] In some embodiments, the disease or condition is selected from the group consisting of: 16pl 1.2 deletion syndrome; Alport syndrome; Arrhythmogenic right ventricular dysplasia 9; Ceroid lipofuscinosis, neuronal, 3; Cognitive impairment with or without cerebellar ataxia; Epileptic encephalopathy, early infantile, 13; Seizures, benign familial infantile, 5; Cone-rod retinal dystrophy-2; Cornelia de Lange; Deafness, autosomal dominant 13; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss ; Epilepsy,generalized, with febrile seizures plus, type 7; Febrile seizures, familial, 3B; Insensitivity to pain, congenital; HSAN2D, autosomal recessive; Epileptic encephalopathy, childhood-onset; Epileptic encephalopathy, early infantile, 11; Seizures, benign familial infantile, 3; Galactose epimerase deficiency; Homocystinuria, B6-responsive and nonresponsive types; Mental retardation, autosomal dominant 1; Mental retardation, autosomal dominant 5; Methyl Malonic Aciduria; Migraine, familial hemiplegic, 1; Episodic ataxia, type 2; NASH; Neurofibromatosis type 1; Neurofibromatosis type 2; Optic atrophy type 1; Propionic acidemia; Retinitis pigmentosa 18; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Tay-Sachs disease; and Wagner syndrome 1.INCORPORATION BY REFERENCE

[0033] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrativeembodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

[0035] FIG. 1 depicts a schematic representation of a target mRNA that contains a non-sense mediated mRNA decay-inducing exon (NMD exon mRNA) and therapeutic agent-mediated exclusion of the nonsense-mediated mRNA decay-inducing exon to increase expression of the full-length target protein or functional RNA. FIG. 1A shows a cell divided into nuclear and cytoplasmic compartments. In the nucleus, a pre-mRNA transcript of a target gene undergoes splicing to generate mRNA, and this mRNA is exported to the cytoplasm and translated into target protein. For this target gene, some fraction of the mRNA contains a nonsense-mediated mRNA decay-inducing exon (NMD exon mRNA) that is degraded in the cytoplasm, thus leading to no target protein production.

[0036] FIG. IB shows an example of the same cell divided into nuclear and cytoplasmic compartments. Treatment with a therapeutic agent, such as an antisense oligomer (ASO), promotes the exclusion of the nonsense-mediated mRNA decay-inducing exon and results in an increase in mRNA, which is in turn translated into higher levels of target protein

[0037] FIG. 2 depicts identification of an exemplary nonsense-mediated mRNA decay ( MD)- inducing exon in the CD46 gene. The identification of the MD-inducing exon in the CD46 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CD46 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 207770363 207783291, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0038] FIG. 3 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the COL11A2 gene. The identification of the NMD-inducing exon in the COL11A2 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the COL11A2 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr6 33181172 33184144, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0039] FIG. 4 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CR1 gene. The identification of the NMD-inducing exon in the CR1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CR1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 207630622 207639396, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0040] FIG. 5 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CR gene. The identification of the NMD-inducing exon in the CR gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CR gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl9 47834545 47836242, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0041] FIG. 6 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the DNAJC8 gene. The identification of the NMD-inducing exon in the DNAJC8 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the DNAJC8 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 28229025 28232920, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0042] FIG. 7 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MYH14 gene. The identification of the NMD-inducing exon in the MYH14 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MYH14 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl9 50230625 50231929, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0043] FIG. 8 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SEMA3C gene. The identification of the NMD-inducing exon in the SEMA3C gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SEMA3C gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr7 80789529 80798091, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0044] FIG. 9 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the VC AN gene. The identification of the NMD-inducing exon in the VCAN gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the VCAN gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr5 83542270 83545536, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0045] FIG. 10 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing ex on in the OPAI gene. The identification of the NMD-inducing exon in the OPAI gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the OPAI gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr3 193626204 193631611, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0046] FIG. 11 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the COL4A3 gene. The identification of the NMD-inducing exon in the COL4A3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the COL4A3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 227295318 227297673, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0047] FIG. 12 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the DHDDS gene. The identification of the NMD-inducing exon in the DHDDS gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the DHDDS gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 26438286 26442730, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0048] FIG. 13 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CFH gene. The identification of the NMD-inducing exon in the CFH gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CFH gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 196673964 196675988, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0049] FIG. 14 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing ex on in the AKT3 gene. The identification of the MD-inducing ex on in the AKT3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the AKT3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 243563849 243572925, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0050] FIG. 15 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the TOPORS gene. The identification of the NMD-inducing exon in the TOPORS gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the TOPORS gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr9 32550970 32552433, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0051] FIG. 16 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the PRPF3 gene. The identification of the NMD-inducing exon in the PRPF3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the PRPF3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 150325883 150328319, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0052] FIG. 17 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the PRPF3 gene. The identification of the NMD-inducing exon in the PRPF3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the PRPF3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 150328468 150332683, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0053] FIG. 18 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NIPBL gene. The identification of the NMD-inducing exon in the NIPBL gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NIPBL gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr5 37046201 37048501, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0054] FIG. 19 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CBS gene. The identification of the NMD-inducing exon in the CBS gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CBS gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr21 43059305 43060440, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0055] FIG. 20 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the PKP2 gene. The identification of the NMD-inducing exon in the PKP2 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the PKP2 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl2 32879034 32896508, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0056] FIG. 21 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the COL4A4 gene. The identification of the NMD-inducing exon in the COL4A4 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the COL4A4 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 227144560 227147412, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0057] FIG. 22 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the COL4A4 gene. The identification of the NMD-inducing exon in the COL4A4 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the COL4A4 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 227012299 227022047, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0058] FIG. 23 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CYP2J2 gene. The identification of the NMD-inducing exon in the CYP2J2 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CYP2J2 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 59901104 59904870, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0059] FIG. 24 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the PPARA gene. The identification of the NMD-inducing exon in the PPARA gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the PPARA gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr22 46198592 46215172, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0060] FIG. 25 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SEMA3D gene. The identification of the NMD-inducing exon in the SEMA3D gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SEMA3D gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr7 85055860 85065423, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0061] FIG. 26 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the ERN1 gene. The identification of the NMD-inducing exon in the ERN1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the ERN1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl7 64098242 64129975, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0062] FIG. 27 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the GUCY2F gene. The identification of the NMD-inducing exon in the GUCY2F gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the GUCY2F gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrX 109382213 109385183, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0063] FIG. 28 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the GUCY2F gene. The identification of the NMD-inducing exon in the GUCY2F gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the GUCY2F gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrx 109430397 109441350, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0064] FIG. 29 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SCN2A gene. The identification of the NMD-inducing exon in the SCN2A gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SCN2A gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 165326986 165331329, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0065] FIG. 30 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SCN8A gene. The identification of the NMD-inducing exon in the SCN8A gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SCN8A gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl2 51687221 51689004, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0066] FIG. 31 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SCN8A gene. The identification of the NMD-inducing exon in the SCN8A gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SCN8A gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl2 51774364 51786541, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0067] FIG. 32 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SCN9A gene. The identification of the NMD-inducing exon in the SCN9A gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SCN9A gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 166304123 166305791, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0068] FIG. 33 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CLN3 gene. The identification of the NMD-inducing exon in the CLN3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CLN3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl6 28477879 28482104, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0069] FIG. 34 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MAPK3 gene. The identification of the NMD-inducing exon in the MAPK3gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MAPK3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl6 30114710 30116635, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0070] FIG. 35 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NF1 gene. The identification of the NMD-inducing exon in the NF1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NF1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl7 31249120 31252937, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0071] FIG. 36 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MBD5 gene. The identification of the NMD-inducing exon in the MBD5 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MBD5 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 148502511 148510059, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0072] FIG. 37 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MBD5 gene. The identification of the NMD-inducing exon in the MBD5 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MBD5 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 148458873 148462581, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0073] FIG. 38 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MBD5 gene. The identification of the NMD-inducing exon in the MBD5 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MBD5 gene to scale. Peaks corresponding to RNAsequencing reads were identified in intron GRCh38 / hg38: chr2 148490596 148502435, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0074] FIG. 39 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NF2 gene. The identification of the NMD-inducing exon in the NF2 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NF2 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr22 29604114 29636750, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0075] FIG. 40 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MY06 gene. The identification of the NMD-inducing exon in the MY06 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MY06 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr6 75867107 75870646, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0076] FIG. 41 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SYNGAP1 gene. The identification of the NMD-inducing exon in the SYNGAP1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SYNGAP1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr6 33447935 33451759, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0077] FIG. 42 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the SIRT3 gene. The identification of the NMD-inducing exon in the SIRT3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the SIRT3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 1 224241 230451, shown in themiddle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0078] FIG. 43 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CACNA1A gene. The identification of the NMD-inducing exon in the CACNA1A gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CACNA1A gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl9 13235732 13241520, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0079] FIG. 44 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the CHD2 gene. The identification of the NMD-inducing exon in the CHD2 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the CHD2 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl5 92997404 92998498, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0080] FIG. 45 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NSD1 gene. The identification of the NMD-inducing exon in the NSD1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NSD1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr5 177136032 177191883, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0081] FIG. 46 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NSD1 gene. The identification of the NMD-inducing exon in the NSD1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NSD1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr5 177192021 177204119, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel,sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0082] FIG. 47 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NSD1 gene. The identification of the NMD-inducing exon in the NSD1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NSD1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr5 177246798 177248180, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0083] FIG. 48 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NSD1 gene. The identification of the NMD-inducing exon in the NSD1 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NSD1 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr5 177273786 177280564, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0084] FIG. 49 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the EIF2AK3 gene. The identification of the NMD-inducing exon in the EIF2AK3 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the EIF2AK3 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr2 88579641 88583429, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0085] FIG. 50 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the GALE gene. The identification of the NMD-inducing exon in the GALE gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the GALE gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl 23798232 23798614, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel,sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0086] FIG. 51 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the HEXA gene. The identification of the NMD-inducing exon in the HEXA gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the HEXA gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl5 72356652 72375719, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0087] FIG. 52 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the HEXA gene. The identification of the NMD-inducing exon in the HEXA gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the HEXA gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl5 72345552 72346234, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0088] FIG. 53 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the NR1H4 gene. The identification of the NMD-inducing exon in the NR1H4 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the NR1H4 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl2 100493403 100505574, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0089] FIG. 54 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the STK11 gene. The identification of the NMD-inducing exon in the STK11 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the STK11 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl9 1207204 1218416, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0090] FIG. 55 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the STK11 gene. The identification of the NMD-inducing exon in the STK11 gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the STK11 gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl9 1221341 1221948, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0091] FIG. 56 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the PCCA gene. The identification of the NMD-inducing exon in the PCCA gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the PCCA gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chrl3 100302999 100307191, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0092] FIG. 57 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the MOT gene. The identification of the NMD-inducing exon in the MOT gene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the MOT gene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr6 49435625 49440205, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0093] FIG. 58 depicts identification of an exemplary nonsense-mediated mRNA decay (NMD)- inducing exon in the OPA1 gene. The identification of the NMD-inducing exon in the OPAlgene using RNA sequencing is shown, visualized in the UCSC genome browser. The upper panel shows a graphic representation of the OPAlgene to scale. Peaks corresponding to RNA sequencing reads were identified in intron GRCh38 / hg38: chr3 193593374 193614710, shown in the middle panel. Bioinformatic analysis identified an exon-like sequence (bottom panel, sequence highlighted in uppercase) flanked by 3' and 5' splice sites. Inclusion of this exon leads to the introduction of a premature termination codon rendering the transcript a target of NMD.

[0094] FIG. 59 depicts confirmation of NMD-inducing exon via puromycin or cycloheximide treatment in various cell lines. RT-PCR analysis using total RNA from water-treated, DMSO-treated, puromycin-treated, or cycloheximide-treated cells confirmed the presence of a band corresponding to the MD-inducing exon 8x (GRCh38 / hg38: chrl 243564285 243564388) of AKT3 gene.

[0095] FIG. 60 depicts an exemplary ASO walk around AKT3 exon 8x (GRCh38 / hg38: chrl 243564285 243564388) region. A graphic representation of an ASO walk performed for around AKT3 exon 8x (GRCh38 / hg38: chrl 243564285 243564388) region targeting sequences upstream of the 3' splice site, across the 3 'splice site, exon 8x, across the 5' splice site, and downstream of the 5' splice site is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time.

[0096] FIG. 61 depicts AKT3 exon 8x (GRCh38 / hg38: chrl 243564285 243564388) region ASO walk evaluated by reverse transcription Taqman-qPCR. A graph of fold-change of the AKT3 productive mRNA product relative to Sham is plotted.

[0097] FIG. 62 depicts confirmation of NMD-inducing exon via cycloheximide treatment in various cell lines. RT-PCR analysis using total RNA from DMSO-treated or cycloheximide- treated cells confirmed the presence of a band corresponding to the NMD-inducing exon 14x (GRCh38 / hg38: chrl3 100305751 100305834) of PCCA gene

[0098] FIG. 63 depicts an exemplary ASO walk around PCCA exon 14x (GRCh38 / hg38: chrl3 100305751 100305834) region. A graphic representation of an ASO walk performed for around PCCA exon 14x (GRCh38 / hg38: chrl3 100305751 100305834) region targeting sequences upstream of the 3' splice site, across the 3 'splice site, exon 14x, across the 5' splice site, and downstream of the 5' splice site is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time.

[0099] FIG. 64 depicts PCCA exon 14x (GRCh38 / hg38: chrl3 100305751 100305834) region ASO walk evaluated by reverse transcription Taqman -qPCR and RT-PCR. A graph of fold- change of the PCCA productive mRNA product relative to Sham (grey) and percentage change in NMD exon inclusion (black) is plotted.

[0100] FIG. 65 depicts confirmation of NMD-inducing exon via puromycin or cycloheximide treatment in various cell lines, as well as the confirmation of NMD-inducing exon in brain and retina samples. RT-PCR analysis using total RNA from water-treated, DMSO-treated, puromycin-treated, or cycloheximide-treated cells confirmed the presence of a bandcorresponding to the NMD-inducing exon 7x (GRCh38 / hg38: chr3 193628509 193628616) of OP A I gene

[0101] FIG. 66 depicts an exemplary ASO walk around OPA1 exon 7x (GRCh38 / hg38: chr3 193628509 193628616) region. A graphic representation of an ASO walk performed for aroundOPA1 exon 7x (GRCh38 / hg38: chr3 193628509 193628616) region targeting sequences upstream of the 3' splice site, across the 3 'splice site, exon 7x, across the 5' splice site, and downstream of the 5' splice site is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time or 3 nucleotides across the splice site regions.

[0102] FIGs. 67 and 68 depict OPA1 exon 7x (GRCh38 / hg38: chr3 193628509 193628616) region ASO walk evaluated by Taqman RT-qPCR. Graphs of fold-change of the OPA1 productive mRNA product relative to Sham are plotted.

[0103] FIG. 69 depicts confirmation of MD-inducing exon via cycloheximide treatment in ReNCell VM and existence of NMD-inducing exon mRNA (NFl) in both human and monkey cortices. RT-PCR analysis using total RNA from DMSO-treated or cycloheximide-treated cells confirmed the presence of a band corresponding to the NMD-inducing exon 3 lx (GRCh38 / hg38: chrl7 31249955 31250125) oiNFl gene

[0104] FIG. 70 depicts an exemplary ASO walk around NFl exon 31x (GRCh38 / hg38: chrl7 31249955 31250125) region. A graphic representation of an ASO walk performed for around NFl exon 31x (GRCh38 / hg38: chrl7 31249955 31250125) region targeting sequences upstream of the 3' splice site, across the 3'splice site, exon 31x, across the 5' splice site, and downstream of the 5' splice site is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time.

[0105] FIG. 71 depicts NFl exon 31x (GRCh38 / hg38: chrl7 31249955 31250125) region ASO walk evaluated by RT-PCR (top) and RT-Taqman-qPCR (bottom). RT-PCR results indicating a decrease in exon 3 lx and a graph of fold-change of the NFl productive mRNA product relative to Sham are shown.

[0106] FIG. 72 depicts confirmation of NMD-inducing exon via puromycin or cycloheximide treatment in various cell lines. RT-PCR analysis using total RNA from water-treated, DMSO- treated, puromycin-treated, or cycloheximide-treated cells confirmed the presence of a band corresponding to the NMD-inducing exon 18x (GRCh38 / hg38: chr6 33448789 33448868) of SYNGAP1 gene

[0107] FIG. 73 depicts an exemplary ASO walk around SYNGAP1 exon 18x (GRCh38 / hg38: chr6 33448789 33448868) region. A graphic representation of an ASO walk performed for around SYNGAP1 exon 18x (GRCh38 / hg38: chr6 33448789 33448868) region targeting sequences upstream of the 3' splice site, across the 3'splice site, exon 18x, across the 5' splice site, and downstream of the 5' splice site is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time.

[0108] FIG. 74 depicts SYNGAPl exon 18x (GRCh38 / hg38: chr6 33448789 33448868) region ASO walk evaluated by RT-PCR (top) and Taqman-qPCR (bottom). Graphs of % exon 18x inclusion and fold-change of the SYNGAPl productive mRNA product relative to Sham are plotted (top and bottom, respectively).

[0109] FIG. 75 depicts confirmation of NMD-inducing exon via cycloheximide treatment. RT- PCR analysis using total RNA from DMSO-treated or cycloheximide-treated cells confirmed the presence of a band corresponding to the NMD-inducing exon 30x (GRCh38 / hg38: chrl5 92998149 92998261) oi CHD2 gene. Also shown is the RT-PCR analysis demonstrating the presence of mRNA containing NMD-inducing exon 3 Ox in cortex samples from mouse, non- human primate and human.

[0110] FIG. 76 depicts an exemplary ASO walk around CHD2 exon 30x (GRCh38 / hg38: chrl5 92998149 92998261) region. A graphic representation of an ASO walk performed for around CHD2 exon 30x (GRCh38 / hg38: chrl5 92998149 92998261) region targeting sequences upstream of the 3' splice site, across the 3 'splice site, exon 3 Ox, across the 5' splice site, and downstream of the 5' splice site is shown. ASOs were designed to cover these regions by shifting 5 nucleotides at a time.

[0111] FIG. 77 depicts CHD2 exon 30x (GRCh38 / hg38: chrl5 92998149 92998261) region ASO walk evaluated by RT-PCR. RT-PCR results are shown demonstrating the changes in amount of mRNA containing NMD-inducing exon 3 Ox.

[0112] FIG. 78 depicts changes induced by different ASOs in levels of CHD2 non-productive exon (exon 3 Ox (GRCh38 / hg38: chrl5 92998149 92998261)) and CHD2 productive mRNA.DETAILED DESCRIPTION

[0113] Alternative splicing events in ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl gene can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events m ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS,ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 gene can modulate the expression level of functional proteins in DS patients and / or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition caused by ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRJN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein deficiency.

[0114] One of the alternative splicing events that can lead to non-productive mRNA transcripts is the inclusion of an extra exon in the mRNA transcript that can induce non-sense mediated mRNA decay. The present disclosure provides compositions and methods for modulating alternative splicing of ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl to increase the production of protein-coding mature mRNA, and thus, translated functional ABCB4, ASS l, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3,R1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein. These compositions and methods include antisense oligomers (ASOs) that can cause exon skipping, e.g., pseudoexon skipping, and promote constitutive splicing of ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl pre-mRNA. In various embodiments, functional ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STKl 1, PPARA, CYP2J2, or SYNGAPl protein can be increased using the methods of the disclosure to treat a condition caused by ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein deficiency.Splicing and Nonsense-mediated mRNA Decay

[0115] Intervening sequences or introns are removed by a large and highly dynamic RNA- protein complex termed the spliceosome, which orchestrates complex interactions between primary transcripts, small nuclear RNAs (snRNAs) and a large number of proteins.Spliceosomes assemble ad hoc on each intron in an ordered manner, starting with recognition of the 5' splice site (5'ss) by Ul snRNA or the 3 'splice site (3'ss) by the U2 pathway, which involves binding of the U2 auxiliary factor (U2AF) to the 3'ss region to facilitate U2 binding tothe branch point sequence (BPS). U2AF is a stable heterodimer composed of a U2AF2-encoded 65-kD subunit (U2AF65), which binds the polypyrimidine tract (PPT), and a U2AF1 -encoded 35-kD subunit (U2AF35), which interacts with highly conserved AG dinucleotides at 3'ss and stabilizes U2AF65 binding. In addition to the BPS / PPT unit and 3'ss / 5'ss, accurate splicing requires auxiliary sequences or structures that activate or repress splice site recognition, known as intronic or exonic splicing enhancers or silencers. These elements allow genuine splice sites to be recognized among a vast excess of cryptic or pseudo-sites in the genome of higher eukaryotes, which have the same sequences but outnumber authentic sites by an order of magnitude. Although they often have a regulatory function, the exact mechanisms of their activation or repression are poorly understood.

[0116] The decision of whether to splice or not to splice can be typically modeled as a stochastic rather than deterministic process, such that even the most defined splicing signals can sometimes splice incorrectly. However, under normal conditions, pre-mRNA splicing proceeds at surprisingly high fidelity. This is attributed in part to the activity of adjacent cis-acting auxiliary exonic and intronic splicing regulatory elements (ESRs or ISRs). Typically, these functional elements are classified as either exonic or intronic splicing enhancers (ESEs or ISEs) or silencers (ESSs or ISSs) based on their ability to stimulate or inhibit splicing, respectively. Although there is now evidence that some auxiliary cis-acting elements may act by influencing the kinetics of spliceosome assembly, such as the arrangement of the complex between Ul snRNP and the 5'ss, it seems very likely that many elements function in concert with transacting RNA-binding proteins (RBPs). For example, the serine- and arginine-rich family of RBPs (SR proteins) is a conserved family of proteins that have a key role in defining exons. SR proteins promote ex on recognition by recruiting components of the pre-spliceosome to adjacent splice sites or by antagonizing the effects of ESSs in the vicinity. The repressive effects of ESSs can be mediated by members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and can alter recruitment of core splicing factors to adjacent splice sites. In addition to their roles in splicing regulation, silencer elements are suggested to have a role in repression of pseudo- exons, sets of decoy intronic splice sites with the typical spacing of an exon but without a functional open reading frame. ESEs and ESSs, in cooperation with their cognate trans-acting RBPs, represent important components in a set of splicing controls that specify how, where and when mRNAs are assembled from their precursors.

[0117] The sequences marking the exon-intron boundaries are degenerate signals of varying strengths that can occur at high frequency within human genes. In multi-exon genes, different pairs of splice sites can be linked together in many different combinations, creating a diversearray of transcripts from a single gene. This is commonly referred to as alternative pre-mRNA splicing. Although most mRNA isoforms produced by alternative splicing can be exported from the nucleus and translated into functional polypeptides, different mRNA isoforms from a single gene can vary greatly in their translation efficiency. Those mRNA isoforms with premature termination codons (PTCs) at least 50 bp upstream of an exon junction complex are likely to be targeted for degradation by the nonsense-mediated mRNA decay (NMD) pathway. Mutations in traditional (BPS / PPT / 3'ss / 5'ss) and auxiliary splicing motifs can cause aberrant splicing, such as exon skipping or cryptic (or pseudo-) exon inclusion or splice-site activation, and contribute significantly to human morbidity and mortality. Both aberrant and alternative splicing patterns can be influenced by natural DNA variants in exons and introns.

[0118] Given that exon-intron boundaries can occur at any of the three positions of a codon, it is clear that only a subset of alternative splicing events can maintain the canonical open reading frame. For example, only exons that are evenly divisible by 3 can be skipped or included in the mRNA without any alteration of reading frame. Splicing events that do not have compatible phases will induce a frame-shift. Unless reversed by downstream events, frame-shifts can certainly lead to one or more PTCs, probably resulting in subsequent degradation by NMD. NMD is a translation-coupled mechanism that eliminates mRNAs containing PTCs. NMD can function as a surveillance pathway that exists in all eukaryotes. NMD can reduce errors in gene expression by eliminating mRNA transcripts that contain premature stop codons. Translation of these aberrant mRNAs could, in some cases, lead to deleterious gain-of-function or dominant- negative activity of the resulting proteins. NMD targets not only transcripts with PTCs but also a broad array of mRNA isoforms expressed from many endogenous genes, suggesting that NMD is a master regulator that drives both fine and coarse adjustments in steady-state RNA levels in the cell.

[0119] A NMD-inducing exon (NIE) is an exon or a pseudo-ex on that is a region within an intron and can activate the NMD pathway if included in a mature RNA transcript. In constitutive splicing events, the intron containing an NIE is usually spliced out, but the intron or a portion thereof (e.g. NIE) may be retained during alternative or aberrant splicing events. Mature mRNA transcripts containing such an NIE may be non-productive due to frame shifts which induce the NMD pathway. Inclusion of a NIE in mature RNA transcripts may downregulate gene expression. mRNA transcripts containing an NIE may be referred to as "NIE containing mRNA" or "NMD exon mRNA" in the current disclosure.

[0120] Cryptic (or pseudo- splice sites) have the same splicing recognition sequences as genuine splice sites but are not used in splicing reactions. They outnumber genuine splice sites inthe human genome by an order of a magnitude and are normally repressed by thus far poorly understood molecular mechanisms. Cryptic 5' splice sites have the consensus NNN / GUNNNN or NNN / GCNNNN where N is any nucleotide and / is the exon-intron boundary. Cryptic 3' splice sites have the consensus NAG / N. Their activation is positively influenced by surrounding nucleotides that make them more similar to the optimal consensus of authentic splice sites, namely MAG / GURAGU and YAG / G, respectively, where M is C or A, R is G or A, and Y is C or U.

[0121] Splice sites and their regulatory sequences can be readily identified by a skilled person using suitable algorithms publicly available, listed for example in Kralovicova, J. andVorechovsky, I. (2007) Global control of aberrant splice site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition. Nucleic Acids Res., 35, 6399- 6413, (http: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC2095810 / pdf / gkm680.pdf)

[0122] The cryptic splice sites or splicing regulatory sequences may compete for RNA-binding proteins, such as U2AF, with a splice site of the NIE. In some embodiments, an agent may bind to a cryptic splice site or splicing regulatory sequence to prevent binding of RNA-binding proteins and thereby favor binding of RNA-binding proteins to the NIE splice sites.

[0123] In some embodiments, the cryptic splice site may not comprise the 5' or 3' splice site of the NIE. In some embodiments, the cryptic splice site may be at least 10 nucleotides, at least 20 nucleotides, at least 50 nucleotides, at least 100 nucleotides or at least 200 nucleotides upstream of the NIE 5' splice site. In some embodiments, the cryptic splice site may be at least 10 nucleotides, at least 20 nucleotides, at least 50 nucleotides, at least 100 nucleotides, at least 200 nucleotides downstream of the NIE 3' splice site.Target Transcripts

[0124] In some embodiments, the methods of the present disclosure exploit the presence of NIE in the pre-mRNA transcribed from ABCB4, ASS1, ATP8B1, BAG3, CACNA1 A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RATI, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl genes. Splicing of the identified ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE,GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAP1 E pre-mRNA species to produce functional mature ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C,SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAP1 mRNA may be induced using a therapeutic agent such as an ASO that stimulates exon skipping of an NIE. Induction of exon skipping may result in inhibition of an NMD pathway. The resulting mature ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPAM, CYP2J2, or SYNGAP1 mRNA can be translated normally without activating NMD pathway, thereby increasing the amount of ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein in the patient's cells and alleviating symptoms of a condition or disease associated with ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1,GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl deficiency, such as Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome; Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder; Cardiomyopathy, dilated, lHH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1; Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epileptic encephalopathy; Epilepsy-aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epileptic encephalopathy, childhood-onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12; Epileptic encephalopathy, early infantile, 13;Epileptic encephalopathy, early infantile, 2; Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes;Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN-related frontotemporal dementia; Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive; Insensitivity to pain, congenital; Kabuki syndrome ;Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1; Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia;Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3; Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3 microdeletion; 16pl 1.2 deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy -2; Deafness, autosomal dominant 4 A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss; Deafness, autosomal dominant 22;Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5.

[0125] In some embodiments, the diseases or conditions that can be treated or ameliorated using the method or composition disclosed herein are not directly associated with the target protein (gene) that the therapeutic agent targets. In some embodiments, a therapeutic agent providedherein can target a protein (gene) that is not directly associated with a disease or condition, but the modulation of expression of the target protein (gene) can treat or ameliorate the disease or condition. For instance, targeting genes like CD46, CFH, CR1, DNAJC8, EIF2AK3, ERN1, GUCY2F, GUCY2F, SEMA3C, SEMA3D, SIRT3, ox ART 3 by a therapeutic agent provided herein can treat or ameliorate eye diseases or conditions. In some embodiments, the targeting genes CD46, CFH, CR1, DNAJC8, EIF2AK3, ERN1, GUCY2F, GUCY2F, SEMA3C, SEMA3D, SIRT3, or AKT3 are said to be indicated for Pathway (eye). In some embodiments, targeting gene like SCN8A can treat or ameliorate central nervous system diseases, e.g., epilepsy, e.g., Dravet syndrome. In some embodiments, such target genes like SCN8A are said to be indicated for Pathway (central nervous system) or Pathway (central nervous system, epilepsy).

[0126] In various embodiments, the present disclosure provides a therapeutic agent which can target ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 mRNA transcripts to modulate splicing or protein expression level. The therapeutic agent can be a small molecule, polynucleotide, or polypeptide. In some embodiments, the therapeutic agent is an ASO. Various regions or sequences on the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA can be targeted by a therapeutic agent, such as an ASO. In some embodiments, the ASO targets a ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS,TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript containing an NIE. In some embodiments, the ASO targets a sequence within an NIE of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. In some embodiments, the ASO targets a sequence upstream (or 5') from the 5' end of an NIE (3'ss) of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. In some embodiments, the ASO targets a sequence downstream (or 3') from the 3' end of an NIE (5'ss) of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. In some embodiments, the ASO targets a sequence that is within an intron flanking on the 5' end of the NIE of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46,COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. In some embodiments, the ASO targets a sequence that is within an intron flanking the 3' end of the NIE of aABCB4, ASSI, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SIC25A13, SIC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COI11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. In some embodiments, the ASO targets a sequence comprising an NIE-intron boundary of a ABCB4, ASSI, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKI5, CFH, CHD2, CHRNA 7, CISD2, CIN3, COI4A3, COI4A4, DEPDC5, DHDDS, EIOVI4, FAH, FXN, GA E, GBE1, GRIN2A, CRN, HEXA, KANSI1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPB , NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, P CBl, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SIC25A13, SIC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COI11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. An NIE-intron boundary can refer to the junction of an intron sequence and an NIE region. The intron sequence can flank the 5' end of the NIE, or the 3' end of the NIE. In some embodiments, the ASO targets a sequence within an exon oi aABCB4, ASSI, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKI5, CFH, CHD2, CHRNA 7, CISD2, CIN3, COI4A3, COI4A4, DEPDC5, DHDDS, EIOVI4, FAH, FXN, GAIE, GBE1, GRIN2A, CRN, HEXA, KANSIl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBI, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PICBl, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SIC25A13, SIC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COI11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl pre-mRNA transcript. In some embodiments, the ASO targets a sequence within an intron of a ABCB4, ASSI, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKI5, CFH, CHD2, CHRNA 7, CISD2, CIN3, COI4A3, COI4A4, DEPDC5, DHDDS, EIOVI4, FAH, FXN, GAIE, GBE1, GRIN2A, CRN, HEXA, KANSIl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBI, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PICBl, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SIC25A13, SIC6A1,SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA transcript. In some embodiments, the ASO targets a sequence comprising both a portion of an intron and a portion of an exon of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C,SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA transcript.

[0127] In some embodiments, the ASO targets a sequence about 4 to about 300 nucleotides upstream (or 5') from the 5' end of the NIE. In some embodiments, the ASO targets a sequence about 1 to about 20 nucleotides, about 20 to about 50 nucleotides, about 50 to about 100 nucleotides, about 100 to about 150 nucleotides, about 150 to about 200 nucleotides, about 200 to about 250 nucleotides, or about 250 to about 300 nucleotides upstream (or 5') from the 5' end of the NIE region. In some embodiments, the ASO may target a sequence more than 300 nucleotides upstream from the 5' end of the NIE. In some embodiments, the ASO targets a sequence about 4 to about 300 nucleotides downstream (or 3 ') from the 3' end of the NIE. In some embodiments, the ASO targets a sequence about 1 to about 20 nucleotides, about 20 to about 50 nucleotides, about 50 to about 100 nucleotides, about 100 to about 150 nucleotides, about 150 to about 200 nucleotides, about 200 to about 250 nucleotides, or about 250 to about 300 nucleotides downstream from the 3' end of the NIE. In some embodiments, the ASO targets a sequence more than 300 nucleotides downstream from the 3' end of the NIE.

[0128] In some embodiments, the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CRl, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA transcript is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%or 100% sequence identity to any one of SEQ ID NO. 1-59 or 192-211. In some embodiments, the ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE pre-mRNA transcript comprises a sequence with at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any one of SEQ ID NOs: 60-191.

[0129] In some embodiments, the ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA transcript (or NMD exon mRNA) comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100%) sequence identity to any one of SEQ ID NOs: 60-191. In some embodiments, ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C,SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA transcript (or NMD exon mRNA) is encoded by a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs: 60-191. In some embodiments, the targeted portion of the NMD exon mRNA comprises a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100%) sequence identity to a region comprising at least 8 contiguous nucleic acids of any one of SEQ ID NOs: 60-191.

[0130] In some embodiments, the ASO targets exon 8x of a ABCB4 NIE containing pre-mRNA comprising NIE exon 8, exon 9x of a ASS1 NIE containing pre-mRNA comprising NIE exon 9,exon 16x of a ATP8B1 NIE containing pre-mRNA comprising NIE exon 16, exon lx of a BAG3 NIE containing pre-mRNA comprising NIE exon 1, exon 3 lx of a CACNA1 A NIE containing pre-mRNA comprising NIE exon 31, exon 36x of a CACNA1 A NIE containing pre-mRNA comprising NIE exon 36, exon 37x of a CACNA1 A NIE containing pre-mRNA comprising NIE exon 37, exon 3x of a CBS NIE containing pre-mRNA comprising NIE exon 3, exon 12x of a CBS NIE containing pre-mRNA comprising NIE exon 12, exon lx of a CD55 NIE containing pre-mRNA comprising NIE exon 1, exon 16x of a CDKL5 NIE containing pre-mRNA comprising NIE exon 16, exon 3x of CFH NIE containing pre-mRNA comprising NIE exon 3, exon 3 Ox of a CHD2 NIE containing pre-mRNA comprising NIE exon 30, exon 4x of CHRNA7 NIE containing pre-mRNA comprising NIE exon 4, exon lx of CISD2 NIE containing pre- mRNA comprising NIE exon 1, exon 15x of CLN3 NIE containing pre-mRNA comprising NIE exon 15, exon 1 lx of a COL4A3 NIE containing pre-mRNA comprising NIE exon 11, exon 41x of a COL4A3 NIE containing pre-mRNA comprising NIE exon 41, exon 22x of a COL4A4 NIE containing pre-mRNA comprising NIE exon 22, exon 44x of a COL4A4 NIE containing pre- mRNA comprising NIE exon 44, exon 20x of DEPDC5 NIE containing pre-mRNA comprising NIE exon 20, exon 2x of a DHDDS NIE containing pre-mRNA comprising NIE exon 2, exon 3x of a ELOVL4 NIE containing pre-mRNA comprising NIE exon 3, exon 5x of a FAH NIE containing pre-mRNA comprising NIE exon 5, exon 4x of FXN NIE containing pre-mRNA comprising NIE exon 4, exon 4x of a GALE NIE containing pre-mRNA comprising NIE exon 4, exon 3x of a GBE1 NIE containing pre-mRNA comprising NIE exon 3, exon 1 lx of GRIN2A NIE containing pre-mRNA comprising NIE exon 11, exon lx of GRN NIE containing pre- mRNA comprising NIE exon 1, exon 2x of a HEXA NIE containing pre-mRNA comprising NIE exon 2, exon 2x of a KANSLl NIE containing pre-mRNA comprising NIE exon 2, exon lx of a KCNQ2 NIE containing pre-mRNA comprising NIE exon 1, exon 5 Ox of a KMT2D NIE containing pre-mRNA comprising NIE exon 50, exon 8x of MAPK3 NIE containing pre-mRNA comprising NIE exon 8, exon 13x of MBD5 NIE containing pre-mRNA comprising NIE exon 13, exon 2x of a MECP2 NIE containing pre-mRNA comprising NIE exon 2, exon 1 lx of MUT NIE containing pre-mRNA comprising NIE exon 11, exon 3 lx of NFl NIE containing pre- mRNA comprising NIE exon 31, exon 7x of a NIPBL NIE containing pre-mRNA comprising NIE exon 7, exon 38x of a NIPBL NIE containing pre-mRNA comprising NIE exon 38, exon 1 lx of a NSD1 NIE containing pre-mRNA comprising NIE exon 11, exon 6x of a OPA1 NIE containing pre-mRNA comprising NIE exon 6, exon 28x of a OPA1 NIE containing pre-mRNA comprising NIE exon 28, exon lx of OPTN NIE containing pre-mRNA comprising NIE exon 1, exon lx of PCCA NIE containing pre-mRNA comprising NIE exon 1, exon 5x of a PCCB NIEcontaining pre-mRNA comprising NIE exon 5, exon 6x of a PCCB NIE containing pre-mRNA comprising NIE exon 6, exon 4x of a PKP2 NIE containing pre-mRNA comprising NIE exon 4, exon 23x of a PLCB1 NIE containing pre-mRNA comprising NIE exon 23, exon 3x of PRPF3 NIE containing pre-mRNA comprising NIE exon 3, exon 9x of PRPF31 NIE containing pre- mRNA comprising NIE exon 9, exon lx of a RAIl NIE containing pre-mRNA comprising NIE exon 1, exon 5x of RBFOX2 NIE containing pre-mRNA comprising NIE exon 5, exon 13x of SCN2A NIE containing pre-mRNA comprising NIE exon 13, exon 6x of SCN3 A NIE containing pre-mRNA comprising NIE exon 6, exon 7x of SCN3 A NIE containing pre-mRNA comprising NIE exon 7, exon 4x of SCN8A NIE containing pre-mRNA comprising NIE exon 4, exon 6x of SCN8A NIE containing pre-mRNA comprising NIE exon 6, exon 20x of SCN8A NIE containing pre-mRNA comprising NIE exon 20, exon 6x of SCN9A NIE containing pre- mRNA comprising NIE exon 6, exon 24x of SHANK3 NIE containing pre-mRNA comprising NIE exon 24, exon 3x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 3, exon 6x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 6, exon 9x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 9, exon 1 lx of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 11, exon 13x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 13, exon lx of SLC6A1 NIE containing pre-mRNA comprising NIE exonI, exon 12x of a SPTAN1 NIE containing pre-mRNA comprising NIE exon 12, exon 1 Ox of a TEK NIE containing pre-mRNA comprising NIE exon 10, exon 15x of a TEK NIE containing pre-mRNA comprising NIE exon 15, exon lx of TOPORS NIE containing pre-mRNA comprising NIE exon 1, exon 1 lx of a TSC2 NIE containing pre-mRNA comprising NIE exonI I, exon 30x of a TSC2 NIE containing pre-mRNA comprising NIE exon 30, exon lx of UBE3 A NIE containing pre-mRNA comprising NIE exon 1, or exon 7x of a VCAN NIE containing pre-mRNA comprising NIE exon 7. In some embodiments, the ASO targets exon (GRCh38 / hg38: chrl 243564285 243564388) of AKT3; exon (GRCh38 / hg38: chrl9 13236449 13236618) of CACNA1A; exon (GRCh38 / hg38: chr21 43059730 43060012) of CBS; exon (GRCh38 / hg38: chrl 207775610 207775745) of CD46; exon (GRCh38 / hg38: chrl 196675450 196675529) of CFH; exon (GRCh38 / hg38: chrl 5 92998149 92998261) of CHD2; exon (GRCh38 / hg38: chrl6 28479644 28479765) of CLN3; exon (GRCh38 / hg38: chr6 33183634 33183698) of COL 11 A2; exon (GRCh38 / hg38: chr2 227296487 227296526) of COL4A3; exon (GRCh38 / hg38: chr2 227144653 227144833) of COL4A4; exon (GRCh38 / hg38: chr2227015283 227015360) of COL4A4; exon (GRCh38 / hg38: chrl 207637688 207637848) of CR1; exon (GRCh38 / hg38: chrl9 47835403 47835579) of CRX; exon (GRCh38 / hg38: chrl 59904366 59904516) of CYP2J2; exon (GRCh38 / hg38: chrl 26442335 26442372) of DHDDS;exon (GRCh38 / hg38: chrl 28230131 28230252 ) of DNAJC8; exon (GRCh38 / hg38: chr2 88582755 88582824) of EIF2AK3; exon (GRCh38 / hg38: chrl7 64102673 64102804) of ERNl; exon (GRCh38 / hg38: chrl 23798311 23798484) of GALE; exon (GRCh38 / hg38: chrX109383365 109383446) of GUCY2F; exon (GRCh38 / hg38: chrX 109439038 109439175) of GUCY2F; exon (GRCh38 / hg38: chrl5 72362376 72362466) of HEXA; exon (GRCh38 / hg38: chrl5 72345677 72345776) of HEXA; exon (GRCh38 / hg38: chrl6 30115595 30115645) of MAPK3; exon (GRCh38 / hg38: chr2 148460219 148460304) of MBD5; exon (GRCh38 / hg38: chr2 148490695 148490787) of MBD5; exon (GRCh38 / hg38: chr2 148505761 148505830) of MBD5; exon (GRCh38 / hg38: chr6 49436522 49436597) of MUT; exon (GRCh38 / hg38: chrl9 50230825 50230999) of MYH14; exon (GRCh38 / hg38: chr6 75867431 75867523) of MY06; exon (GRCh38 / hg38: chrl7 31249955 31250125) ofNFl; exon (GRCh38 / hg38: chr2229628658 29628773) of NF2; exon (GRCh38 / hg38: chr5 37048127 37048354) ofNIPBL; exon (GRCh38 / hg38: chrl2 100499841 100500024) of NR1H4; exon (GRCh38 / hg38: chr5177169394 177169559) ofNSDl; exon (GRCh38 / hg38: chr5 177200761 177200783) ofNSDl; exon (GRCh38 / hg38: chr5 177247924 177248079) ofNSDl; exon (GRCh38 / hg38: chr5 177275947 177276101) ofNSDl; exon (GRCh38 / hg38: chr3 193628509 193628616) of OPAl; exon (GRCh38 / hg38: chr3 193603500 193603557) of OPAl; exon (GRCh38 / hg38: chrl3 100305751 100305834) of PCCA; exon (GRCh38 / hg38: chrl2 32894516 32894778) of PKP2; exon (GRCh38 / hg38: chr22 46203575 46203752) of PPARA; exon (GRCh38 / hg38: chrl 150327557 150327652) of PRPF3; exon (GRCh38 / hg38: chrl 150330401 150330498) of PRPF3; exon (GRCh38 / hg38: chr2 165327155 165327202) of SCN2A; exon (GRCh38 / hg38: chrl2 51688758 51688849) of SCN8A; exon (GRCh38 / hg38: chrl2 51780202 51780271) of SCN8A; exon (GRCh38 / hg38: chr2 166304238 166304329) of SCN9A; exon (GRCh38 / hg38: chr7 80794854 80794957) of SEMA3C; exon (GRCh38 / hg38: chr7 85059498 85059541) of SEMA3D; exon (GRCh38 / hg38: chrl l 225673 226081) of SIRT3; exon (GRCh38 / hg38: chrl9 1216268 1216398) of STK11; exon (GRCh38 / hg38: chrl9 1221621 1221846) of STK11; exon (GRCh38 / hg38: chr6 33448789 33448868) of SYNGAPl; exon (GRCh38 / hg38: chr932551365 32551469) of TOPORS; exon (GRCh38 / hg38: chr5 83544965 83545070) of VCAN.

[0131] In some embodiments, the ASO targets a sequence about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream (or 5') from the 5' end of exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1 A, exon 36x of CACNA1 A, exon 37x ofCACNAIA, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon l lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of NF1, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSD1, exon 6x of OPA1, exon 28x of OPA1, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCB1, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x of SLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon 1 lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN. In some embodiments, the ASO targets a sequence about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream (or 5') from GRCh38 / hg38: chrl 243564388 of AKT3; GRCh38 / hg38: chrl9 13236618 ofCACNAIA; GRCh38 / hg38: chr21 43060012 of CBS; GRCh38 / hg38: chrl 207775610 of CD46; GRCh38 / hg38: chrl 196675450 of CFH; GRCh38 / hg38: chrl5 92998149 of CHD2; GRCh38 / hg38: chrl6 28479765 of CLN3; GRCh38 / hg38: chr6 33183698 of COL11A2;GRCh38 / hg38: chr2 227296487 of COL4A3; GRCh38 / hg38: chr2 227144833 of COL4A4; GRCh38 / hg38: chr2 227015360 of COL4A4; GRCh38 / hg38: chrl 207637688 of CR1;GRCh38 / hg38: chrl9 47835403 of CRX; GRCh38 / hg38: chrl 59904516 of CYP2J2; GRCh38 / hg38: chrl 26442335 of DHDDS; GRCh38 / hg38: chrl 28230252 of DNAJC8; GRCh38 / hg38: chr2 88582824 of EIF2AK3; GRCh38 / hg38: chrl7 64102804 of ERN1; GRCh38 / hg38: chrl 23798484 of GALE; GRCh38 / hg38: chrX 109383446 of GUCY2F; GRCh38 / hg38: chrX 109439175 of GUCY2F; GRCh38 / hg38: chrl5 72362466 of HEXA; GRCh38 / hg38: chrl5 72345776 of HEXA; GRCh38 / hg38: chrl6 30115645 of MAPK3; GRCh38 / hg38: chr2148460219 of MBD5; GRCh38 / hg38: chr2 148490695 of MBD5; GRCh38 / hg38: chr2148505761 of MBD5; GRCh38 / hg38: chr6 49436597 of MUT; GRCh38 / hg38: chrl950230825 of MYH14; GRCh38 / hg38: chr6 75867431 of MY06; GRCh38 / hg38: chrl731249955 of NF1; GRCh38 / hg38: chr22 29628658 of F2; GRCh38 / hg38: chr5 37048127 of NIRBL; GRCh38 / hg38: chrl2 100499841 of R1H4; GRCh38 / hg38: chr5 177169394 of NSD1; GRCh38 / hg38: chr5 177200761 of NSD1; GRCh38 / hg38: chr5 177247924 of NSD1; GRCh38 / hg38: chr5 177275947 ofNSDl; GRCh38 / hg38: chr3 193628509 of OPAl; GRCh38 / hg38: chr3 193603500 of OPAl; GRCh38 / hg38: chrl3 100305751 of PCCA; GRCh38 / hg38: chrl2 32894778 of PKP2; GRCh38 / hg38: chr22 46203575 of PPARA; GRCh38 / hg38: chrl 150327557 of PRPF3; GRCh38 / hg38: chrl 150330401 of PRPF3; GRCh38 / hg38: chr2165327155 of SCN2A; GRCh38 / hg38: chrl2 51688758 of SCN8A; GRCh38 / hg38: chrl2 51780202 of SCN8A; GRCh38 / hg38: chr2 166304329 of SCN9A; GRCh38 / hg38: chr7 80794957 of SEMA3C; GRCh38 / hg38: chr7 85059541 of SEMA3D; GRCh38 / hg38: chrl l 226081 of SIRT3; GRCh38 / hg38: chrl9 1216268 of STK11; GRCh38 / hg38: chrl9 1221621 of STK11; GRCh38 / hg38: chr6 33448789 of SYNGAPl; GRCh38 / hg38: chr9 32551469 of TOPORS; or GRCh38 / hg38: chr5 83544965 of VCAN.

[0132] In some embodiments, the ASO targets a sequence at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream (or 5') from the 5' end of exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1A, exon 36x of CACNA1A, exon 37x of CACNA1A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRF 2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of F1, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx ofNSDl, exon 6x of OPAl, exon 28x of OPAl, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCBl, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x ofSLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x ofVCAN. In some embodiments, the ASO targets a sequence at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream (or 5') from GRCh38 / hg38: chrl 243564388 of AKT3; GRCh38 / hg38: chrl9 13236618 of CACNAIA; GRCh38 / hg38: chr21 43060012 of CBS; GRCh38 / hg38: chrl 207775610 of CD46; GRCh38 / hg38: chrl 196675450 of CFH; GRCh38 / hg38: chrl5 92998149 of CHD2; GRCh38 / hg38: chrl6 28479765 of CLN3; GRCh38 / hg38: chr6 33183698 ofCOL11A2; GRCh38 / hg38: chr2 227296487 of COL4A3; GRCh38 / hg38: chr2 227144833 of COL4A4; GRCh38 / hg38: chr2 227015360 of COL4A4; GRCh38 / hg38: chrl 207637688 of CR1; GRCh38 / hg38: chrl 9 47835403 of CRX; GRCh38 / hg38: chrl 59904516 of CYP2J2; GRCh38 / hg38: chrl 26442335 of DHDDS; GRCh38 / hg38: chrl 28230252 of DNAJC8;GRCh38 / hg38: chr2 88582824 of EIF2AK3; GRCh38 / hg38: chrl7 64102804 of ERN1;GRCh38 / hg38: chrl 23798484 of GALE; GRCh38 / hg38: chrX 109383446 of GUCY2F;GRCh38 / hg38: chrX 109439175 of GUCY2F; GRCh38 / hg38: chrl5 72362466 of HEXA; GRCh38 / hg38: chrl5 72345776 of HEXA; GRCh38 / hg38: chrl6 30115645 of MAPK3;GRCh38 / hg38: chr2 148460219 of MBD5; GRCh38 / hg38: chr2 148490695 of MBD5;GRCh38 / hg38: chr2 148505761 of MBD5; GRCh38 / hg38: chr6 49436597 of MUT; GRCh38 / hg38: chrl9 50230825 of MYH14; GRCh38 / hg38: chr6 75867431 of MY06; GRCh38 / hg38: chrl7 31249955 ofNFl; GRCh38 / hg38: chr22 29628658 of NF2; GRCh38 / hg38: chr537048127 of NIPBL; GRCh38 / hg38: chrl2 100499841 of NR1H4; GRCh38 / hg38: chr5 177169394 ofNSDl; GRCh38 / hg38: chr5 177200761 ofNSDl; GRCh38 / hg38: chr5177247924 ofNSDl; GRCh38 / hg38: chr5 177275947 ofNSDl; GRCh38 / hg38: chr3193628509 of OPA1; GRCh38 / hg38: chr3 193603500 of OPA1; GRCh38 / hg38: chrl3100305751 of PCCA; GRCh38 / hg38: chrl2 32894778 of PKP2; GRCh38 / hg38: chr2246203575 of PPARA; GRCh38 / hg38: chrl 150327557 of PRPF3; GRCh38 / hg38: chrl150330401 of PRPF3; GRCh38 / hg38: chr2 165327155 of SCN2A; GRCh38 / hg38: chrl2 51688758 of SCN8A; GRCh38 / hg38: chrl2 51780202 of SCN8A; GRCh38 / hg38: chr2166304329 of SCN9A; GRCh38 / hg38: chr7 80794957 of SEMA3C; GRCh38 / hg38: chr7 85059541 of SEMA3D; GRCh38 / hg38: chrl l 226081 of SIRT3; GRCh38 / hg38: chrl91216268 of STKl l; GRCh38 / hg38: chrl9 1221621 of STKl l; GRCh38 / hg38: chr6 33448789 of SYNGAPl; GRCh38 / hg38: chr9 32551469 of TOPORS; or GRCh38 / hg38: chr5 83544965 of VCAN.

[0133] In some embodiments, the ASO targets a sequence about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream (or 3') from the 3' end of exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1A, exon 36x of CACNA1A, exon 37x of CACNA1A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRJN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of F1, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSD1, exon 6x of OPA1, exon 28x of OPA1, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCBl, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x ofSCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHA K3, exon 3x ofSLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN. In some embodiments, the ASO targets a sequence about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream (or 3') from GRCh38 / hg38: chrl 243564285 of AKT3; GRCh38 / hg38: chrl9 13236449 of CACNA1A; GRCh38 / hg38: chr21 43059730 of CBS; GRCh38 / hg38: chrl 207775745 of CD46; GRCh38 / hg38: chrl 196675529 of CFH; GRCh38 / hg38: chrl5 92998261 of CHD2; GRCh38 / hg38: chrl6 28479644 of CLN3; GRCh38 / hg38: chr6 33183634 of COL11A2; GRCh38 / hg38: chr2 227296526 of COL4A3; GRCh38 / hg38: chr2 227144653 of COL4A4; GRCh38 / hg38: chr2 227015283 of COL4A4; GRCh38 / hg38: chrl 207637848 of CR1; GRCh38 / hg38: chrl9 47835579 of CRX; GRCh38 / hg38: chrl 59904366 of CYP2J2; GRCh38 / hg38: chrl 26442372 of DHDDS; GRCh38 / hg38: chrl 28230131 of DNAJC8;GRCh38 / hg38: chr2 88582755 of EIF2AK3; GRCh38 / hg38: chrl7 64102673 of ERNl;GRCh38 / hg38: chrl 23798311 of GALE; GRCh38 / hg38: chrX 109383365 of GUCY2F;GRCh38 / hg38: chrX 109439038 of GUCY2F; GRCh38 / hg38: chrl5 72362376 of HEXA; GRCh38 / hg38: chrl5 72345677 of HEXA; GRCh38 / hg38: chrl6 30115595 of MAPK3;GRCh38 / hg38: chr2 148460304 of MBD5; GRCh38 / hg38: chr2 148490787 of MBD5;GRCh38 / hg38: chr2 148505830 of MBD5; GRCh38 / hg38: chr6 49436522 of MUT; GRCh38 / hg38: chrl9 50230999 of MYH14; GRCh38 / hg38: chr6 75867523 of MY06; GRCh38 / hg38: chrl7 31250125 of NFl; GRCh38 / hg38: chr22 29628773 of NF2; GRCh38 / hg38: chr5 37048354 of NIPBL; GRCh38 / hg38: chrl2 100500024 of NR1H4; GRCh38 / hg38: chr5 177169559 of NSDl; GRCh38 / hg38: chr5 177200783 of NSDl; GRCh38 / hg38: chr5177248079 of NSDl; GRCh38 / hg38: chr5 177276101 of NSDl; GRCh38 / hg38: chr3193628616 of OPAl; GRCh38 / hg38: chr3 193603557 of OPAl; GRCh38 / hg38: chrl3 100305834 of PCCA; GRCh38 / hg38: chrl2 32894516 of PKP2; GRCh38 / hg38: chr22 46203752 of PPARA; GRCh38 / hg38: chrl 150327652 of PRPF3; GRCh38 / hg38: chrl 150330498 of PRPF3; GRCh38 / hg38: chr2 165327202 of SCN2A; GRCh38 / hg38: chrl2 51688849 of SCN8A; GRCh38 / hg38: chrl2 51780271 of SCN8A; GRCh38 / hg38: chr2 166304238 of SCN9A; GRCh38 / hg38: chr7 80794854 of SEMA3C; GRCh38 / hg38: chr7 85059498 of SEMA3D; GRCh38 / hg38: chrl l 225673 of SIRT3; GRCh38 / hg38: chrl9 1216398 of STK11; GRCh38 / hg38: chrl9 1221846 of STK11; GRCh38 / hg38: chr6 33448868 of SYNGAPl; GRCh38 / hg38: chr9 32551365 of TOPORS; or GRCh38 / hg38: chr5 83545070 of VCAN.

[0134] In some embodiments, the ASO targets a sequence at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream (or 3') from the 3' end of exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1 A, exon 36x of CACNA1 A, exon 37x of CACNA1 A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSLl, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of NFl, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSDl, exon 6x of OPAl, exon 28x of OPAl, exonlx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCB1, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHA K3, exon 3x ofSLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTANl, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN. In some embodiments, the ASO targets a sequence at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream (or 3') from GRCh38 / hg38: chrl 243564285 of AKT3; GRCh38 / hg38: chrl9 13236449 of CACNAIA; GRCh38 / hg38: chr21 43059730 of CBS; GRCh38 / hg38: chrl 207775745 of CD46; GRCh38 / hg38: chrl 196675529 of CFH; GRCh38 / hg38: chrl5 92998261 of CHD2; GRCh38 / hg38: chrl6 28479644 of CLN3; GRCh38 / hg38: chr6 33183634 of COL11A2; GRCh38 / hg38: chr2 227296526 of COL4A3; GRCh38 / hg38: chr2 227144653 of COL4A4; GRCh38 / hg38: chr2 227015283 of COL4A4; GRCh38 / hg38: chrl 207637848 of CR1; GRCh38 / hg38: chrl9 47835579 of CRX; GRCh38 / hg38: chrl 59904366 of CYP2J2; GRCh38 / hg38: chrl 26442372 of DHDDS; GRCh38 / hg38: chrl 28230131 of DNAJC8;GRCh38 / hg38: chr2 88582755 of EIF2AK3; GRCh38 / hg38: chrl7 64102673 of ERNl;GRCh38 / hg38: chrl 23798311 of GALE; GRCh38 / hg38: chrX 109383365 of GUCY2F;GRCh38 / hg38: chrX 109439038 of GUCY2F; GRCh38 / hg38: chrl5 72362376 of HEXA; GRCh38 / hg38: chrl5 72345677 of HEXA; GRCh38 / hg38: chrl6 30115595 of MAPK3;GRCh38 / hg38: chr2 148460304 of MBD5; GRCh38 / hg38: chr2 148490787 of MBD5;GRCh38 / hg38: chr2 148505830 of MBD5; GRCh38 / hg38: chr6 49436522 of MUT; GRCh38 / hg38: chrl9 50230999 of MYH14; GRCh38 / hg38: chr6 75867523 of MY06; GRCh38 / hg38: chrl7 31250125 ofNFl; GRCh38 / hg38: chr22 29628773 of NF2; GRCh38 / hg38: chr537048354 of NIPBL; GRCh38 / hg38: chrl2 100500024 of NR1H4; GRCh38 / hg38: chr5 177169559 ofNSDl; GRCh38 / hg38: chr5 177200783 ofNSDl; GRCh38 / hg38: chr5177248079 ofNSDl; GRCh38 / hg38: chr5 177276101 ofNSDl; GRCh38 / hg38: chr3193628616 of OPA1; GRCh38 / hg38: chr3 193603557 of OPA1; GRCh38 / hg38: chrl3100305834 of PCCA; GRCh38 / hg38: chrl2 32894516 of PKP2; GRCh38 / hg38: chr2246203752 of PPARA; GRCh38 / hg38: chrl 150327652 of PRPF3; GRCh38 / hg38: chrl150330498 of PRPF3; GRCh38 / hg38: chr2 165327202 of SCN2A; GRCh38 / hg38: chrl251688849 of SCN8A; GRCh38 / hg38: chrl2 51780271 of SCN8A; GRCh38 / hg38: chr2166304238 of SCN9A; GRCh38 / hg38: chr7 80794854 of SEMA3C; GRCh38 / hg38: chr7 85059498 of SEMA3D; GRCh38 / hg38: chrl l 225673 of SIRT3; GRCh38 / hg38: chrl91216398 of STK11; GRCh38 / hg38: chrl9 1221846 of STK11; GRCh38 / hg38: chr6 33448868 of SYNGAP1; GRCh38 / hg38: chr9 32551365 of TOPORS; or GRCh38 / hg38: chr5 83545070 of VCAN.

[0135] In some embodiments, the ASO has a sequence complementary to the targeted portion of the NMD exon mRNA according to any one of SEQ ID NOs: 60-191.

[0136] In some embodiments, the ASO targets a sequence upstream from the 5' end of an NIE. For example, ASOs targeting a sequence upstream from the 5' end of an NIE (e.g. exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1 A, exon 36x of CACNA1 A, exon 37x of CACNA1 A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon 1 lx of MUT, exon 31x of NFl, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSDl, exon 6x of OPA1, exon 28x of OPA1, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCB1, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x of SLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon 1 lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN) comprises a sequence that is at least about 80%, 85%, 90%, 95%, 97%), or 100%) complimentary to at least 8 contiguous nucleic acids of any one of SEQ ID NOs: 60-134. For example, ASOs targeting a sequence upstream from the 5' end of an NIE (e.g., exon (GRCh38 / hg38: chrl 243564285 243564388) of AKT3; exon (GRCh38 / hg38: chrl9 13236449 13236618) of CACNA1A; exon (GRCh38 / hg38: chr21 43059730 43060012) of CBS; exon (GRCh38 / hg38: chrl 207775610 207775745) of CD46; exon (GRCh38 / hg38: chrl 196675450 196675529) of CFH; exon (GRCh38 / hg38: chrl 5 92998149 92998261) of CHD2; exon(GRCh38 / hg38: chrl6 28479644 28479765) of CLN3; exon (GRCh38 / hg38: chr6 3318363433183698) of COL 11 A2; exon (GRCh38 / hg38: chr2 227296487 227296526) of COL4A3; exon (GRCh38 / hg38: chr2 227144653 227144833) of COL4A4; exon (GRCh38 / hg38: chr2227015283 227015360) of COL4A4; exon (GRCh38 / hg38: chrl 207637688 207637848) of CR1; exon (GRCh38 / hg38: chrl9 47835403 47835579) of CRX; exon (GRCh38 / hg38: chrl 59904366 59904516) of CYP2J2; exon (GRCh38 / hg38: chrl 26442335 26442372) of DHDDS; exon (GRCh38 / hg38: chrl 28230131 28230252 ) of DNAJC8; exon (GRCh38 / hg38: chr2 88582755 88582824) of EIF2AK3; exon (GRCh38 / hg38: chrl7 64102673 64102804) of ERNl; exon (GRCh38 / hg38: chrl 23798311 23798484) of GALE; exon (GRCh38 / hg38: chrX109383365 109383446) of GUCY2F; exon (GRCh38 / hg38: chrX 109439038 109439175) of GUCY2F; exon (GRCh38 / hg38: chrl5 72362376 72362466) of HEXA; exon (GRCh38 / hg38: chrl5 72345677 72345776) of HEXA; exon (GRCh38 / hg38: chrl6 30115595 30115645) of MAPK3; exon (GRCh38 / hg38: chr2 148460219 148460304) of MBD5; exon (GRCh38 / hg38: chr2 148490695 148490787) of MBD5; exon (GRCh38 / hg38: chr2 148505761 148505830) of MBD5; exon (GRCh38 / hg38: chr6 49436522 49436597) of MUT; exon (GRCh38 / hg38: chrl9 50230825 50230999) of MYH14; exon (GRCh38 / hg38: chr6 75867431 75867523) of MY06; exon (GRCh38 / hg38: chrl7 31249955 31250125) ofNFl; exon (GRCh38 / hg38: chr2229628658 29628773) of NF2; exon (GRCh38 / hg38: chr5 37048127 37048354) ofNIPBL; exon (GRCh38 / hg38: chrl2 100499841 100500024) of NR1H4; exon (GRCh38 / hg38: chr5177169394 177169559) ofNSDl; exon (GRCh38 / hg38: chr5 177200761 177200783) ofNSDl; exon (GRCh38 / hg38: chr5 177247924 177248079) ofNSDl; exon (GRCh38 / hg38: chr5 177275947 177276101) ofNSDl; exon (GRCh38 / hg38: chr3 193628509 193628616) of OPA1; exon (GRCh38 / hg38: chr3 193603500 193603557) of OPA1; exon (GRCh38 / hg38: chrl3 100305751 100305834) of PCCA; exon (GRCh38 / hg38: chrl2 32894516 32894778) of PKP2; exon (GRCh38 / hg38: chr22 46203575 46203752) of PPARA; exon (GRCh38 / hg38: chrl 150327557 150327652) of PRPF3; exon (GRCh38 / hg38: chrl 150330401 150330498) of PRPF3; exon (GRCh38 / hg38: chr2 165327155 165327202) of SCN2A; exon (GRCh38 / hg38: chrl2 51688758 51688849) of SCN8A; exon (GRCh38 / hg38: chrl2 51780202 51780271) of SCN8A; exon (GRCh38 / hg38: chr2 166304238 166304329) of SCN9A; exon (GRCh38 / hg38: chr7 80794854 80794957) of SEMA3C; exon (GRCh38 / hg38: chr7 85059498 85059541) of SEMA3D; exon (GRCh38 / hg38: chrl l 225673 226081) of SIRT3; exon (GRCh38 / hg38: chrl9 1216268 1216398) of STK11; exon (GRCh38 / hg38: chrl9 1221621 1221846) of STK11; exon (GRCh38 / hg38: chr6 33448789 33448868) of SYNGAPl; exon (GRCh38 / hg38: chr932551365 32551469) of TOPORS; exon (GRCh38 / hg38: chr5 83544965 83545070) of VCAN)can comprise a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs: 135-191.

[0137] In some embodiments, the ASOs target a sequence containing an exon-intron boundary (or junction). For example, ASOs targeting a sequence containing an exon-intron boundary can comprise a sequence that is at least about 80%, 85%, 90%, 95%, 97%, or 100% complimentary to at least 8 contiguous nucleic acids of any one of SEQ ID NOs: 60-191. In some embodiments, the ASOs target a sequence downstream from the 3' end of an E. For example, ASOs targeting a sequence downstream from the 3' end of an ME (e.g. exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1 A, exon 36x ofCACNA1A, exon 37x of CACNA1 A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of NFl, exon 7x of NIPBL, exon 38x of NIPBL, exon 1 lx of NSDl, exon 6x of OPAl, exon 28x of OPAl, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCB1, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x of SLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN) can comprise a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to any one of SEQ ID NOs: 60-134. For example, ASOs targeting a sequence downstream from the 3' end of an ME (e.g., exon (GRCh38 / hg38: chrl 243564285 243564388) of AKT3; exon (GRCh38 / hg38: chrl9 13236449 13236618) of CACNA1A; exon (GRCh38 / hg38: chr21 43059730 43060012) of CBS; exon (GRCh38 / hg38: chrl 207775610 207775745) of CD46; exon (GRCh38 / hg38: chrl 196675450 196675529) of CFH; exon (GRCh38 / hg38: chrl5 92998149 92998261) of CHD2; exon (GRCh38 / hg38: chrl6 28479644 28479765) of CLN3; exon (GRCh38 / hg38: chr6 33183634 33183698) of COL11A2; exon (GRCh38 / hg38: chr2 227296487 227296526) of COL4A3; exon (GRCh38 / hg38: chr2 227144653 227144833) of COL4A4; exon (GRCh38 / hg38: chr2 227015283 227015360) of COL4A4; exon (GRCh38 / hg38: chrl 207637688 207637848) of CR1; exon (GRCh38 / hg38: chrl9 47835403 47835579) of CRX; exon (GRCh38 / hg38: chrl 59904366 59904516) of CYP2J2; exon (GRCh38 / hg38: chrl 26442335 26442372) of DHDDS; exon (GRCh38 / hg38: chrl 28230131 28230252 ) of DNAJC8; exon (GRCh38 / hg38: chr2 88582755 88582824) of EIF2AK3; exon (GRCh38 / hg38: chrl7 64102673 64102804) of ERN1; exon (GRCh38 / hg38: chrl 23798311 23798484) of GALE; exon (GRCh38 / hg38: chrX 109383365 109383446) of GUCY2F; exon (GRCh38 / hg38: chrX 109439038 109439175) of GUCY2F; exon (GRCh38 / hg38: chrl5 72362376 72362466) of HEXA; exon (GRCh38 / hg38: chrl 5 72345677 72345776) of HEXA; exon (GRCh38 / hg38: chrl6 30115595 30115645) of MAPK3; exon (GRCh38 / hg38: chr2 148460219 148460304) of MBD5; exon (GRCh38 / hg38: chr2 148490695 148490787) of MBD5; exon (GRCh38 / hg38: chr2 148505761 148505830) of MBD5; exon (GRCh38 / hg38: chr6 49436522 49436597) of MUT; exon (GRCh38 / hg38: chrl9 50230825 50230999) of MYH14; exon (GRCh38 / hg38: chr6 75867431 75867523) of MY06; exon (GRCh38 / hg38: chrl7 31249955 31250125) of NFl; exon (GRCh38 / hg38: chr22 29628658 29628773) of NF2; exon (GRCh38 / hg38: chr537048127 37048354) of NIRBL; exon (GRCh38 / hg38: chrl2 100499841 100500024) of NR1H4; exon (GRCh38 / hg38: chr5 177169394 177169559) of NSD1; exon (GRCh38 / hg38: chr5 177200761 177200783) of NSD1; exon (GRCh38 / hg38: chr5 177247924 177248079) of NSD1; exon (GRCh38 / hg38: chr5 177275947 177276101) of NSD1; exon (GRCh38 / hg38: chr3 193628509 193628616) of OPA1; exon (GRCh38 / hg38: chr3 193603500 193603557) of OPA1; exon (GRCh38 / hg38: chrl3 100305751 100305834) of PCCA; exon (GRCh38 / hg38: chrl2 32894516 32894778) of PKP2; exon (GRCh38 / hg38: chr22 46203575 46203752) of PPARA; exon (GRCh38 / hg38: chrl 150327557 150327652) of PRPF3; exon (GRCh38 / hg38: chrl 150330401 150330498) of PRPF3; exon (GRCh38 / hg38: chr2 165327155 165327202) of SCN2A; exon (GRCh38 / hg38: chrl2 51688758 51688849) of SCN8A; exon (GRCh38 / hg38: chrl2 51780202 51780271) of SCN8A; exon (GRCh38 / hg38: chr2 166304238 166304329) of SCN9A; exon (GRCh38 / hg38: chr7 80794854 80794957) of SEMA3C; exon (GRCh38 / hg38: chr7 85059498 85059541) of SEMA3D; exon (GRCh38 / hg38: chrl l 225673 226081) of SIRT3; exon (GRCh38 / hg38: chrl9 1216268 1216398) of STKl l; exon (GRCh38 / hg38: chrl9 1221621 1221846) of STKl l; exon (GRCh38 / hg38: chr6 33448789 33448868) of SYNGAPl; exon (GRCh38 / hg38: chr9 32551365 32551469) of TOPORS; exon (GRCh38 / hg38: chr5 83544965 83545070) of VCAN) can comprise a sequence with at least 80%, 85%, 90%, 95%, 97%), or 100%) sequence identity to any one of SEQ ID NOs: 135-191. In some embodiments, ASOs target a sequence within an NIE.

[0138] In some embodiments, the ASO targets exon 8x of a ABCB4 NIE containing pre-mRNA comprising NIE exon 8, exon 9x of a ASS1 NIE containing pre-mRNA comprising NIE exon 9, exon 16x of a ATP8B1 NIE containing pre-mRNA comprising NIE exon 16, exon lx of a BAG3 NIE containing pre-mRNA comprising NIE exon 1, exon 3 lx of a CACNA1 A NIE containing pre-mRNA comprising NIE exon 31, exon 36x of a CACNA1 A NIE containing pre-mRNA comprising NIE exon 36, exon 37x of a CACNA1 A NIE containing pre-mRNA comprising NIE exon 37, exon 3x of a CBS NIE containing pre-mRNA comprising NIE exon 3, exon 12x of a CBS NIE containing pre-mRNA comprising NIE exon 12, exon lx of a CD55 NIE containing pre-mRNA comprising NIE exon 1, exon 16x of a CDKL5 NIE containing pre-mRNA comprising NIE exon 16, exon 3x of CFH NIE containing pre-mRNA comprising NIE exon 3, exon 3 Ox of a CHD2 NIE containing pre-mRNA comprising NIE exon 30, exon 4x of CHRNA7 NIE containing pre-mRNA comprising NIE exon 4, exon lx of CISD2 NIE containing pre- mRNA comprising NIE exon 1, exon 15x of CLN3 NIE containing pre-mRNA comprising NIE exon 15, exon 1 lx of a COL4A3 NIE containing pre-mRNA comprising NIE exon 11, exon 41x of a COL4A3 NIE containing pre-mRNA comprising NIE exon 41, exon 22x of a COL4A4 NIE containing pre-mRNA comprising NIE exon 22, exon 44x of a COL4A4 NIE containing pre- mRNA comprising NIE exon 44, exon 20x of DEPDC5 NIE containing pre-mRNA comprising NIE exon 20, exon 2x of a DHDDS NIE containing pre-mRNA comprising NIE exon 2, exon 3x of a ELOVL4 NIE containing pre-mRNA comprising NIE exon 3, exon 5x of a FAH NIE containing pre-mRNA comprising NIE exon 5, exon 4x of FXN NIE containing pre-mRNA comprising NIE exon 4, exon 4x of a GALE NIE containing pre-mRNA comprising NIE exon 4, exon 3x of a GBE1 NIE containing pre-mRNA comprising NIE exon 3, exon 1 lx of GRIN2A NIE containing pre-mRNA comprising NIE exon 11, exon lx of GRN NIE containing pre- mRNA comprising NIE exon 1, exon 2x of a HEXA NIE containing pre-mRNA comprising NIE exon 2, exon 2x of a KANSLl NIE containing pre-mRNA comprising NIE exon 2, exon lx of a KCNQ2 NIE containing pre-mRNA comprising NIE exon 1, exon 5 Ox of a KMT2D NIE containing pre-mRNA comprising NIE exon 50, exon 8x of MAPK3 NIE containing pre-mRNA comprising NIE exon 8, exon 13x of MBD5 NIE containing pre-mRNA comprising NIE exon 13, exon 2x of a MECP2 NIE containing pre-mRNA comprising NIE exon 2, exon 1 lx of MUT NIE containing pre-mRNA comprising NIE exon 11, exon 3 lx of NFl NIE containing pre- mRNA comprising NIE exon 31, exon 7x of a NIPBL NIE containing pre-mRNA comprising NIE exon 7, exon 38x of a NIPBL NIE containing pre-mRNA comprising NIE exon 38, exon 1 lx of a NSD1 NIE containing pre-mRNA comprising NIE exon 11, exon 6x of a OPA1 NIE containing pre-mRNA comprising NIE exon 6, exon 28x of a OPA1 NIE containing pre-mRNAcomprising NIE exon 28, exon lx of OPTN NIE containing pre-mRNA comprising NIE exon 1, exon lx of PCCA NIE containing pre-mRNA comprising NIE exon 1, exon 5x of a PCCB NIE containing pre-mRNA comprising NIE exon 5, exon 6x of a PCCB NIE containing pre-mRNA comprising NIE exon 6, exon 4x of a PKP2 NIE containing pre-mRNA comprising NIE exon 4, exon 23x of a PLCB1 NIE containing pre-mRNA comprising NIE exon 23, exon 3x of PRPF3 NIE containing pre-mRNA comprising NIE exon 3, exon 9x of PRPF31 NIE containing pre- mRNA comprising NIE exon 9, exon lx of a RAIl NIE containing pre-mRNA comprising NIE exon 1, exon 5x of RBFOX2 NIE containing pre-mRNA comprising NIE exon 5, exon 13x of SCN2A NIE containing pre-mRNA comprising NIE exon 13, exon 6x of SCN3 A NIE containing pre-mRNA comprising NIE exon 6, exon 7x of SCN3 A NIE containing pre-mRNA comprising NIE exon 7, exon 4x of SCN8A NIE containing pre-mRNA comprising NIE exon 4, exon 6x of SCN8A NIE containing pre-mRNA comprising NIE exon 6, exon 20x of SCN8A NIE containing pre-mRNA comprising NIE exon 20, exon 6x of SCN9A NIE containing pre- mRNA comprising NIE exon 6, exon 24x of SHANK3 NIE containing pre-mRNA comprising NIE exon 24, exon 3x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 3, exon 6x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 6, exon 9x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 9, exon 1 lx of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 11, exon 13x of a SLC25A13 NIE containing pre-mRNA comprising NIE exon 13, exon lx of SLC6A1 NIE containing pre-mRNA comprising NIE exonI, exon 12x of a SPTAN1 NIE containing pre-mRNA comprising NIE exon 12, exon 1 Ox of a TEK NIE containing pre-mRNA comprising NIE exon 10, exon 15x of a TEK NIE containing pre-mRNA comprising NIE exon 15, exon lx of TOPORS NIE containing pre-mRNA comprising NIE exon 1, exon 1 lx of a TSC2 NIE containing pre-mRNA comprising NIE exonI I, exon 30x of a TSC2 NIE containing pre-mRNA comprising NIE exon 30, exon lx of UBE3 A NIE containing pre-mRNA comprising NIE exon 1, or exon 7x of a VCAN NIE containing pre-mRNA comprising NIE exon 7. In some embodiments, the ASO targets a sequence downstream (or 3') from the 5' end of the exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNAl A, exon 36x of CACNAl A, exon 37x of CACNAl A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRJN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3,exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of F1, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSDl, exon 6x of OPAl, exon 28x of OPAl, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCBl, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAIl, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x ofSLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN pre-mRNA. In some embodiments, the ASO targets an exon 20x sequence upstream (or 5') from the 3' end of the exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1 A, exon 36x of CACNA1 A, exon 37x of CACNA1A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of NFl, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSDl, exon 6x of OPAl, exon 28x of OPAl, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCBl, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAIl, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x of SLC25A13, exon 6x ofSLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon 1 lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN pre-mRNA.

[0139] In some embodiments, the targeted portion of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCBl, PRPF3, PRPF31, RAIl, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1,GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA is in intron 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, hybridization of an ASO to the targeted portion of the NIE pre-mRNA results in exon skipping of at least one of NIE within intron 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, and subsequently increases ABCB4, ASS1,ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein production. In some embodiments, the targeted portion of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, or VCANNIE containing pre-mRNA is in intron 8 of ABCB4, intron 9 of ASS1, intron 16 of ATP8B1, intron 1 of BAG3, intron 31 of CACNA1 A, intron 36 of CACNA1 A, intron 37 of CACNA1A, intron 3 of CBS, intron 12 of CBS, intron 1 of CD55, intron 16 of CDKL5, intron 3 of CFH, intron 30 of CHD2, intron 4 of CHRNA7, intron 1 of CISD2, intron 15 of CLN3, intron 11 of COL4A3, intron 41 of COL4A3, intron 22 of COL4A4, intron 44 of COL4A4, intron 20 of DEPDC5, intron 2 of DHDDS, intron 3 of ELOVL4, intron 5 of FAH, intron 4 of FN, intron 4 of GALE, intron 3 of GBE1, intron 11 of GRIN2A, intron 1 of GRN, intron 2 of HEA, intron 2 of KANSLl, intron 50 of KMT2D, intron 8 of MAPK3, intron 13 of MBD5, intron 2 of MECP2, intron 11 of MUT, intron 31 of NFl, intron 7 of NIPBL, intron 38 of NIPBL, intron 11 of NSDl, intron 6 of OPAl, intron 28 of OPAl, intron 1 of OPTN, intron 1 of PCCA, intron 5 of PCCB, intron 6 of PCCB, intron 4 of PKP2, intron 23 of PLCB 1, intron 3 of PRPF3, intron 9 ofPRPF31, intron 1 of RAI1, intron 5 of RBF02, intron 13 of SCN2A, intron 6 of SCN3A, intron 7 of SCN3A, intron 4 of SCN8A, intron 6 of SCN8A, intron 20 of SCN8A, intron 6 of SCN9A, intron 24 of SHANK3, intron 3 of SLC25A13, intron 6 of SLC25A13, intron 9 of SLC25A13,intron 11 of SLC25A13, intron 13 of SLC25A13, intron 1 of SLC6A1, intron 12 of SPTAN1, intron 10 of TEK, intron 15 of TEK, intron 1 of TOPORS, intron 11 of TSC2, intron 30 of TSC2, intron 1 of UBE3A, or intron 7 of VCAN. In some embodiments, the targeted portion of the AKT3, CACNA1A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3, COL4A4, COL4A4, CR1, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERN1, GALE, GUCY2F,GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NF1, NF2, NIPBL, NR1H4, NSD1, NSD1, NSD1, NSD1, OPA1, OPA1, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11,SYNGAP1, TOPORS, or VCAN E containing pre-mRNA is intron (GRCh38 / hg38: chrl 243563849 243572925) of AKT3; intron (GRCh38 / hg38: chrl9 13235731 13241520) of CACNA1A; intron (GRCh38 / hg38: chr21 43059304 43060440) of CBS; intron (GRCh38 / hg38: chrl 207770363 207783291) of CD46; intron (GRCh38 / hg38: chrl 196673963196675988) of CFH; intron (GRCh38 / hg38: chrl 5 92997404 92998498) of CHD2; intron (GRCh38 / hg38: chrl 6 28477878 28482104) of CLN3; intron (GRCh38 / hg38: chr6 33181172 33184144) of COL11A2; intron (GRCh38 / hg38: chr2 227295317 227297673) of COL4A3; intron (GRCh38 / hg38: chr2 227144559 227147412) of COL4A4; intron (GRCh38 / hg38: chr2 227012299 227022047) of COL4A4; intron (GRCh38 / hg38: chrl 207630622 207639396) of CR1; intron (GRCh38 / hg38: chrl9 47834544 47836242) of CRX; intron (GRCh38 / hg38: chrl 59901104 59904870) of CYP2J2; intron (GRCh38 / hg38: chrl 26438285 26442730) ofDHDDS; intron (GRCh38 / hg38: chrl 28229025 28232920) of DNAJC8; intron (GRCh38 / hg38: chr2 88579641 88583429) of EIF2AK3; intron (GRCh38 / hg38: chrl7 6409824264129975) of ERN1; intron (GRCh38 / hg38: chrl 23798231 23798614) of GALE; intron (GRCh38 / hg38: chrx 109382213 109385183) of GUCY2F; intron (GRCh38 / hg38: chrx 109430397 109441350) of GUCY2F; intron (GRCh38 / hg38: chrl5 72356651 72375719) of HEXA; intron (GRCh38 / hg38: chrl5 72345552 72346234) of HEXA; intron (GRCh38 / hg38: chrl6 30114709 30116635) of MAPK3; intron (GRCh38 / hg38: chr2 148458872 148462581) of MBD5; intron (GRCh38 / hg38: chr2 148490595 148502435) of MBD5; intron (GRCh38 / hg38: chr2 148502510 148510059) of MBD5; intron (GRCh38 / hg38: chr6 49435625 49440205) of MUT; intron (GRCh38 / hg38: chrl9 50230624 50231929) of MYH14; intron (GRCh38 / hg38: chr6 75867106 75870646) of MY06; intron (GRCh38 / hg38: chrl 7 31249120 31252937) of NF1; intron (GRCh38 / hg38: chr22 29604113 29636750) of NF2; intron (GRCh38 / hg38: chr5 37046200 37048501) of NIPBL; intron (GRCh38 / hg38: chrl2 100493403 100505574) of NR1H4; intron (GRCh38 / hg38 : chr5 177136031 177191883) of NSD 1 ; intron (GRCh38 / hg38 : chr5 177192020 177204119) of NSD 1; intron (GRCh38 / hg38: chr5 177246797 177248180) ofNSD1; intron (GRCh38 / hg38: chr5 177273785 177280564) of NSD1; intron (GRCh38 / hg38: chr3 193626203 193631611) of OPA1; intron (GRCh38 / hg38: chr3 193593374 193614710) of OPA1; intron (GRCh38 / hg38: chrl3 100302999 100307191) of PCCA; intron (GRCh38 / hg38: chrl2 32879033 32896508) of PKP2; intron (GRCh38 / hg38: chr22 46198592 46215172) of PPARA; intron (GRCh38 / hg38: chrl 150325882 150328319) of PRPF3; intron (GRCh38 / hg38: chrl 150328467 150332683) of PRPF3; intron (GRCh38 / hg38: chr2 165326985 165331329) of SCN2A; intron (GRCh38 / hg38: chrl2 51687220 51689004) of SCN8A; intron (GRCh38 / hg38: chrl2 51774363 51786541) of SCN8A; intron (GRCh38 / hg38: chr2 166304122 166305791) of SCN9A; intron (GRCh38 / hg38: chr7 80789529 80798091) of SEMA3C; intron (GRCh38 / hg38: chr7 85055860 85065423) of SEMA3D; intron (GRCh38 / hg38: chrl l 224241 230451) of SIRT3; intron (GRCh38 / hg38: chrl9 1207204 1218416) of STK11; intron (GRCh38 / hg38: chrl9 1221341 1221948) of STK11; intron (GRCh38 / hg38: chr6 33447934 33451759) of SYNGAPl; intron (GRCh38 / hg38: chr9 32550969 32552433) of TOPORS; or intron (GRCh38 / hg38: chr5 83542269 83545536) of VCAN.

[0140] In some embodiments, the methods and compositions of the present disclosure are used to increase the expression of ABCB4, ASS1, ATP8B 1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl by inducing exon skipping of a pseudo-exon of an ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl NIE containing pre-mRNA. In some embodiments, the pseudo-exon is a sequence within any of introns 1-50. In some embodiments, the pseudo-exon is a sequence within any of introns 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, the pseudo-exon can be any ABCB 4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C,SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 intron or a portion thereof. In some embodiments, the pseudo-exon is within intron 8 of ABCB4, intron 9 of ASSl, intron 16 of ATP8B1, intron 1 of BAG3, intron 31 of CACNAIA, intron 36 of CACNAIA, intron 37 of CACNAIA, intron 3 of CBS, intron 12 of CBS, intron 1 of CD55, intron 16 of CDKL5, intron 3 of CFH, intron 30 of CHD2, intron 4 of CHRNA7, intron 1 of CISD2, intron 15 of CLN3, intron 11 of COL4A3, intron 41 of COL4A3, intron 22 of COL4A4, intron 44 of COL4A4, intron 20 of DEPDC5, intron 2 of DHDDS, intron 3 of ELOVL4, intron 5 of FAH, intron 4 of FN, intron 4 of GALE, intron 3 of GBE1, intron 11 of GRIN2A, intron 1 of GRN, intron 2 of HE A, intron 2 of KANSLl, intron 50 of KMT2D, intron 8 of MAPK3, intron 13 of MBD5, intron 2 of MECP2, intron 11 of MUT, intron 31 of NFl, intron 7 of NIPBL, intron 38 of NIPBL, intron 11 of NSDl, intron 6 of OPAl, intron 28 of OPAl, intron 1 of OPTN, intron 1 of PCCA, intron 5 of PCCB, intron 6 of PCCB, intron 4 of PKP2, intron 23 of PLCB1, intron 3 of PRPF3, intron 9 of PRPF31, intron 1 of RAI1, intron 5 of RBF02, intron 13 of SCN2A, intron 6 of SCN3A, intron 7 of SCN3A, intron 4 of SCN8A, intron 6 of SCN8A, intron 20 of SCN8A, intron 6 of SCN9A, intron 24 of SHANK3, intron 3 of SLC25A13, intron 6 of SLC25A13, intron 9 of SLC25A13, intron 11 of SLC25A13, intron 13 of SLC25A13, intron 1 of SLC6A1, intron 12 of SPTAN1, intron 10 of TEK, intron 15 of TEK, intron 1 of TOPORS, intron 11 of TSC2, intron 30 of TSC2, intron 1 of UBE3A, or intron 7 of VCAN. In some embodiments, the pseudo-exon is within intron (GRCh38 / hg38: chrl 243563849 243572925) of AKT3; intron (GRCh38 / hg38: chrl9 13235731 13241520) of CACNAIA; intron (GRCh38 / hg38: chr21 43059304 43060440) of CBS; intron (GRCh38 / hg38: chrl 207770363 207783291) of CD46; intron (GRCh38 / hg38: chrl 196673963 196675988) of CFH; intron (GRCh38 / hg38: chrl 5 92997404 92998498) of CHD2; intron (GRCh38 / hg38: chrl 6 28477878 28482104) of CLN3 ; intron (GRCh38 / hg38 : chr6 33181172 33184144) of COL 11 A2; intron (GRCh38 / hg38 : chr2 227295317 227297673) of COL4A3; intron (GRCh38 / hg38: chr2 227144559 227147412) of COL4A4; intron (GRCh38 / hg38: chr2 227012299 227022047) of COL4A4; intron (GRCh38 / hg38: chrl 207630622 207639396) of CR1; intron (GRCh38 / hg38: chrl9 47834544 47836242)of CRX; intron (GRCh38 / hg38: chrl 59901104 59904870) of CYP2J2; intron (GRCh38 / hg38: chrl 26438285 26442730) of DHDDS; intron (GRCh38 / hg38: chrl 28229025 28232920) of DNAJC8; intron (GRCh38 / hg38: chr2 88579641 88583429) of EIF2AK3; intron (GRCh38 / hg38: chrl7 64098242 64129975) of ERN1; intron (GRCh38 / hg38: chrl 23798231 23798614) of GALE; intron (GRCh38 / hg38: chrx 109382213 109385183) of GUCY2F; intron (GRCh38 / hg38: chrx 109430397 109441350) of GUCY2F; intron (GRCh38 / hg38: chrl5 72356651 72375719) of HEXA; intron (GRCh38 / hg38: chrl5 72345552 72346234) of HEXA; intron (GRCh38 / hg38: chrl6 30114709 30116635) of MAPK3; intron (GRCh38 / hg38: chr2148458872 148462581) of MBD5; intron (GRCh38 / hg38: chr2 148490595 148502435) of MBD5; intron (GRCh38 / hg38: chr2 148502510 148510059) of MBD5; intron (GRCh38 / hg38: chr6 49435625 49440205) of MUT; intron (GRCh38 / hg38: chrl9 50230624 50231929) of MYH14; intron (GRCh38 / hg38: chr6 75867106 75870646) of MY06; intron (GRCh38 / hg38: chrl7 31249120 31252937) of NFl; intron (GRCh38 / hg38: chr22 29604113 29636750) of NF2; intron (GRCh38 / hg38: chr5 37046200 37048501) of NIPBL; intron (GRCh38 / hg38: chrl2 100493403 100505574) of NR1H4; intron (GRCh38 / hg38: chr5 177136031 177191883) of NSD1; intron (GRCh38 / hg38: chr5 177192020 177204119) ofNSDl; intron (GRCh38 / hg38: chr5 177246797 177248180) ofNSDl; intron (GRCh38 / hg38: chr5 177273785 177280564) of NSD1; intron (GRCh38 / hg38: chr3 193626203 193631611) of OPAl; intron (GRCh38 / hg38: chr3 193593374 193614710) of OPAl; intron (GRCh38 / hg38: chrl3 100302999 100307191) of PCCA; intron (GRCh38 / hg38: chrl2 32879033 32896508) of PKP2; intron (GRCh38 / hg38: chr22 46198592 46215172) of PPARA; intron (GRCh38 / hg38: chrl 150325882 150328319) of PRPF3; intron (GRCh38 / hg38: chrl 150328467 150332683) of PRPF3; intron (GRCh38 / hg38: chr2 165326985 165331329) of SCN2A; intron (GRCh38 / hg38: chrl2 51687220 51689004) of SCN8A; intron (GRCh38 / hg38: chrl2 51774363 51786541) of SCN8A; intron (GRCh38 / hg38: chr2 166304122 166305791) of SCN9A; intron (GRCh38 / hg38: chr7 80789529 80798091) of SEMA3C; intron (GRCh38 / hg38: chr7 85055860 85065423) of SEMA3D; intron (GRCh38 / hg38: chrl l 224241 230451) of SIRT3; intron (GRCh38 / hg38: chrl9 1207204 1218416) of STK11; intron (GRCh38 / hg38: chrl9 1221341 1221948) of STK11; intron (GRCh38 / hg38: chr6 33447934 33451759) of SYNGAPl; intron (GRCh38 / hg38: chr9 32550969 32552433) of TOPORS; or intron (GRCh38 / hg38: chr5 83542269 83545536) of VCAN.Protein Expression

[0141] In some embodiments, the methods described herein are used to increase the production of a functional ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH,FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein or RNA. As used herein, the term "functional" refers to the amount of activity or function of a ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein or RNA that is necessary to eliminate any one or more symptoms of a treated condition or disease, e.g., Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome;Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder; Cardiomyopathy, dilated, lHH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1; Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epileptic encephalopathy; Epilepsy- aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epilepticencephalopathy, childhood-onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12; Epileptic encephalopathy, early infantile, 13; Epileptic encephalopathy, early infantile, 2; Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes; Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN- related frontotemporal dementia; Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive; Insensitivity to pain, congenital; Kabuki syndrome ; Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1; Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia; Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3;Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith- Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3microdeletion; 16pl l .2 deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss; Deafness, autosomal dominant 22; Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5. In some embodiments, the methods are used to increase the production of a partially functional ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRTN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein or RNA. As used herein, the term "partially functional" refers to any amount of activity or function of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STKl 1, PPARA, CYP2J2, or SYNGAPl protein or RNA that is less than the amount of activity or function that is necessary to eliminate or prevent any one or more symptoms of a disease or condition. In some embodiments, a partially functional protein or RNA will have at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%), at least 80%>, at least 85%>, at least 90%, or at least 95% less activity relative to the fully functional protein or RNA.

[0142] In some embodiments, the method is a method of increasing the expression of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein by cells of a subject having a NIE containing pre- mRNA encoding the ABCB4, ASSl, ATP8B 1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein, wherein the subject has Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome; Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder;Cardiomyopathy, dilated, lHH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1;Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epileptic encephalopathy; Epilepsy-aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epileptic encephalopathy, childhood- onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12; Epileptic encephalopathy, early infantile, 13; Epileptic encephalopathy, early infantile, 2;Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes; Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN-related frontotemporal dementia;Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive;Insensitivity to pain, congenital; Kabuki syndrome ; Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1; Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia; Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3; Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3 microdeletion; 16pl l .2deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss;Deafness, autosomal dominant 22; Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5 caused by a deficient amount of activity of ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, orSYNGAPl protein, and wherein the deficient amount of the ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein is caused by haploinsufficiency of the ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein. In such an embodiment, the subject has a first allele encoding a functional ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2,SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein, and a second allele from which the ABCB4, ASS1, ATP8B 1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein is not produced. In another such embodiment, the subject has a first allele encoding a functional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein, and a second allele encoding a nonfunctional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1,GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein. In another such embodiment, the subject has a first allele encoding a functional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55,CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein, and asecond allele encoding a partially functional ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRJN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAIl, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein. In any of these embodiments, the antisense oligomer binds to a targeted portion of the NIE containing pre-mRNA transcribed from the second allele, thereby inducing exon skipping of the pseudo-exon from the pre-mRNA, and causing an increase in the level of mature mRNA encoding functional ABCB4, ASS 1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAIl, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein, and an increase in the expression of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2,CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAIl, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein in the cells of the subject.

[0143] In some embodiments, the method is a method of increasing the expression of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAIl,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14,MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein by cells of a subject having a NIE containing pre- mRNA encoding the ABCB4, ASSl, ATP8B 1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein, wherein the subject has Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome; Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder;Cardiomyopathy, dilated, lHH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1;Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epileptic encephalopathy; Epilepsy-aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epileptic encephalopathy, childhood- onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12; Epileptic encephalopathy, early infantile, 13; Epileptic encephalopathy, early infantile, 2;Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes; Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN-related frontotemporal dementia;Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive;Insensitivity to pain, congenital; Kabuki syndrome ; Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1; Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia; Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3; Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3 microdeletion; 16pl l .2 deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss;Deafness, autosomal dominant 22; Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5 caused by a deficient amount of activity of ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, orSYNGAPl protein, and wherein the deficient amount of the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein is caused by autosomal recessive inheritance.

[0144] In some embodiments, the method is a method of increasing the expression of the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein by cells of a subject having a NIE containing pre- mRNA encoding the ABCB4, ASSl, ATP8B 1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3,NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 protein, wherein the subject has Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome; Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder;Cardiomyopathy, dilated, 1HH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1;Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epileptic encephalopathy; Epilepsy-aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epileptic encephalopathy, childhood- onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12; Epileptic encephalopathy, early infantile, 13; Epileptic encephalopathy, early infantile, 2;Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes; Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN-related frontotemporal dementia;Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive;Insensitivity to pain, congenital; Kabuki syndrome ; Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1; Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia; Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3; Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3 microdeletion; 16pl 1.2 deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss;Deafness, autosomal dominant 22; Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5 caused by a deficient amount of activity of ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, orSYNGAPl protein, and wherein the deficient amount of the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein is caused by autosomal dominant inheritance.

[0145] In some embodiments, the method is a method of increasing the expression of the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein by cells of a subject having a NIE containing pre- mRNA encoding the ABCB4, ASSl, ATP8B 1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein, wherein the subject has Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome; Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder;Cardiomyopathy, dilated, lHH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1;Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epileptic encephalopathy; Epilepsy-aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epileptic encephalopathy, childhood- onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12;Epileptic encephalopathy, early infantile, 13; Epileptic encephalopathy, early infantile, 2;Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes; Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN-related frontotemporal dementia;Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive;Insensitivity to pain, congenital; Kabuki syndrome ; Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1; Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia; Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3; Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3 microdeletion; 16pl 1.2 deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss;Deafness, autosomal dominant 22; Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5 caused by a deficient amount of activity of ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, orSYNGAPl protein, and wherein the deficient amount of the ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein is caused by X-linked dominant inheritance.

[0146] In related embodiments, the method is a method of using an ASO to increase the expression of a protein or functional RNA. In some embodiments, an ASO may be used to increase the expression of ABCB4, ASSl, ATP8B 1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRJN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein in cells of a subject having a NIE containing pre-mRNA encoding ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein, wherein the subject has a deficiency, e.g., Alport syndrome; Amyotrophic lateral sclerosis (ALS); Angelman syndrome; Aphasia, primary progressive; Arrhythmogenic right ventricular dysplasia 9; Autism spectrum disorder; Cardiomyopathy, dilated, lHH; Myopathy, myofibrillar 6; Ceriod lipofuscinosis, neuronal, 3; Cholestasis, intrahepatic, of pregnancy, 3; Cholestasis, progressive familial intrahepatic 1; Citrullinemia Type II; Citrullinemia, Type 1; Cognitive impairment with or without cerebral ataxia; Cornelia de Lange; Early-onset epilepticencephalopathy; Epilepsy-aphasia spectrum; Epilepsy, generalized, with febrile seizures plus, type 7; Epileptic encephalopathy, childhood-onset; Epileptic encephalopathy, early infantile, 11; Epileptic encephalopathy, early infantile, 12; Epileptic encephalopathy, early infantile, 13;Epileptic encephalopathy, early infantile, 2; Episodic ataxia, type 2; Familial focal epilepsy; Febrile seizures, familial, 3B; Friedreich ataxia; Friedreich ataxia with retained reflexes;Galactose epimerase deficiency; Glaucoma 3, primary congenital, E; Glycogen storage disease IV; GRN-related frontotemporal dementia; Homocystinuria, B6-responsive and nonresponsive types; HSAN2D, autosomal recessive; Insensitivity to pain, congenital; Kabuki syndrome ;Koolen-De Vries syndrome; Mental retardation, autosomal dominant 1; Methyl malonic aciduria; Migraine, Myoclonic-atonic epilepsy; familial hemiplegic, 1; Neurofibromatosis type 1;Opioid addiction; Optic atrophy type 1; Phelan-McDermid syndrome; Propionicacidemia;Primary open angle glaucoma; Propionic academia; Retinitis pigmentosa 11; Retinitis pigmentosa 18; Retinitis pigmentosa 31; Retinitis pigmentosa 59; Rett syndrome; Seizures, benign familial infantile, 3; Seizures, benign familial infantile, 5; Smith-Magenis syndrome; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Stargardt disease 3; Tay-Sachs disease; Tuberous sclerosis; Tyrosinemia, type I; Wagner syndrome 1; West syndrome; Wolfram syndrome 2 / NAFLD; 15ql3.3 microdeletion; 16pl 1.2 deletion syndrome; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy -2; Deafness, autosomal dominant 4 A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss; Deafness, autosomal dominant 22;Neurofibromatosis type 2; NASH; or Mental retardation, autosomal dominant 5, in the amount or function of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein.

[0147] In some embodiments, the NIE containing pre-mRNA transcript that encodes the protein that is causative of the disease or condition is targeted by the ASOs described herein. In some embodiments, a NIE containing pre-mRNA transcript that encodes a protein that is not causative of the disease is targeted by the ASOs. For example, a disease that is the result of a mutation or deficiency of a first protein in a particular pathway may be ameliorated by targeting a NIE containing pre-mRNA that encodes a second protein, thereby increasing production of the second protein. In some embodiments, the function of the second protein is able to compensate for the mutation or deficiency of the first protein (which is causative of the disease or condition).

[0148] In some embodiments, the subject has:(a) a first mutant allele from which(i) the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STKl 1, PPARA, CYP2J2, or SYNGAPl protein is produced at a reduced level compared to production from a wild-type allele,(ii) the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STKl 1, PPARA, CYP2J2, or SYNGAPl protein is produced in a form having reduced function compared to an equivalent wild-type protein, or(iii) the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STKl 1, PPARA, CYP2J2, or SYNGAPl protein or functional RNA is not produced; anda second mutant allele from which(i) the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, R1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein is produced at a reduced level compared to production from a wild-type allele,(ii) the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein is produced in a form having reduced function compared to an equivalent wild-type protein, or(iii) the ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein is not produced, and wherein the NIE containing pre-mRNA is transcribed from the first allele and / or the second allele. In these embodiments, the ASO binds to a targeted portion of the NIE containing pre- mRNA transcribed from the first allele or the second allele, thereby inducing exon skipping of the pseudo-exon from the NIE containing pre-mRNA, and causing an increase in the level of mRNA encoding ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3,PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein and an increase in the expression of the target protein or functional RNA in the cells of the subject. In these embodiments, the target protein or functional RNA having an increase in expression level resulting from the exon skipping of the pseudo-exon from the NIE containing pre-mRNA may be either in a form having reduced function compared to the equivalent wild-type protein (partially-functional), or having full function compared to the equivalent wild-type protein (fully-functional).

[0149] In some embodiments, the level of mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein is increased 1.1 to 10-fold, when compared to the amount of mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein that is produced in a control cell, e.g., one that is not treated with the anti sense oligomer or one that is treated with an anti sense oligomer that does not bind to the targeted portion of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14,MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl E containing pre-mRNA.

[0150] In some embodiments, a subject treated using the methods of the present disclosure expresses a partially functional ABCB4, ASS1, ATP8B 1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein from one allele, wherein the partially functional ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein may be caused by a frameshift mutation, a nonsense mutation, a missense mutation, or a partial gene deletion. In some embodiments, a subject treated using the methods of the disclosure expresses a nonfunctional ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein from one allele, wherein the nonfunctional ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein may be caused by a frameshift mutation, a nonsense mutation, a missense mutation, a partial gene deletion, in one allele. In some embodiments, a subject treated using the methods of the disclosure has aABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C,SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAPl whole gene deletion, in one allele.Exon Inclusion

[0151] As used herein, a "NIE containing pre-mRNA" is a pre-mRNA transcript that contains at least one pseudo-exon. Alternative or aberrant splicing can result in inclusion of the at least one pseudo-exon in the mature mRNA transcripts. The terms "mature mRNA," and "fully-spliced mRNA," are used interchangeably herein to describe a fully processed mRNA. Inclusion of the at least one pseudo-exon can be non-productive mRNA and lead to NMD of the mature mRNA. NIE containing mature mRNA may sometimes lead to aberrant protein expression.

[0152] In some embodiments, the included pseudo-exon is the most abundant pseudo-exon in a population of NIE containing pre-mRNAs transcribed from the gene encoding the target protein in a cell. In some embodiments, the included pseudo-exon is the most abundant pseudo-exon in a population of NIE containing pre-mRNAs transcribed from the gene encoding the target protein in a cell, wherein the population of NIE containing pre-mRNAs comprises two or more included pseudo-exons. In some embodiments, an antisense oligomer targeted to the most abundant pseudo-exon in the population of NIE containing pre-mRNAs encoding the target protein induces exon skipping of one or two or more pseudo-exons in the population, including the pseudo-exon to which the antisense oligomer is targeted or binds. In some embodiments, the targeted region is in a pseudo-exon that is the most abundant pseudo-exon in a NIE containing pre-mRNA encoding the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCB1,PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHA K3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, F2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, R1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein.

[0153] The degree of exon inclusion can be expressed as percent exon inclusion, e.g., the percentage of transcripts in which a given pseudo-exon is included. In brief, percent exon inclusion can be calculated as the percentage of the amount of RNA transcripts with the exon inclusion, over the sum of the average of the amount of RNA transcripts with exon inclusion plus the average of the amount of RNA transcripts with exon exclusion.

[0154] In some embodiments, an included pseudo-exon is an exon that is identified as an included pseudo-exon based on a determination of at least about 5%, at least about 10%, at least about 15%), at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%, inclusion. In embodiments, a included pseudo-exon is an exon that is identified as a included pseudo-exon based on a determination of about 5%) to about 100%, about 5% to about 95%, about 5% to about 90%, about 5% to about 85%, about 5% to about 80%, about 5% to about 75%, about 5% to about 70%, about 5% to about 65%), about 5% to about 60%, about 5% to about 55%, about 5% to about 50%, about 5% to about 45%), about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 10% to about 100%, about 10% to about 95%, about 10% to about 90%, about 10% to about 85%, about 10% to about 80%, about 10% to about 75%, about 10% to about 70%, about 10% to about 65%, about 10% to about 60%, about 10% to about 55%, about 10% to about 50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 15% to about 100%, about 15% to about 95%, about 15% to about 90%, about 15% to about 85%, about 15% to about 80%, about 15% to about 75%, about 15% to about 70%, about 15% to about 65%, about 15% to about 60%, about 15% to about 55%, about 15% to about 50%, about 15% to about 45%, about 15% to about 40%, about 15% to about 35%, about 15% to about 30%, about 15% to about 25%, about 20% to about 100%, about 20% to about 95%, about 20% to about 90%, about 20% to about 85%, about 20% to about 80%, about 20% to about 75%, about 20% to about 70%, about 20% to about 65%, about 20% to about 60%, about 20% to about 55%, about 20% to about 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, about 20% to about 30%, about 25% to about 100%, about 25% to about 95%, about 25% to about 90%, about 25% to about 85%, about 25% to about 80%, about 25% to about 75%, about 25% to about 70%, about 25% to about 65%, about 25% to about60%, about 25% to about 55%, about 25% to about 50%, about 25% to about 45%, about 25% to about 40%), or about 25% to about 35%, inclusion. ENCODE data (described by, e.g., Tilgner, et al, 2012, "Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for IncRNAs," Genome Research22(9): 1616-25) can be used to aid in identifying exon inclusion.

[0155] In some embodiments, contacting cells with an ASO that is complementary to a targeted portion of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SIC25A13, SIC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COI11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA transcript results in an increase in the amount of ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1,GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein produced by at least 10, 20, 30, 40, 50, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 1000%, compared to the amount of the protein produced by a cell in the absence of the ASO / absence of treatment. In some embodiments, the total amount of ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein produced by the cell to which the antisense oligomer is contacted is increased about 20% to about 300%, about 50% to about 300%, about 100% to about 300%, about 150% to about 300%, about 20% to about 50%, about20% to about 100%, about 20% to about 150%, about 20% to about 200%, about 20% to about 250%, about 50% to about 100%, about 50% to about 150%, about 50% to about 200%, about 50% to about 250%, about 100% to about 150%, about 100% to about 200%, about 100% to about 250%, about 150% to about 200%, about 150% to about 250%, about 200% to about 250%), at least about 10%, at least about 20%, at least about 50%, at least about 100%, at least about 150%), at least about 200%, at least about 250%, or at least about 300%, compared to the amount of target protein produced by a control compound. In some embodiments, the total amount of ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein produced by the cell to which the antisense oligomer is contacted is increased about 1.1 to about 10-fold, about 1.5 to about 10- fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to the amount of target protein produced by a control compound. A control compound can be, for example, an oligonucleotide that is not complementary to a targeted portion of the pre-mRNA.

[0156] In some embodiments, contacting cells with an ASO that is complementary to a targeted portion of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA,CYP2J2, or SYNGAPl pre-mRNA transcript results in an increase in the amount of mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl, including the mature mRNA encoding the target protein. In some embodiments, the amount of mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, orSYNGAPl protein, or the mature mRNA encoding the ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein, is increased by at least 10, 20, 30, 40, 50, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 1000%, compared to the amount of the protein produced by a cell in the absence of theASO / absence of treatment. In some embodiments, the total amount of the mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1,RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14,MY06, F2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, R1H4, STK11, PPARA, CYP2J2, or SYNGAP1 protein, or the mature mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein produced in the cell to which the antisense oligomer is contacted is increased about 20% to about 300%, about 50% to about 300%, about 100% to about 300%, about 150% to about 300%, about 20% to about 50%, about 20% to about 100%, about 20% to about 150%, about 20% to about 200%, about 20% to about 250%, about 50% to about 100%, about 50% to about 150%, about 50% to about 200%, about 50% to about 250%, about 100% to about 150%, about 100% to about 200%, about 100% to about 250%, about 150% to about 200%, about 150% to about 250%, about 200% to about 250%, at least about 10%, at least about 20%), at least about 50%, at least about 100%, at least about 150%, at least about 200%, at least about 250%), or at least about 300%, compared to the amount of mature RNA produced in an untreated cell, e.g., an untreated cell or a cell treated with a control compound. In some embodiments, the total amount of the mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein, or the mature mRNA encoding ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3,ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 protein produced in the cell to which the antisense oligomer is contacted is increased about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about4 to about 8-fold, about 4 to about 9-fold, at least about 1.1 -fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4- fold, at least about 5-fold, or at least about 10-fold compared to the amount of mature RNA produced in an untreated cell, e.g., an untreated cell or a cell treated with a control compound. A control compound can be, for example, an oligonucleotide that is not complementary to a targeted portion of the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRTN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl NIE containing pre-mRNA.

[0157] The NIE can be in any length. In some embodiments, the NIE comprises a full sequence of an intron, in which case, it can be referred to as intron retention. In some embodiments, the NIE can be a portion of the intron. In some embodiments, the NIE can be a 5' end portion of an intron including a 5'ss sequence. In some embodiments, the NIE can be a 3' end portion of an intron including a 3'ss sequence. In some embodiments, the NIE can be a portion within an intron without inclusion of a 5'ss sequence. In some embodiments, the NIE can be a portion within an intron without inclusion of a 3'ss sequence. In some embodiments, the NIE can be a portion within an intron without inclusion of either a 5'ss or a 3'ss sequence. In someembodiments, the NIE can be from 5 nucleotides to 10 nucleotides in length, from 10 nucleotides to 15 nucleotides in length, from 15 nucleotides to 20 nucleotides in length, from 20 nucleotides to 25 nucleotides in length, from 25 nucleotides to 30 nucleotides in length, from 30 nucleotides to 35 nucleotides in length, from 35 nucleotides to 40 nucleotides in length, from 40 nucleotides to 45 nucleotides in length, from 45 nucleotides to 50 nucleotides in length, from 50 nucleotides to 55 nucleotides in length, from 55 nucleotides to 60 nucleotides in length, from 60 nucleotidesto 65 nucleotides in length, from 65 nucleotides to 70 nucleotides in length, from 70 nucleotides to 75 nucleotides in length, from 75 nucleotides to 80 nucleotides in length, from 80 nucleotides to 85 nucleotides in length, from 85 nucleotides to 90 nucleotides in length, from 90 nucleotides to 95 nucleotides in length, or from 95 nucleotides to 100 nucleotides in length. In some embodiments, the NIE can be at least 10 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleoids, at least 70 nucleotides, at least 80 nucleotides in length, at least 90 nucleotides, or at least 100 nucleotides in length. In some embodiments, the NIE can be from 100 to 200 nucleotides in length, from 200 to 300 nucleotides in length, from 300 to 400 nucleotides in length, from 400 to 500 nucleotides in length, from 500 to 600 nucleotides in length, from 600 to 700 nucleotides in length, from 700 to 800 nucleotides in length, from 800 to 900 nucleotides in length, from 900 to 1,000 nucleotides in length. In some embodiments, the NIE may be longer than 1,000 nucleotides in length.

[0158] Inclusion of a pseudo-exon can lead to a frameshift and the introduction of a premature termination codon (PIC) in the mature mRNA transcript rendering the transcript a target of NMD. Mature mRNA transcript containing NIE can be non-productive mRNA transcript which does not lead to protein expression. The PIC can be present in any position downstream of an NIE. In some embodiments, the PIC can be present in any exon downstream of an NIE. In some embodiments, the PIC can be present within the NIE. For example, inclusion of exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNA1 A, exon 36x of CACNA1 A, exon 37x of CACNA1 A, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBE1, exon 1 lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSL1, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon 1 lx of MUT, exon 31x of NFl, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSDl, exon 6x of OPA1, exon 28x of OPA1, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCB1, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x of SCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHANK3, exon 3x of SLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon 1 lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx ofTEK, exon 15x of TEK, exon lx of TOPORS, exon l lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN in an mRNA transcript encoded by the ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, F1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHA K3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, or VCAN gene can induce a PIC in the mRNA transcript. For example, inclusion of exon (GRCh38 / hg38: chrl 243564285 243564388) of AKT3; exon (GRCh38 / hg38: chrl9 13236449 13236618) of CACNA1A; exon (GRCh38 / hg38: chr21 43059730 43060012) of CBS; exon (GRCh38 / hg38: chrl 207775610 207775745) of CD46; exon (GRCh38 / hg38: chrl 196675450 196675529) of CFH; exon (GRCh38 / hg38: chrl 5 92998149 92998261) of CHD2; exon(GRCh38 / hg38: chrl6 28479644 28479765) of CLN3; exon (GRCh38 / hg38: chr6 33183634 33183698) of COL 11 A2; exon (GRCh38 / hg38: chr2 227296487 227296526) of COL4A3; exon (GRCh38 / hg38: chr2 227144653 227144833) of COL4A4; exon (GRCh38 / hg38: chr2227015283 227015360) of COL4A4; exon (GRCh38 / hg38: chrl 207637688 207637848) of CR1; exon (GRCh38 / hg38: chrl9 47835403 47835579) of CRX; exon (GRCh38 / hg38: chrl 59904366 59904516) of CYP2J2; exon (GRCh38 / hg38: chrl 26442335 26442372) of DHDDS; exon (GRCh38 / hg38: chrl 28230131 28230252 ) of DNAJC8; exon (GRCh38 / hg38: chr2 88582755 88582824) of EIF2AK3; exon (GRCh38 / hg38: chrl7 64102673 64102804) of ERNl; exon (GRCh38 / hg38: chrl 23798311 23798484) of GALE; exon (GRCh38 / hg38: chrX109383365 109383446) of GUCY2F; exon (GRCh38 / hg38: chrX 109439038 109439175) of GUCY2F; exon (GRCh38 / hg38: chrl5 72362376 72362466) of HEXA; exon (GRCh38 / hg38: chrl5 72345677 72345776) of HEXA; exon (GRCh38 / hg38: chrl6 30115595 30115645) of MAPK3; exon (GRCh38 / hg38: chr2 148460219 148460304) of MBD5; exon (GRCh38 / hg38: chr2 148490695 148490787) of MBD5; exon (GRCh38 / hg38: chr2 148505761 148505830) of MBD5; exon (GRCh38 / hg38: chr6 49436522 49436597) of MUT; exon (GRCh38 / hg38: chrl9 50230825 50230999) of MYH14; exon (GRCh38 / hg38: chr6 75867431 75867523) of MY06; exon (GRCh38 / hg38: chrl7 31249955 31250125) ofNFl; exon (GRCh38 / hg38: chr2229628658 29628773) of NF2; exon (GRCh38 / hg38: chr5 37048127 37048354) ofNIPBL; exon (GRCh38 / hg38: chrl2 100499841 100500024) of NR1H4; exon (GRCh38 / hg38: chr5177169394 177169559) ofNSDl; exon (GRCh38 / hg38: chr5 177200761 177200783) ofNSDl; exon (GRCh38 / hg38: chr5 177247924 177248079) ofNSDl; exon (GRCh38 / hg38: chr5 177275947 177276101) ofNSDl; exon (GRCh38 / hg38: chr3 193628509 193628616) of OPA1;exon (GRCh38 / hg38: chr3 193603500 193603557) of OPA1; exon (GRCh38 / hg38: chrl3 100305751 100305834) of PCCA; exon (GRCh38 / hg38: chrl2 32894516 32894778) of PKP2; exon (GRCh38 / hg38: chr22 46203575 46203752) of PPARA; exon (GRCh38 / hg38: chrl 150327557 150327652) of PRPF3; exon (GRCh38 / hg38: chrl 150330401 150330498) of PRPF3; exon (GRCh38 / hg38: chr2 165327155 165327202) of SCN2A; exon (GRCh38 / hg38: chrl2 51688758 51688849) of SCN8A; exon (GRCh38 / hg38: chrl2 51780202 51780271) of SCN8A; exon (GRCh38 / hg38: chr2 166304238 166304329) of SCN9A; exon (GRCh38 / hg38: chr7 80794854 80794957) of SEMA3C; exon (GRCh38 / hg38: chr7 85059498 85059541) of SEMA3D; exon (GRCh38 / hg38: chrl l 225673 226081) of SIRT3; exon (GRCh38 / hg38: chrl9 1216268 1216398) of STK11; exon (GRCh38 / hg38: chrl9 1221621 1221846) of STK11; exon (GRCh38 / hg38: chr6 33448789 33448868) of SYNGAPl; exon (GRCh38 / hg38: chr932551365 32551469) of TOPORS; exon (GRCh38 / hg38: chr5 83544965 83545070) of VCAN in an mRNA transcript encoded by the AKT3, CACNA1 A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3, COL4A4, COL4A4, CR1, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERN1, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NF1, NF2, NIPBL, R1H4, NSD1, NSD1, NSD1, NSD1, OPA1, OPA1, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAPl, TOPORS, or VCAN.Therapeutic Agents

[0159] In various embodiments of the present disclosure, compositions and methods comprising a therapeutic agent are provided to modulate protein expression level of ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RATI, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl . In some embodiments, provided herein are compositions and methods to modulate alternative splicing oiABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3,SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA. In some embodiments, provided herein are compositions and methods to induce exon skipping in the splicing of ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCBl, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA, e.g., to induce skipping of a pseudo-exon during splicing oiABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCBl, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C,SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 pre-mRNA. In other embodiments, therapeutic agents may be used to induce the inclusion of an exon in order to decrease the protein expression level.

[0160] A therapeutic agent disclosed herein can be a NIE repressor agent. A therapeutic agent may comprise a polynucleic acid polymer.According to one aspect of the present disclosure, provided herein is a method of treatment or prevention of a condition or disease associated with a functional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSDl, OPAl, OPTN, PCCA, PCCB, PKP2, PLCBl, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, orSYNGAPl protein deficiency, comprising administering a NIE repressor agent to a subject to increase levels of functional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55,CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein, wherein the agent binds to a region of the pre-mRNA transcript to decrease inclusion of the NIE in the mature transcript. For example, provided herein is a method of treatment or prevention of a condition associated with a functional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, or VCAN protein deficiency, comprising administering a NIE repressor agent to a subject to increase levels of functional ABCB4, ASS1, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTAN1, TEK, TOPORS, TSC2, UBE3A, or VCAN protein, wherein the agent binds to a region of an intron containing an NIE (e.g., exon 8x of ABCB4, exon 9x of ASS1, exon 16x of ATP8B1, exon lx of BAG3, exon 31x of CACNAIA, exon 36x of CACNAIA, exon 37x of CACNAIA, exon 3x of CBS, exon 12x of CBS, exon lx of CD55, exon 16x of CDKL5, exon 3x of CFH, exon 30x of CHD2, exon 4x of CHRNA7, exon lx of CISD2, exon 15x of CLN3, exon l lx of COL4A3, exon 41x of COL4A3, exon 22x of COL4A4, exon 44x of COL4A4, exon 20x of DEPDC5, exon 2x of DHDDS, exon 3x of ELOVL4, exon 5x of FAH, exon 4x of FXN, exon 4x of GALE, exon 3x of GBEl, exon l lx of GRIN2A, exon lx of GRN, exon 2x of HEXA, exon 2x of KANSLl, exon lx of KCNQ2, exon 50x of KMT2D, exon 8x of MAPK3, exon 13x of MBD5, exon 2x of MECP2, exon l lx of MUT, exon 31x of NFl, exon 7x of NIPBL, exon 38x of NIPBL, exon l lx of NSD1, exon 6x of OPA1, exon 28x of OPA1, exon lx of OPTN, exon lx of PCCA, exon 5x of PCCB, exon 6x of PCCB, exon 4x of PKP2, exon 23x of PLCB1, exon 3x of PRPF3, exon 9x of PRPF31, exon lx of RAI1, exon 5x of RBFOX2, exon 13x ofSCN2A, exon 6x of SCN3A, exon 7x of SCN3A, exon 4x of SCN8A, exon 6x of SCN8A, exon 20x of SCN8A, exon 6x of SCN9A, exon 24x of SHA K3, exon 3x of SLC25A13, exon 6x of SLC25A13, exon 9x of SLC25A13, exon l lx of SLC25A13, exon 13x of SLC25A13, exon lx of SLC6A1, exon 12x of SPTAN1, exon lOx of TEK, exon 15x of TEK, exon lx of TOPORS, exon 1 lx of TSC2, exon 30x of TSC2, exon lx of UBE3A, or exon 7x of VCAN) of the pre- mRNA transcript or to a NIE-activating regulatory sequence in the same intron. For example, provided herein is a method of treatment or prevention of a condition associated with a functional AKT3, CACNAl A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3,COL4A4, COL4A4, CR1, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERN1, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NF1, NF2, NIPBL, NR1H4, NSD1, NSD1, NSD1, NSD1, OPA1, OPA1, PCCA, PKP2,PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAPl, TOPORS, or VCAN protein deficiency, comprising administering a NIE repressor agent to a subject to increase levels of functional AKT3, CACNAl A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3, COL4A4, COL4A4, CR1, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERN1, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NF1, NF2, NIPBL, NR1H4, NSD1, NSD1, NSD1, NSD1, OPA1, OPA1, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAPl, TOPORS, or VCAN protein, wherein the agent binds to a region of an intron containing an NIE (e.g., exon (GRCh38 / hg38: chrl 243564285 243564388) of AKT3; exon (GRCh38 / hg38: chrl9 13236449 13236618) of CACNAl A; exon (GRCh38 / hg38: chr21 43059730 43060012) of CBS; exon (GRCh38 / hg38: chrl 207775610 207775745) of CD46; exon (GRCh38 / hg38: chrl 196675450196675529) of CFH; exon (GRCh38 / hg38: chrl 5 92998149 92998261) of CHD2; exon(GRCh38 / hg38: chrl6 28479644 28479765) of CLN3; exon (GRCh38 / hg38: chr6 33183634 33183698) of COL 11 A2; exon (GRCh38 / hg38: chr2 227296487 227296526) of COL4A3; exon (GRCh38 / hg38: chr2 227144653 227144833) of COL4A4; exon (GRCh38 / hg38: chr2227015283 227015360) of COL4A4; exon (GRCh38 / hg38: chrl 207637688 207637848) of CR1; exon (GRCh38 / hg38: chrl9 47835403 47835579) of CRX; exon (GRCh38 / hg38: chrl 59904366 59904516) of CYP2J2; exon (GRCh38 / hg38: chrl 26442335 26442372) of DHDDS; exon (GRCh38 / hg38: chrl 28230131 28230252 ) of DNAJC8; exon (GRCh38 / hg38: chr2 88582755 88582824) of EIF2AK3; exon (GRCh38 / hg38: chrl7 64102673 64102804) of ERN1; exon (GRCh38 / hg38: chrl 23798311 23798484) of GALE; exon (GRCh38 / hg38: chrX109383365 109383446) of GUCY2F; exon (GRCh38 / hg38: chrX 109439038 109439175) ofGUCY2F; exon (GRCh38 / hg38: chrl5 72362376 72362466) of HEXA; exon (GRCh38 / hg38: chrl5 72345677 72345776) of HEXA; exon (GRCh38 / hg38: chrl6 30115595 30115645) of MAPK3; exon (GRCh38 / hg38: chr2 148460219 148460304) of MBD5; exon (GRCh38 / hg38: chr2 148490695 148490787) of MBD5; exon (GRCh38 / hg38: chr2 148505761 148505830) of MBD5; exon (GRCh38 / hg38: chr6 49436522 49436597) of MUT; exon (GRCh38 / hg38: chrl9 50230825 50230999) of MYH14; exon (GRCh38 / hg38: chr6 75867431 75867523) of MY06; exon (GRCh38 / hg38: chrl7 31249955 31250125) ofNFl; exon (GRCh38 / hg38: chr2229628658 29628773) of NF2; exon (GRCh38 / hg38: chr5 37048127 37048354) ofNIPBL; exon (GRCh38 / hg38: chrl2 100499841 100500024) of NR1H4; exon (GRCh38 / hg38: chr5177169394 177169559) ofNSDl; exon (GRCh38 / hg38: chr5 177200761 177200783) ofNSDl; exon (GRCh38 / hg38: chr5 177247924 177248079) ofNSDl; exon (GRCh38 / hg38: chr5 177275947 177276101) ofNSDl; exon (GRCh38 / hg38: chr3 193628509 193628616) of OPA1; exon (GRCh38 / hg38: chr3 193603500 193603557) of OPA1; exon (GRCh38 / hg38: chrl3 100305751 100305834) of PCCA; exon (GRCh38 / hg38: chrl2 32894516 32894778) of PKP2; exon (GRCh38 / hg38: chr22 46203575 46203752) of PPARA; exon (GRCh38 / hg38: chrl 150327557 150327652) of PRPF3; exon (GRCh38 / hg38: chrl 150330401 150330498) of PRPF3; exon (GRCh38 / hg38: chr2 165327155 165327202) of SCN2A; exon (GRCh38 / hg38: chrl2 51688758 51688849) of SCN8A; exon (GRCh38 / hg38: chrl2 51780202 51780271) of SCN8A; exon (GRCh38 / hg38: chr2 166304238 166304329) of SCN9A; exon (GRCh38 / hg38: chr7 80794854 80794957) of SEMA3C; exon (GRCh38 / hg38: chr7 85059498 85059541) of SEMA3D; exon (GRCh38 / hg38: chrl l 225673 226081) of SIRT3; exon (GRCh38 / hg38: chrl9 1216268 1216398) of STK11; exon (GRCh38 / hg38: chrl9 1221621 1221846) of STK11; exon (GRCh38 / hg38: chr6 33448789 33448868) of SYNGAPl; exon (GRCh38 / hg38: chr932551365 32551469) of TOPORS; exon (GRCh38 / hg38: chr5 83544965 83545070) of VCAN) of the pre-mRNA transcript or to a NIE-activating regulatory sequence in the same intron.

[0161] Where reference is made to reducing NIE inclusion in the mature mRNA, the reduction may be complete, e.g., 100%, or may be partial. The reduction may be clinically significant. The reduction / correction may be relative to the level of NIE inclusion in the subject without treatment, or relative to the amount of NIE inclusion in a population of similar subjects. The reduction / correction may be at least 10% less NIE inclusion relative to the average subject, or the subject prior to treatment. The reduction may be at least 20% less NIE inclusion relative to an average subject, or the subject prior to treatment. The reduction may be at least 40% less NIE inclusion relative to an average subject, or the subject prior to treatment. The reduction may be at least 50% less NIE inclusion relative to an average subject, or the subject prior to treatment. Thereduction may be at least 60% less NIE inclusion relative to an average subject, or the subject prior to treatment. The reduction may be at least 80% less NIE inclusion relative to an average subject, or the subject prior to treatment. The reduction may be at least 90% less NIE inclusion relative to an average subject, or the subject prior to treatment.

[0162] Where reference is made to increasing active ABCB4, ASS1, ATP8B1, BAG3,CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein levels, the increase may be clinically significant. The increase may be relative to the level of active ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein in the subject without treatment, or relative to the amount of active ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKl l, PPARA, CYP2J2, or SYNGAPl protein in a population of similar subjects. The increase may be at least 10% more active ABCB4, ASS1, ATP8B1, BAG3, CACNAl A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A,SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment. The increase may be at least 20% more active ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment. The increase may be at least 40% more active ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1,SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment. The increase may be at least 50% more active ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment. The increase may be at least 80% more active ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSLl, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB,PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment. The increase may be at least 100% more active ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment. The increase may be at least 200% more active ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment The increase may be at least 500% more active ABCB4, ASSl, ATP8B1, BAG3, CACNAIA, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBEl, GRF 2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NFl, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A,SHANK3, SLC25A13, SLC6A1, SPTANl, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D,EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAPl protein relative to the average subject, or the subject prior to treatment.

[0163] In embodiments wherein the NIE repressor agent comprises a polynucleic acid polymer, the polynucleic acid polymer may be about 50 nucleotides in length. The polynucleic acid polymer may be about 45 nucleotides in length. The polynucleic acid polymer may be about 40nucleotides in length. The polynucleic acid polymer may be about 35 nucleotides in length. The polynucleic acid polymer may be about 30 nucleotides in length. The polynucleic acid polymer may be about 24 nucleotides in length. The polynucleic acid polymer may be about 25 nucleotides in length. The polynucleic acid polymer may be about 20 nucleotides in length. The polynucleic acid polymer may be about 19 nucleotides in length. The polynucleic acid polymer may be about 18 nucleotides in length. The polynucleic acid polymer may be about 17 nucleotides in length. The polynucleic acid polymer may be about 16 nucleotides in length. The polynucleic acid polymer may be about 15 nucleotides in length. The polynucleic acid polymer may be about 14 nucleotides in length. The polynucleic acid polymer may be about 13 nucleotides in length. The polynucleic acid polymer may be about 12 nucleotides in length. The polynucleic acid polymer may be about 11 nucleotides in length. The polynucleic acid polymer may be about 10 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 50 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 45 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 40 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 35 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 30 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 25 nucleotides in length. The polynucleic acid polymer may be between about 10 and about 20 nucleotides in length. The polynucleic acid polymer may be between about 15 and about 25 nucleotides in length. The polynucleic acid polymer may be between about 15 and about 30 nucleotides in length. The polynucleic acid polymer may be between about 12 and about 30 nucleotides in length.

[0164] The sequence of the polynucleic acid polymer may be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% complementary to a target sequence of an mRNA transcript, e.g., a partially processed mRNA transcript. The sequence of the polynucleic acid polymer may be 100% complementary to a target sequence of a pre-mRNA transcript.

[0165] The sequence of the polynucleic acid polymer may have 4 or fewer mismatches to a target sequence of the pre-mRNA transcript. The sequence of the polynucleic acid polymer may have 3 or fewer mismatches to a target sequence of the pre-mRNA transcript. The sequence of the polynucleic acid polymer may have 2 or fewer mismatches to a target sequence of the pre- mRNA transcript. The sequence of the polynucleic acid polymer may have 1 or fewer mismatches to a target sequence of the pre-mRNA transcript. The sequence of the polynucleic acid polymer may have no mismatches to a target sequence of the pre-mRNA transcript.

[0166] The polynucleic acid polymer may specifically hybridize to a target sequence of the pre- mRNA transcript. For example, the polynucleic acid polymer may have 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% sequence complementarity to a target sequence of the pre-mRNA transcript. The hybridization may be under high stringent hybridization conditions.

[0167] The polynucleic acid polymer comprising a sequence with at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 60-191. The polynucleic acid polymer may comprise a sequence with 100% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 60-191.

[0168] Where reference is made to a polynucleic acid polymer sequence, the skilled person will understand that one or more substitutions may be tolerated, optionally two substitutions may be tolerated in the sequence, such that it maintains the ability to hybridize to the target sequence; or where the substitution is in a target sequence, the ability to be recognized as the target sequence. References to sequence identity may be determined by BLAST sequence alignment using standard / default parameters. For example, the sequence may have 99% identity and still function according to the present disclosure. In other embodiments, the sequence may have 98% identity and still function according to the present disclosure. In another embodiment, the sequence may have 95%) identity and still function according to the present disclosure. In another embodiment, the sequence may have 90% identity and still function according to the present disclosure.Antisense Oligomers

[0169] Provided herein is a composition comprising an antisense oligomer that induces exon skipping by binding to a targeted portion oi aABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA. As used herein, the terms "ASO" and "antisense oligomer" are used interchangeably and refer to an oligomer such as a polynucleotide, comprising nucleobases that hybridizes to a target nucleic acid (e.g., a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE,GBE1, GRIN2A, GRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, Mil, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SIC25A13, SIC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COI11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERNl, GUCY2F, SIRT3, NR1H4, STKll, PPARA, CYP2J2, or SYNGAP1 E containing pre-mRNA) sequence by Watson-Crick base pairing or wobble base pairing (G-U). The ASO may have exact sequence complementary to the target sequence or near complementarity (e.g., sufficient complementarity to bind the target sequence and enhancing splicing at a splice site). ASOs are designed so that they bind (hybridize) to a target nucleic acid (e.g., a targeted portion of a pre-mRNA transcript) and remain hybridized under physiological conditions. Typically, if they hybridize to a site other than the intended (targeted) nucleic acid sequence, they hybridize to a limited number of sequences that are not a target nucleic acid (to a few sites other than a target nucleic acid). Design of an ASO can take into consideration the occurrence of the nucleic acid sequence of the targeted portion of the pre- mRNA transcript or a sufficiently similar nucleic acid sequence in other locations in the genome or cellular pre-mRNA or transcriptome, such that the likelihood the ASO will bind other sites and cause "off-target" effects is limited. Any antisense oligomers known in the art, for example in PCT Application No. PCT / US2014 / 054151, published as WO 2015 / 035091, titled "Reducing Nonsense-Mediated mRNA Decay," incorporated by reference herein, can be used to practice the methods described herein.

[0170] In some embodiments, ASOs "specifically hybridize" to or are "specific" to a target nucleic acid or a targeted portion of a NIE containing pre-mRNA. Typically such hybridization occurs with a Tmsubstantially greater than 37 °C, preferably at least 50 °C, and typically between 60 °C to approximately 90 °C. Such hybridization preferably corresponds to stringent hybridization conditions. At a given ionic strength and pH, the Tmis the temperature at which 50% of a target sequence hybridizes to a complementary oligonucleotide.

[0171] Oligomers, such as oligonucleotides, are "complementary" to one another when hybridization occurs in an antiparallel configuration between two single-strandedpolynucleotides. A double-stranded polynucleotide can be "complementary" to another polynucleotide, if hybridization can occur between one of the strands of the first polynucleotide and the second. Complementarity (the degree to which one polynucleotide is complementary with another) is quantifiable in terms of the proportion (e.g., the percentage) of bases in opposing strands that are expected to form hydrogen bonds with each other, according to generally accepted base-pairing rules. The sequence of an antisense oligomer (ASO) need not be 100%complementary to that of its target nucleic acid to hybridize. In certain embodiments, ASOs can comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%), at least 97%, at least 98%, or at least 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an ASO in which 18 of 20 nucleobases of the oligomeric compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining non-complementary nucleobases may be clustered together or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. Percent complementarity of an ASO with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul, et al, J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656).

[0172] An ASO need not hybridize to all nucleobases in a target sequence and the nucleobases to which it does hybridize may be contiguous or noncontiguous. ASOs may hybridize over one or more segments of a pre-mRNA transcript, such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure may be formed). In certain embodiments, an ASO hybridizes to noncontiguous nucleobases in a target pre-mRNA transcript. For example, an ASO can hybridize to nucleobases in a pre-mRNA transcript that are separated by one or more nucleobase(s) to which the ASO does not hybridize.

[0173] The ASOs described herein comprise nucleobases that are complementary tonucleobases present in a target portion of a NIE containing pre-mRNA. The term ASO embodies oligonucleotides and any other oligomeric molecule that comprises nucleobases capable of hybridizing to a complementary nucleobase on a target mRNA but does not comprise a sugar moiety, such as a peptide nucleic acid (PNA). The ASOs may comprise naturally-occurring nucleotides, nucleotide analogs, modified nucleotides, or any combination of two or three of the preceding. The term "naturally occurring nucleotides" includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" includes nucleotides with modified or substituted sugar groups and / or having a modified backbone. In some embodiments, all of the nucleotides of the ASO are modified nucleotides. Chemical modifications of ASOs or components of ASOs that are compatible with the methods and compositions described herein will be evident to one of skill in the art and can be found, for example, in U.S. Patent No.8,258, 109 B2, U.S. Patent No. 5,656,612, U.S. Patent Publication No. 2012 / 0190728, and Dias and Stein, Mol. Cancer Ther. 2002, 347-355, herein incorporated by reference in their entirety.

[0174] One or more nucleobases of an ASO may be any naturally occurring, unmodified nucleobase such as adenine, guanine, cytosine, thymine and uracil, or any synthetic or modified nucleobase that is sufficiently similar to an unmodified nucleobase such that it is capable of hydrogen bonding with a nucleobase present on a target pre-mRNA. Examples of modified nucleobases include, without limitation, hypoxanthine, xanthine, 7-methylguanine, 5, 6- dihydrouracil, 5-methylcytosine, and 5-hydroxymethoyl cytosine.

[0175] The ASOs described herein also comprise a backbone structure that connects the components of an oligomer. The term "backbone structure" and "oligomer linkages" may be used interchangeably and refer to the connection between monomers of the ASO. In naturally occurring oligonucleotides, the backbone comprises a 3'-5' phosphodiester linkage connecting sugar moieties of the oligomer. The backbone structure or oligomer linkages of the ASOs described herein may include (but are not limited to) phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoramidate, and the like. See, e.g., LaPlanche, et a / ., Nucleic Acids Res. 14:9081 (1986); Stec, et a / ., J. Am. Chem. Soc. 106:6077 (1984), Stein, et a / ., Nucleic Acids Res. 16:3209 (1988), Zon, et a / ., Anti-Cancer Drug Design 6:539 (1991); Zon, et a / ., Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec, et a / ., U.S. Pat. No. 5, 151,510; Uhlmann and Peyman, Chemical Reviews 90:543 (1990). In some embodiments, the backbone structure of the ASO does not contain phosphorous but rather contains peptide bonds, for example in a peptide nucleic acid (PNA), or linking groups including carbamate, amides, and linear and cyclic hydrocarbon groups. In some embodiments, the backbone modification is a phosphothioate linkage. In some embodiments, the backbone modification is a phosphoramidate linkage.

[0176] In some embodiments, the stereochemistry at each of the phosphorus internucleotide linkages of the ASO backbone is random. In some embodiments, the stereochemistry at each of the phosphorus internucleotide linkages of the ASO backbone is controlled and is not random. For example, U.S. Pat. App. Pub. No. 2014 / 0194610, "Methods for the Synthesis ofFunctionalized Nucleic Acids," incorporated herein by reference, describes methods for independently selecting the handedness of chirality at each phosphorous atom in a nucleic acid oligomer. In some embodiments, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in Tables 5 and 6, comprises an ASO having phosphorus internucleotide linkages that are not random. In some embodiments, a composition used in the methods of the disclosure comprises a pure diastereomeric ASO. In someembodiments, a composition used in the methods of the disclosure comprises an ASO that hasdiastereomeric purity of at least about 90%, at least about 91%, at least about 92%, at least about 93%), at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, about 100%, about 90% to about 100%, about 91% to about 100%, about 92% to about 100%, about 93% to about 100%, about 94% to about 100%, about 95% to about 100%, about 96% to about 100%, about 97% to about 100%, about 98% to about 100% , or about 99% to about 100%.

[0177] In some embodiments, the ASO has a nonrandom mixture of Rp and Sp configurations at its phosphorus internucleotide linkages. For example, it has been suggested that a mix of Rp and Sp is required in antisense oligonucleotides to achieve a balance between good activity and nuclease stability (Wan, et al., 2014, "Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages," Nucleic Acids Research 42(22): 13456-13468, incorporated herein by reference). In some embodiments, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein in SEQ ID NOs: 60-191, comprises about 5-100%> Rp, at least about 5%> Rp, at least about 10% Rp, at least about 15% Rp, at least about 20% Rp, at least about 25% Rp, at least about 30% Rp, at least about 35% Rp, at least about 40% Rp, at least about 45% Rp, at least about 50% Rp, at least about 55% Rp, at least about 60% Rp, at least about 65% Rp, at least about 70% Rp, at least about 75% Rp, at least about 80% Rp, at least about 85% Rp, at least about 90% Rp, or at least about 95% Rp, with the remainder Sp, or about 100% Rp. In some embodiments, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein comprise a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100%) sequence identity to a region comprising at least 8 contiguous nucleic acids of any one of SEQ ID NOs: 60-191, comprises about 10% to about 100% Rp, about 15% to about 100% Rp, about 20% to about 100% Rp, about 25% to about 100% Rp, about 30% to about 100% Rp, about 35% to about 100% Rp, about 40% to about 100% Rp, about 45% to about 100% Rp, about 50% to about 100% Rp, about 55% to about 100% Rp, about 60% to about 100% Rp, about 65% to about 100% Rp, about 70% to about 100% Rp, about 75% to about 100% Rp, about 80% to about 100% Rp, about 85% to about 100% Rp, about 90% to about 100% Rp, or about 95% to about 100% Rp, about 20% to about 80% Rp, about 25% to about 75% Rp, about 30% to about 70% Rp, about 40% to about 60% Rp, or about 45% to about 55% Rp, with the remainder Sp.

[0178] In some embodiments, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein comprise a sequence with at least about 80%, 85%, 90%), 95%), 97%), or 100% sequence identity to a region comprising at least 8 contiguous nucleicacids of any one of SEQ ID NOs: 60-191, comprises about 5-100% Sp, at least about 5% Sp, at least about 10% Sp, at least about 15% Sp, at least about 20% Sp, at least about 25% Sp, at least about 30%) Sp, at least about 35% Sp, at least about 40% Sp, at least about 45% Sp, at least about 50%) Sp, at least about 55% Sp, at least about 60% Sp, at least about 65% Sp, at least about 70% Sp, at least about 75% Sp, at least about 80% Sp, at least about 85% Sp, at least about 90% Sp, or at least about 95% Sp, with the remainder Rp, or about 100% Sp. In embodiments, an ASO used in the methods of the disclosure, including, but not limited to, any of the ASOs set forth herein comprise a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of any one of SEQ ID NOs: 60-191, comprises about 10% to about 100% Sp, about 15% to about 100% Sp, about 20% to about 100% Sp, about 25% to about 100% Sp, about 30% to about 100% Sp, about 35% to about 100% Sp, about 40% to about 100% Sp, about 45% to about 100% Sp, about 50% to about 100% Sp, about 55% to about 100% Sp, about 60% to about 100% Sp, about 65% to about 100% Sp, about 70% to about 100% Sp, about 75% to about 100% Sp, about 80% to about 100% Sp, about 85% to about 100% Sp, about 90% to about 100% Sp, or about 95% to about 100% Sp, about 20% to about 80% Sp, about 25% to about 75% Sp, about 30% to about 70% Sp, about 40% to about 60%) Sp, or about 45% to about 55% Sp, with the remainder Rp.

[0179] Any of the ASOs described herein may contain a sugar moiety that comprises ribose or deoxyribose, as present in naturally occurring nucleotides, or a modified sugar moiety or sugar analog, including a morpholine ring. Non-limiting examples of modified sugar moieties include 2' substitutions such as 2'-0-methyl (2'-0-Me), 2'-0-methoxyethyl (2'MOE), 2'-0-aminoethyl, 2'F; N3'->P5' phosphoramidate, 2'dimethylaminooxyethoxy, 2'dimethylaminoethoxyethoxy, 2'-guanidinidium, 2'-0-guanidinium ethyl, carbamate modified sugars, and bicyclic modified sugars. In some embodiments, the sugar moiety modification is selected from 2'-0-Me, 2'F, and 2'MOE. In some embodiments, the sugar moiety modification is an extra bridge bond, such as in a locked nucleic acid (LNA). In some embodiments the sugar analog contains a morpholine ring, such as phosphorodiamidate morpholino (PMO). In some embodiments, the sugar moiety comprises a ribofuransyl or 2'deoxyribofuransyl modification. In some embodiments, the sugar moiety comprises 2'4' -constrained 2'O-methyloxyethyl (cMOE) modifications. In some embodiments, the sugar moiety comprises cEt 2', 4' constrained 2'-0 ethyl BNA modifications. In some embodiments, the sugar moiety comprises tricycloDNA (tcDNA) modifications. In some embodiments, the sugar moiety comprises ethylene nucleic acid (ENA) modifications. In some embodiments, the sugar moiety comprises MCE modifications. Modifications are known in the art and described in the literature, e.g., by Jarver, et al., 2014, "A Chemical View ofOligonucleotides for Exon Skipping and Related Drug Applications," Nucleic Acid Therapeutics 24(1): 37-47, incorporated by reference for this purpose herein.

[0180] In some embodiments, each monomer of the ASO is modified in the same way, for example each linkage of the backbone of the ASO comprises a phosphorothioate linkage or each ribose sugar moiety comprises a 2'O-methyl modification. Such modifications that are present on each of the monomer components of an ASO are referred to as "uniform modifications." In some examples, a combination of different modifications may be desired, for example, an ASO may comprise a combination of phosphorodiamidate linkages and sugar moieties comprising morpholine rings (morpholinos). Combinations of different modifications to an ASO are referred to as "mixed modifications" or "mixed chemistries."

[0181] In some embodiments, the ASO comprises one or more backbone modifications. In some embodiments, the ASO comprises one or more sugar moiety modification. In some embodiments, the ASO comprises one or more backbone modifications and one or more sugar moiety modifications. In some embodiments, the ASO comprises a 2'MOE modification and a phosphorothioate backbone. In some embodiments, the ASO comprises a phosphorodiamidate morpholino (PMO). In some embodiments, the ASO comprises a peptide nucleic acid (PNA). Any of the ASOs or any component of an ASO (e.g., a nucleobase, sugar moiety, backbone) described herein may be modified in order to achieve desired properties or activities of the ASO or reduce undesired properties or activities of the ASO. For example, an ASO or one or more components of any ASO may be modified to enhance binding affinity to a target sequence on a pre-mRNA transcript; reduce binding to any non-target sequence; reduce degradation by cellular nucleases (i.e., RNase H); improve uptake of the ASO into a cell and / or into the nucleus of a cell; alter the pharmacokinetics or pharmacodynamics of the ASO; and / or modulate the half-life of the ASO.

[0182] In some embodiments, the ASOs are comprised of 2'-0-(2-methoxyethyl) (MOE) phosphorothioate-modified nucleotides. ASOs comprised of such nucleotides are especially well-suited to the methods disclosed herein; oligomers having such modifications have been shown to have significantly enhanced resistance to nuclease degradation and increased bioavailability, making them suitable, for example, for oral delivery in some embodiments described herein. See e.g., Geary, et al, J Pharmacol Exp Ther. 2001; 296(3):890-7; Geary, et al, J Pharmacol Exp Ther. 2001; 296(3):898-904.

[0183] Methods of synthesizing ASOs will be known to one of skill in the art. Alternatively or in addition, ASOs may be obtained from a commercial source.

[0184] Unless specified otherwise, the left-hand end of single- stranded nucleic acid (e.g., pre- mRNA transcript, oligonucleotide, ASO, etc.) sequences is the 5' end and the left-hand direction of single or double-stranded nucleic acid sequences is referred to as the 5' direction. Similarly, the right-hand end or direction of a nucleic acid sequence (single or double stranded) is the 3' end or direction. Generally, a region or sequence that is 5' to a reference point in a nucleic acid is referred to as "upstream," and a region or sequence that is 3' to a reference point in a nucleic acid is referred to as "downstream." Generally, the 5' direction or end of an mRNA is where the initiation or start codon is located, while the 3' end or direction is where the termination codon is located. In some aspects, nucleotides that are upstream of a reference point in a nucleic acid may be designated by a negative number, while nucleotides that are downstream of a reference point may be designated by a positive number. For example, a reference point (e.g., an exon-exon junction in mRNA) may be designated as the "zero" site, and a nucleotide that is directly adjacent and upstream of the reference point is designated "minus one," e.g., while a nucleotide that is directly adjacent and downstream of the reference point is designated "plus one,"

[0185] In some embodiments, the ASOs are complementary to (and bind to) a targeted portion of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA that is downstream (in the 3' direction) of the 5' splice site (or 3' end of the NIE) of the included exon in a ABCB4, ASSJ, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRIN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NIPBL, NSD1, OPA1, OPTN, PCCA, PCCB, PKP2, PLCB1, PRPF3, PRPF31, RAI1, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, EIF2AK3, ERN1, GUCY2F, SIRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA (e.g., the direction designated by positive numbers relative to the 5' splice site). In some embodiments, the ASOs are complementary to a targeted portion of the ABCB4, ASS1, ATP8B1, BAG3,CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CISD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRLN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NLPBL, NSDl, OPA1, OPTN, PCCA, PCCB, PKP2, PLCBl, PRPF3, PRPF31, PALI, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, ELF2AK3, ERN1, GUCY2F, SLRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA that is within the region about +1 to about +500 relative to the 5' splice site (or 3' end) of the included exon. In some embodiments, the ASOs may be complementary to a targeted portion of a ABCB4, ASS1, ATP8B1, BAG3, CACNA1A, CBS, CD55, CDKL5, CFH, CHD2, CHRNA 7, CLSD2, CLN3, COL4A3, COL4A4, DEPDC5, DHDDS, ELOVL4, FAH, FXN, GALE, GBE1, GRLN2A, CRN, HEXA, KANSL1, KCNQ2, KMT2D, MAPK3, MBD5, MECP2, MUT, NF1, NLPBL, NSDl, OPA1, OPTN, PCCA, PCCB, PKP2, PLCBl, PRPF3, PRPF31, PALI, RBFOX2, SCN2A, SCN3A, SCN8A, SCN9A, SHANK3, SLC25A13, SLC6A1, SPTAN1, TEK, TOPORS, TSC2, UBE3A, VCAN, AKT3, CD46, COL11A2, CR1, CRX, DNAJC8, MYH14, MY06, NF2, SEMA3C, SEMA3D, ELF2AK3, ERN1, GUCY2F, SLRT3, NR1H4, STK11, PPARA, CYP2J2, or SYNGAP1 NIE containing pre-mRNA that is within the region between nucleotides +6 and +40,000 relative to the 5' splice site (or 3' end) of the included exon. In some aspects, the ASOs are complementary to a targeted portion that is within the region about +1 to about +40,000, about +1 to about +30,000, about +1 to about +20,000, about +1 to about +15,000, about +1 to about +10,000, about +1 to about +5,000, about +1 to about +4,000, about +1 to about +3,000, about +1 to about +2,000, about +1 to about +1,000, about +1 to about +500, about +1 to about +490, about +1 to about +480, about +1 to about +470, about +1 to about +460, about +1 to about +450, about +1 to about +440, about +1 to about +430, about +1 to about +420, about +1 to about +410, about +1 to about +400, about +1 to about +390, about +1 to about +380, about +1 to about +370, about +1 to about +360, about +1 to...

Claims

CLAIMSWhat is claimed is:

1. A method of modulating expression of a target protein, by a cell having an mRNA that comprises a non-sense mediated RNA decay-inducing exon (NMD exon) and encodes the target protein, the method comprising contacting a therapeutic agent to the cell, whereby the therapeutic agent modulates splicing of the NMD exon from the mRNA, thereby modulating level of processed mRNA encoding the target protein, and modulating the expression of the target protein in the cell, wherein the target protein is selected from the group consisting of: AKT3, CACNA1A, CBS, CD46, CFH, CHD2, CLN3, COL11A2, COL4A3, COL4A4, COL4A4, CRl, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERNl, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NF1, NF2, NIPBL, NR1H4, NSD 1, NSD1, NSD 1, NSD1, OPA1, OPA1, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAP1, TOPORS, and VCAN proteins.

2. A method of treating a disease or condition in a subject in need thereof by modulating expression of a target protein in a cell of the subject, comprising: contacting the cell of the subject with a therapeutic agent that modulates splicing of a non-sense mediated mRNA decay-inducing exon (NMD exon) from an mRNA in the cell, wherein the mRNA comprises the NMD exon and encodes the target protein, thereby modulating level of processed mRNA encoding the target protein, and modulating expression of the target protein in the cell of the subject, wherein the target protein is selected from the group consisting of: AKT3, CACNA1A, CBS, CD46, CFH, CHD2, CLN3, COL1 1A2, COL4A3, COL4A4, COL4A4, CRl, CRX, CYP2J2, DHDDS, DNAJC8, EIF2AK3, ERNl, GALE, GUCY2F, GUCY2F, HEXA, HEXA, MAPK3, MBD5, MBD5, MBD5, MUT, MYH14, MY06, NF1, NF2, NIPBL, NR1H4, NSD1, NSD1, NSD1, NSD1, OPA1, OPA1, PCCA, PKP2, PPARA, PRPF3, PRPF3, SCN2A, SCN8A, SCN8A, SCN9A, SEMA3C, SEMA3D, SIRT3, STK11, STK11, SYNGAP1, TOPORS, and VCAN proteins.

3. The method of claim 1 or 2, wherein the therapeutic agent(a) binds to a targeted portion of the mRNA encoding the target protein;(b) modulates binding of a factor involved in splicing of the NMD exon; or(c) a combination of (a) and (b).

4. The method of claim 3, wherein the therapeutic agent interferes with binding of the factor involved in splicing of the NMD exon to a region of the targeted portion.

5. The method of claim 3, wherein the targeted portion is proximal to the NMD exon.

6. The method of claim 5, wherein the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream of 5' end of the NMD exon.

7. The method of claim 5, wherein the targeted portion is at least about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides, about 40 nucleotides, about 30 nucleotides, about 20 nucleotides, about 10 nucleotides, about 5 nucleotides, about 4 nucleotides, about 2 nucleotides, about 1 nucleotides upstream of 5' end of the NMD exon.

8. The method of claim 5, wherein the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream of 3' end of the NMD exon.

9. The method of claim 5, wherein the targeted portion is at least about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides, about 40 nucleotides, about 30 nucleotides, about 20 nucleotides, about 10 nucleotides, about 5 nucleotides, about 4 nucleotides, about 2 nucleotides, about 1 nucleotides downstream of 3' end of the NMD exon.

10. The method of claim 5, wherein the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564388; GRCh38 / hg38: chrl9 13236618; GRCh38 / hg38: chr21 43060012; GRCh38 / hg38: chrl 207775610; GRCh38 / hg38: chrl 196675450; GRCh38 / hg38: chrl5 92998149; GRCh38 / hg38: chrl6 28479765; GRCh38 / hg38: chr6 33183698; GRCh38 / hg38: chr2 227296487; GRCh38 / hg38: chr2 227144833; GRCh38 / hg38: chr2 227015360; GRCh38 / hg38: chrl 207637688; GRCh38 / hg38: chrl9 47835403;GRCh38 / hg38: chrl 59904516; GRCh38 / hg38: chrl 26442335; GRCh38 / hg38: chrl 28230252; GRCh38 / hg38: chr288582824; GRCh38 / hg38: chrl764102804; GRCh38 / hg38: chrl 23798484; GRCh38 / hg38: chrX 109383446; GRCh38 / hg38: chrX 109439175; GRCh38 / hg38: chrl572362466; GRCh38 / hg38: chrl572345776; GRCh38 / hg38: chrl630115645; GRCh38 / hg38: chr2148460219; GRCh38 / hg38: chr2148490695; GRCh38 / hg38: chr2148505761; GRCh38 / hg38: chr649436597; GRCh38 / hg38: chrl950230825; GRCh38 / hg38: chr675867431; GRCh38 / hg38: chrl731249955; GRCh38 / hg38: chr2229628658; GRCh38 / hg38: chr537048127; GRCh38 / hg38: chrl2100499841; GRCh38 / hg38: chr5177169394; GRCh38 / hg38: chr5177200761; GRCh38 / hg38: chr5177247924; GRCh38 / hg38: chr5177275947; GRCh38 / hg38: chr3193628509; GRCh38 / hg38: chr3193603500; GRCh38 / hg38: chrl3100305751; GRCh38 / hg38: chrl232894778; GRCh38 / hg38: chr2246203575; GRCh38 / hg38: chrl 150327557; GRCh38 / hg38: chrl 150330401; GRCh38 / hg38: chr2165327155; GRCh38 / hg38: chrl251688758; GRCh38 / hg38: chrl251780202; GRCh38 / hg38: chr2166304329; GRCh38 / hg38: chr780794957; GRCh38 / hg38: chr785059541; GRCh38 / hg38: chrll 226081; GRCh38 / hg38: chrl91216268; GRCh38 / hg38: chrl91221621; GRCh38 / hg38: chr633448789; GRCh38 / hg38: chr932551469; and GRCh38 / hg38: chr583544965.

11. The method of claim 5, wherein the targeted portion is about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides upstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564388; GRCh38 / hg38: chrl913236618; GRCh38 / hg38: chr2143060012; GRCh38 / hg38: chrl 207775610; GRCh38 / hg38: chrl 196675450; GRCh38 / hg38: chrl592998149; GRCh38 / hg38: chrl628479765; GRCh38 / hg38: chr633183698; GRCh38 / hg38: chr2227296487; GRCh38 / hg38: chr2227144833; GRCh38 / hg38: chr2227015360; GRCh38 / hg38: chrl 207637688; GRCh38 / hg38: chrl947835403; GRCh38 / hg38: chrl 59904516; GRCh38 / hg38: chrl 26442335; GRCh38 / hg38: chrl 28230252; GRCh38 / hg38: chr288582824; GRCh38 / hg38: chrl764102804; GRCh38 / hg38: chrl 23798484; GRCh38 / hg38: chrX 109383446; GRCh38 / hg38: chrX 109439175; GRCh38 / hg38: chrl572362466; GRCh38 / hg38: chrl572345776; GRCh38 / hg38: chrl630115645; GRCh38 / hg38: chr2148460219; GRCh38 / hg38: chr2148490695; GRCh38 / hg38: chr2148505761; GRCh38 / hg38: chr649436597; GRCh38 / hg38: chrl950230825; GRCh38 / hg38: chr675867431; GRCh38 / hg38: chrl731249955; GRCh38 / hg38: chr2229628658; GRCh38 / hg38: chr537048127; GRCh38 / hg38: chrl2100499841; GRCh38 / hg38: chr5177169394; GRCh38 / hg38: chr5177200761; GRCh38 / hg38: chr5177247924; GRCh38 / hg38: chr5177275947; GRCh38 / hg38: chr3193628509; GRCh38 / hg38: chr3193603500; GRCh38 / hg38: chrl3100305751; GRCh38 / hg38: chrl232894778; GRCh38 / hg38: chr2246203575; GRCh38 / hg38: chrl 150327557; GRCh38 / hg38: chrl 150330401; GRCh38 / hg38: chr2165327155; GRCh38 / hg38: chrl251688758; GRCh38 / hg38: chrl251780202; GRCh38 / hg38: chr2166304329;GRCh38 / hg38: chr780794957; GRCh38 / hg38: chr785059541; GRCh38 / hg38: chrll 226081; GRCh38 / hg38: chrl91216268; GRCh38 / hg38: chrl91221621; GRCh38 / hg38: chr633448789; GRCh38 / hg38: chr932551469; and GRCh38 / hg38: chr583544965.

12. The method of claim 5, wherein the targeted portion is at most about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564285; GRCh38 / hg38: chrl913236449; GRCh38 / hg38: chr2143059730; GRCh38 / hg38: chrl 207775745; GRCh38 / hg38: chrl 196675529; GRCh38 / hg38: chrl592998261; GRCh38 / hg38: chrl628479644; GRCh38 / hg38: chr633183634; GRCh38 / hg38: chr2227296526; GRCh38 / hg38: chr2227144653; GRCh38 / hg38: chr2227015283; GRCh38 / hg38: chrl 207637848; GRCh38 / hg38: chrl947835579; GRCh38 / hg38: chrl 59904366; GRCh38 / hg38: chrl 26442372; GRCh38 / hg38: chrl 28230131; GRCh38 / hg38: chr288582755; GRCh38 / hg38: chrl764102673; GRCh38 / hg38: chrl 23798311; GRCh38 / hg38: chrX 109383365; GRCh38 / hg38: chrX 109439038; GRCh38 / hg38: chrl572362376; GRCh38 / hg38: chrl572345677; GRCh38 / hg38: chrl630115595; GRCh38 / hg38: chr2148460304; GRCh38 / hg38: chr2148490787; GRCh38 / hg38: chr2148505830; GRCh38 / hg38: chr649436522; GRCh38 / hg38: chrl950230999; GRCh38 / hg38: chr675867523; GRCh38 / hg38: chrl731250125; GRCh38 / hg38: chr2229628773; GRCh38 / hg38: chr537048354; GRCh38 / hg38: chrl2100500024; GRCh38 / hg38: chr5177169559; GRCh38 / hg38: chr5177200783; GRCh38 / hg38: chr5177248079; GRCh38 / hg38: chr5177276101; GRCh38 / hg38: chr3193628616; GRCh38 / hg38: chr3193603557; GRCh38 / hg38: chrl3100305834; GRCh38 / hg38: chrl232894516; GRCh38 / hg38: chr2246203752; GRCh38 / hg38: chrl 150327652; GRCh38 / hg38: chrl 150330498; GRCh38 / hg38: chr2165327202; GRCh38 / hg38: chrl251688849; GRCh38 / hg38: chrl251780271; GRCh38 / hg38: chr2166304238; GRCh38 / hg38: chr780794854; GRCh38 / hg38: chr785059498; GRCh38 / hg38: chrll 225673; GRCh38 / hg38: chrl91216398; GRCh38 / hg38: chrl91221846; GRCh38 / hg38: chr633448868; GRCh38 / hg38: chr932551365; and GRCh38 / hg38: chr583545070.

13. The method of claim 5, wherein the targeted portion is about 1500 nucleotides, about 1000 nucleotides, about 800 nucleotides, about 700 nucleotides, about 600 nucleotides, about 500 nucleotides, about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, about 100 nucleotides, about 80 nucleotides, about 70 nucleotides, about 60 nucleotides, about 50 nucleotides downstream of genomic site selected from the group consisting of: GRCh38 / hg38: chrl 243564285; GRCh38 / hg38: chrl913236449; GRCh38 / hg38: chr2143059730; GRCh38 / hg38: chrl 207775745; GRCh38 / hg38: chrl 196675529; GRCh38 / hg38: chrl592998261; GRCh38 / hg38: chrl628479644; GRCh38 / hg38: chr633183634; GRCh38 / hg38: chr2227296526; GRCh38 / hg38: chr2227144653;GRCh38 / hg38: chr2227015283; GRCh38 / hg38: chrl 207637848; GRCh38 / hg38: chrl947835579; GRCh38 / hg38: chrl 59904366; GRCh38 / hg38: chrl 26442372; GRCh38 / hg38: chrl 28230131; GRCh38 / hg38: chr288582755; GRCh38 / hg38: chrl764102673; GRCh38 / hg38: chrl 23798311; GRCh38 / hg38: chrX 109383365; GRCh38 / hg38: chrX 109439038; GRCh38 / hg38: chrl572362376; GRCh38 / hg38: chrl572345677; GRCh38 / hg38: chrl630115595; GRCh38 / hg38: chr2148460304; GRCh38 / hg38: chr2148490787; GRCh38 / hg38: chr2148505830; GRCh38 / hg38: chr649436522; GRCh38 / hg38: chrl950230999; GRCh38 / hg38: chr675867523; GRCh38 / hg38: chrl731250125; GRCh38 / hg38: chr2229628773; GRCh38 / hg38: chr537048354; GRCh38 / hg38: chrl2100500024; GRCh38 / hg38: chr5177169559; GRCh38 / hg38: chr5177200783; GRCh38 / hg38: chr5177248079; GRCh38 / hg38: chr5177276101; GRCh38 / hg38: chr3193628616; GRCh38 / hg38: chr3193603557; GRCh38 / hg38: chrl3100305834; GRCh38 / hg38: chrl232894516; GRCh38 / hg38: chr2246203752; GRCh38 / hg38: chrl 150327652; GRCh38 / hg38: chrl 150330498; GRCh38 / hg38: chr2165327202; GRCh38 / hg38: chrl251688849; GRCh38 / hg38: chrl251780271; GRCh38 / hg38: chr2166304238; GRCh38 / hg38: chr780794854; GRCh38 / hg38: chr785059498; GRCh38 / hg38: chrll 225673; GRCh38 / hg38: chrl91216398; GRCh38 / hg38: chrl91221846; GRCh38 / hg38: chr633448868; GRCh38 / hg38: chr932551365; and GRCh38 / hg38: chr583545070.

14. The method of claim 3, wherein the targeted portion is located in an intronic region between two canonical exonic regions of the mRNA encoding the target protein, and wherein the intronic region contains the NMD exon.

15. The method of claim 3, wherein the targeted portion at least partially overlaps with the NMD exon.

16. The method of claim 3, wherein the targeted portion at least partially overlaps with an intron upstream or downstream of the NMD exon.

17. The method of claim 3, wherein the targeted portion comprises 5' NMD exon-intron junction or 3' NMD exon-intron junction.

18. The method of claim 3, wherein the targeted portion is within the NMD exon.

19. The method of claim 3, wherein the targeted portion comprises about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more consecutive nucleotides of the NMD exon.

20. The method of claim 1 or 2, wherein the mRNA encoding the target protein comprises a sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 135-191 .

21. The method of claim 1 or 2, wherein the mRNA encoding the target protein is encoded by a genetic sequence with at least about 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1-5, 12, 19-21, 25, 26, 28, 30, 33, 35, 38, 40, 41, 44, 45, 51, 53, 55-57, and 192-211.

22. The method of claim 3, wherein the targeted portion of the mRNA comprises a sequence with at least 80%, 85%, 90%, 95%, 97%, or 100% sequence identity to a region comprising at least 8 contiguous nucleic acids of a sequence selected from the group consisting of SEQ ID NOs: 135-191 .

23. The method of claim 1 or 2, wherein the agent is an antisense oligomer (ASO) and wherein the ASO comprises a sequence that is at least about 80%, 85%, 90%, 95%, 97%, or 100% complementary to at least 8 contiguous nucleic acids of a sequence selected from the group consisting of SEQ ID NOs: 135-191.

24. The method of claim 3, wherein the targeted portion of the mRNA is within the non-sense mediated RNA decay-inducing exon selected from the group consisting of: GRCh38 / hg38: chrl 243564285 243564388 ; GRCh38 / hg38: chrl9 13236449 13236618; GRCh38 / hg38: chr21 43059730 43060012; GRCh38 / hg38: chrl 207775610 207775745; GRCh38 / hg38: chrl 196675450 196675529; GRCh38 / hg38: chrl5 92998149 92998261; GRCh38 / hg38: chrl6 28479644 28479765; GRCh38 / hg38: chr6 33183634 33183698; GRCh38 / hg38: chr2 227296487 227296526; GRCh38 / hg38: chr2 227144653 227144833; GRCh38 / hg38: chr2 227015283 227015360; GRCh38 / hg38: chrl 207637688 207637848; GRCh38 / hg38: chrl9 47835403 47835579; GRCh38 / hg38: chrl 59904366 59904516; GRCh38 / hg38: chrl 26442335 26442372; GRCh38 / hg38: chrl 28230131 28230252 ; GRCh38 / hg38: chr2 88582755 88582824; GRCh38 / hg38: chrl7 64102673 64102804; GRCh38 / hg38: chrl 23798311 23798484; GRCh38 / hg38: chrX 109383365 109383446; GRCh38 / hg38: chrX 109439038 109439175; GRCh38 / hg38: chrl5 72362376 72362466; GRCh38 / hg38: chrl5 72345677 72345776; GRCh38 / hg38: chrl6 30115595 30115645; GRCh38 / hg38: chr2 148460219 148460304; GRCh38 / hg38: chr2 148490695 148490787; GRCh38 / hg38: chr2 148505761 148505830; GRCh38 / hg38: chr6 49436522 49436597; GRCh38 / hg38: chrl9 50230825 50230999; GRCh38 / hg38: chr6 75867431 75867523; GRCh38 / hg38: chrl7 31249955 31250125; GRCh38 / hg38: chr22 29628658 29628773; GRCh38 / hg38: chr5 37048127 37048354; GRCh38 / hg38: chrl2 100499841 100500024; GRCh38 / hg38: chr5 177169394 177169559; GRCh38 / hg38: chr5 177200761 177200783; GRCh38 / hg38: chr5 177247924 177248079; GRCh38 / hg38: chr5 177275947 177276101; GRCh38 / hg38: chr3 193628509 193628616;GRCh38 / hg38: chr3193603500193603557; GRCh38 / hg38: chrl3100305751100305834; GRCh38 / hg38: chrl23289451632894778; GRCh38 / hg38: chr224620357546203752; GRCh38 / hg38: chrl 150327557150327652; GRCh38 / hg38: chrl 150330401150330498; GRCh38 / hg38: chr2165327155 165327202; GRCh38 / hg38: chrl25168875851688849; GRCh38 / hg38: chrl25178020251780271; GRCh38 / hg38: chr2166304238166304329; GRCh38 / hg38: chr78079485480794957; GRCh38 / hg38: chr78505949885059541; GRCh38 / hg38: chrll 225673226081; GRCh38 / hg38: chrl912162681216398; GRCh38 / hg38: chrl912216211221846; GRCh38 / hg38: chr63344878933448868; GRCh38 / hg38: chr93255136532551469; and GRCh38 / hg38: chr58354496583545070.

25. The method of claim 3, wherein the targeted portion of the mRNA is upstream or downstream of the non-sense mediated RNA decay-inducing exon selected from the group consisting of: GRCh38 / hg38: chrl 243564285243564388 ; GRCh38 / hg38: chrl91323644913236618; GRCh38 / hg38: chr21 4305973043060012; GRCh38 / hg38: chrl 207775610207775745; GRCh38 / hg38: chrl 196675450 196675529; GRCh38 / hg38: chrl59299814992998261; GRCh38 / hg38: chrl62847964428479765; GRCh38 / hg38: chr63318363433183698; GRCh38 / hg38: chr2227296487227296526; GRCh38 / hg38: chr2227144653227144833; GRCh38 / hg38: chr2227015283227015360; GRCh38 / hg38: chrl 207637688207637848; GRCh38 / hg38: chrl94783540347835579; GRCh38 / hg38: chrl 59904366 59904516; GRCh38 / hg38: chrl 2644233526442372; GRCh38 / hg38: chrl 2823013128230252 ; GRCh38 / hg38: chr28858275588582824; GRCh38 / hg38: chrl76410267364102804; GRCh38 / hg38: chrl 2379831123798484; GRCh38 / hg38: chrX 109383365109383446; GRCh38 / hg38: chrX109439038109439175; GRCh38 / hg38: chrl57236237672362466; GRCh38 / hg38: chrl572345677 72345776; GRCh38 / hg38: chrl63011559530115645; GRCh38 / hg38: chr2148460219148460304; GRCh38 / hg38: chr2148490695148490787; GRCh38 / hg38: chr2148505761148505830; GRCh38 / hg38: chr64943652249436597; GRCh38 / hg38: chrl95023082550230999; GRCh38 / hg38: chr6 7586743175867523; GRCh38 / hg38: chrl73124995531250125; GRCh38 / hg38: chr2229628658 29628773; GRCh38 / hg38: chr53704812737048354; GRCh38 / hg38: chrl2100499841100500024; GRCh38 / hg38: chr5177169394177169559; GRCh38 / hg38: chr5177200761177200783; GRCh38 / hg38: chr5177247924177248079; GRCh38 / hg38: chr5177275947177276101; GRCh38 / hg38: chr3 193628509193628616; GRCh38 / hg38: chr3193603500193603557; GRCh38 / hg38: chrl3100305751 100305834; GRCh38 / hg38: chrl23289451632894778; GRCh38 / hg38: chr224620357546203752; GRCh38 / hg38: chrl 150327557150327652; GRCh38 / hg38: chrl 150330401150330498; GRCh38 / hg38: chr2165327155165327202; GRCh38 / hg38: chrl25168875851688849; GRCh38 / hg38: chrl2 5178020251780271; GRCh38 / hg38: chr2166304238166304329; GRCh38 / hg38: chr780794854 80794957; GRCh38 / hg38: chr78505949885059541; GRCh38 / hg38: chrll 225673226081; GRCh38 / hg38: chrl912162681216398; GRCh38 / hg38: chrl912216211221846; GRCh38 / hg38: chr63344878933448868; GRCh38 / hg38: chr93255136532551469; and GRCh38 / hg38: chr583544965 83545070.

26. The method of claim 3, wherein the targeted portion of the mRNA comprises an exon-intron junction of exon selected from the group consisting of: GRCh38 / hg38: chrl 243564285 243564388; GRCh38 / hg38: chrl9 13236449 13236618; GRCh38 / hg38: chr21 43059730 43060012; GRCh38 / hg38: chrl 207775610 207775745; GRCh38 / hg38: chrl 196675450 196675529; GRCh38 / hg38: chrl5 92998149 92998261; GRCh38 / hg38: chrl6 28479644 28479765; GRCh38 / hg38: chr6 33183634 33183698; GRCh38 / hg38: chr2 227296487 227296526; GRCh38 / hg38: chr2 227144653 227144833; GRCh38 / hg38: chr2 227015283 227015360; GRCh38 / hg38: chrl 207637688 207637848; GRCh38 / hg38: chrl9 47835403 47835579; GRCh38 / hg38: chrl 59904366 59904516; GRCh38 / hg38: chrl 26442335 26442372; GRCh38 / hg38: chrl 28230131 28230252 ; GRCh38 / hg38: chr2 88582755 88582824; GRCh38 / hg38: chrl7 64102673 64102804; GRCh38 / hg38: chrl 23798311 23798484; GRCh38 / hg38: chrX 109383365 109383446; GRCh38 / hg38: chrX 109439038 109439175; GRCh38 / hg38: chrl5 72362376 72362466; GRCh38 / hg38: chrl5 72345677 72345776; GRCh38 / hg38: chrl6 30115595 30115645; GRCh38 / hg38: chr2 148460219 148460304; GRCh38 / hg38: chr2 148490695 148490787; GRCh38 / hg38: chr2 148505761 148505830; GRCh38 / hg38: chr6 49436522 49436597; GRCh38 / hg38: chrl9 50230825 50230999; GRCh38 / hg38: chr6 75867431 75867523; GRCh38 / hg38: chrl7 31249955 31250125; GRCh38 / hg38: chr22 29628658 29628773; GRCh38 / hg38: chr5 37048127 37048354; GRCh38 / hg38: chrl2 100499841 100500024; GRCh38 / hg38: chr5 177169394 177169559; GRCh38 / hg38: chr5 177200761 177200783; GRCh38 / hg38: chr5 177247924 177248079; GRCh38 / hg38: chr5 177275947 177276101; GRCh38 / hg38: chr3 193628509 193628616; GRCh38 / hg38: chr3 193603500 193603557; GRCh38 / hg38: chrl3 100305751 100305834; GRCh38 / hg38: chrl2 32894516 32894778; GRCh38 / hg38: chr22 46203575 46203752; GRCh38 / hg38: chrl 150327557 150327652; GRCh38 / hg38: chrl 150330401 150330498; GRCh38 / hg38: chr2 165327155 165327202; GRCh38 / hg38: chrl2 51688758 51688849; GRCh38 / hg38: chrl2 51780202 51780271; GRCh38 / hg38: chr2 166304238 166304329; GRCh38 / hg38: chr7 80794854 80794957; GRCh38 / hg38: chr7 85059498 85059541; GRCh38 / hg38: chrl l 225673 226081; GRCh38 / hg38: chrl9 1216268 1216398; GRCh38 / hg38: chrl9 1221621 1221846; GRCh38 / hg38: chr6 33448789 33448868; GRCh38 / hg38: chr9 32551365 32551469; and GRCh38 / hg38: chr5 83544965 83545070.

27. The method of claim 1 or 2, wherein the target protein produced is a full-length protein or a wild- type protein.

28. The method of claim 1 or 2, wherein the therapeutic agent promotes exclusion of the NMD exon from the processed mRNA encoding the target protein.

29. The method of claim 28, wherein exclusion of the NMD exon from the processed mRNA encoding the target protein in the cell contacted with the therapeutic agent is increased by about 1.1 toabout 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5 -fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1 -fold, at least about 1.5 -fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to exclusion of the NMD exon from the processed mRNA encoding the target protein in a control cell.

30. The method of claim 28, wherein the therapeutic agent increases the level of the processed mRNA encoding the target protein in the cell.

31. The method of claim 28, wherein the level of the processed mRNA encoding the target protein produced in the cell contacted with the therapeutic agent is increased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5 -fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3 -fold, at least about 3.5 -fold, at least about 4-fold, at least about 5 -fold, or at least about 10-fold, compared to a level of the processed mRNA encoding the target protein in a control cell.

32. The method of claim 28, wherein the therapeutic agent increases the expression of the target protein in the cell.

33. The method of claim 28, wherein a level of the target protein produced in the cell contacted with the therapeutic agent is increased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5 -fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1 -fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5 -fold, or at least about 10-fold, compared to a level of the target protein produced in a control cell.

34. The method of claim 2, wherein the disease or condition is induced by a loss-of-function mutation in the target protein.

35. The method of claim 34, wherein the disease or condition is associated with haploinsufficiency of a gene encoding the target protein, and wherein the subject has a first allele encoding a functional target protein, and a second allele from which the target protein is not produced or produced at a reduced level, or a second allele encoding a nonfunctional target protein or a partially functional target protein.

36. The method of claim 35, wherein the disease or condition is selected from the group consisting of: Sotos syndrome 1; Beckwith-Wiedemann syndrome; Migraine, familial hemiplegic, 1; Episodic ataxia, type 2; Epileptic encephalopathy, childhood-onset; Wagner syndrome 1; Optic atrophy type 1; Alport syndrome; Arrhythmogenic right ventricular dysplasia 9; Neurofibromatosis type 1; Epileptic encephalopathy, early infantile, 11; Seizures, benign familial infantile, 3; Cognitive impairment with or without cerebellar ataxia; Epileptic encephalopathy, early infantile, 13; Seizures, benign familial infantile, 5; Pathway (CNS); 16pl 1.2 deletion syndrome?; Mental retardation, autosomal dominant 1; Retinitis pigmentosa 18; Retinitis pigmentosa 31 ; Deafness, autosomal dominant 13; Cone-rod retinal dystrophy-2; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss ; Deafness, autosomal dominant 22; Neurofibromatosis type 2; Mental retardation, autosomal dominant 5; Epilepsy, generalized, with febrile seizures plus, type 7; and Febrile seizures, familial, 3B.

37. The method of claim 34, wherein the disease or condition is associated with an autosomal recessive mutation of a gene encoding the target protein, wherein the subject has a first allele encoding from which:(i) the target protein is not produced or produced at a reduced level compared to a wild-type allele; or(ii) the target protein produced is nonfunctional or partially functional compared to a wild-type allele, anda second allele from which:(iii) the target protein is produced at a reduced level compared to a wild-type allele and the target protein produced is at least partially functional compared to a wild-type allele; or(iv) the target protein produced is partially functional compared to a wild-type allele.

38. The method of claim 37, wherein the disease or condition is selected from the group consisting of: Alport syndrome; Ceroid lipofuscinosis, neuronal, 3; Galactose epimerase deficiency;Homocystinuria, B6-responsive and nonresponsive types; Methyl Malonic Aciduria; Propionicacidemia; Retinitis pigmentosa 59; Tay-Sachs disease; Insensitivity to pain, congenital; and HSAN2D, autosomal recessive.

39. The method of claim 34, wherein the therapeutic agent promotes exclusion of the NMD exon from the processed mRNA encoding the target protein and increases the expression of the target protein in the cell.

40. The method of claim 1 or 2, wherein the therapeutic agent inhibits exclusion of the NMD exon from the processed mRNA encoding the target protein.

41. The method of claim 40, wherein exclusion of the NMD exon from the processed mRNA encoding the target protein in the cell contacted with the therapeutic agent is decreased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5 -fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about7- fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1 -fold, at least about 1.5 -fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5-fold, or at least about 10-fold, compared to exclusion of the NMD exon from the processed mRNA encoding the target protein in a control cell.

42. The method of claim 40, wherein the therapeutic agent decreases the level of the processed mRNA encoding the target protein in the cell.

43. The method of claim 40, wherein the level of the processed mRNA encoding the target protein in the cell contacted with the therapeutic agent is decreased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5-fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5 -fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about8- fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5 -fold, at least about 4-fold, at least about 5 -fold, or at least about 10-fold, compared to a level of the processed mRNA encoding the target protein in a control cell.

44. The method of claim 40, wherein the therapeutic agent decreases the expression of the target protein in the cell.

45. The method of claim 40, wherein a level of the target protein produced in the cell contacted with the therapeutic agent is decreased by about 1.1 to about 10-fold, about 1.5 to about 10-fold, about 2 to about 10-fold, about 3 to about 10-fold, about 4 to about 10-fold, about 1.1 to about 5 -fold, about 1.1 to about 6-fold, about 1.1 to about 7-fold, about 1.1 to about 8-fold, about 1.1 to about 9-fold, about 2 to about 5-fold, about 2 to about 6-fold, about 2 to about 7-fold, about 2 to about 8-fold, about 2 to about 9-fold, about 3 to about 6-fold, about 3 to about 7-fold, about 3 to about 8-fold, about 3 to about 9-fold, about 4 to about 7-fold, about 4 to about 8-fold, about 4 to about 9-fold, at least about 1.1 -fold, at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 5 -fold, or at least about 10-fold, compared to a level of the target protein produced in a control cell.

46. The method of claim 2, wherein the disease or condition is induced by a gain-of-function mutation in the target protein47. The method of claim 46, wherein the subject has an allele from which the target protein is produced at an increased level, or an allele encoding a mutant target protein that exhibits increased activity in the cell.

48. The method of claim 46, wherein the therapeutic agent inhibits exclusion of the NMD exon from the processed mRNA encoding the target protein and decreases the expression of the target protein in the cell.

49. The method of claim 40, wherein the target protein comprises SCN8A.

50. The method of claim 49, wherein the disease or condition comprises a central nervous system disease.

51. The method of claim 50, wherein the disease or condition comprises epilepsy.

52. The method of claim 51, wherein the disease or condition comprises Dravet syndrome.

53. The method of claim 1 or 2, wherein the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer comprises a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage.

54. The method of claim 1 or 2, wherein the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer comprises a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-0-methyl, a 2'-Fluoro, or a 2'-0-methoxyethyl moiety.

55. The method of claim 1 or 2, wherein the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer comprises at least one modified sugar moiety.

56. The method of claim 55, wherein each sugar moiety is a modified sugar moiety.

57. The method of claim 1 or 2, wherein the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer consists of from 8 to 50 nucleobases, 8 to 40 nucleobases, 8 to 35 nucleobases, 8 to 30 nucleobases, 8 to 25 nucleobases, 8 to 20 nucleobases, 8 to 15 nucleobases, 9 to 50 nucleobases, 9 to 40 nucleobases, 9 to 35 nucleobases, 9 to 30 nucleobases, 9 to 25 nucleobases, 9 to 20 nucleobases, 9 to 15 nucleobases, 10 to 50 nucleobases, 10 to 40 nucleobases, 10 to 35 nucleobases, 10 to 30 nucleobases, 10 to 25 nucleobases, 10 to 20 nucleobases, 10 to 15 nucleobases, 11 to 50 nucleobases, 11 to 40 nucleobases, 11 to 35 nucleobases, 11 to 30 nucleobases, 11 to 25 nucleobases, 11 to 20 nucleobases, 11 to 15 nucleobases, 12 to 50 nucleobases, 12 to 40 nucleobases, 12 to 35 nucleobases, 12 to 30 nucleobases, 12 to 25 nucleobases, 12 to 20 nucleobases, or 12 to 15 nucleobases.

58. The method of claim 3, wherein the therapeutic agent is an antisense oligomer (ASO) and wherein the antisense oligomer is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, complementary to the targeted portion of the mR A.

59. The method of claim 1 or 2, wherein the method further comprises assessing mRNA level or expression level of the target protein.

60. The method of claim 2, wherein the subject is a human.

61. The method of claim 2, wherein the subj ect is a non-human animal .

62. The method of claim 2, wherein the subject is a fetus, an embryo, or a child.

63. The method of claim 1 or 2, wherein the cells are ex vivo.

64. The method of claim 2, wherein the therapeutic agent is administered by intrathecal injection, intracerebroventricular injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, intravitreal, or intravenous injection of the subject.

65. The method of claim 2, wherein the method further comprises administering a second therapeutic agent to the subject.

66. The method of claim 65, wherein the second therapeutic agent is a small molecule.

67. The method of claim 65, wherein the second therapeutic agent is an antisense oligomer.

68. The method of claim 65, wherein the second therapeutic agent corrects intron retention.

69. The method of claim 2, wherein the disease or condition is selected from the group consisting of: 16pl 1.2 deletion syndrome; Alport syndrome; Arrhythmogenic right ventricular dysplasia 9; Ceroid lipofuscinosis, neuronal, 3; Cognitive impairment with or without cerebellar ataxia; Epileptic encephalopathy, early infantile, 13; Seizures, benign familial infantile, 5; Cone-rod retinal dystrophy-2; Cornelia de Lange; Deafness, autosomal dominant 13; Deafness, autosomal dominant 4A; Peripheral neuropathy, myopathy, hoarseness, and hearing loss ; Epilepsy, generalized, with febrile seizures plus, type 7; Febrile seizures, familial, 3B; Insensitivity to pain, congenital; HSAN2D, autosomal recessive; Epileptic encephalopathy, childhood-onset; Epileptic encephalopathy, early infantile, 1 1; Seizures, benign familial infantile, 3; Galactose epimerase deficiency; Homocystinuria, B6-responsive and nonresponsive types; Mental retardation, autosomal dominant 1; Mental retardation, autosomal dominant 5; Methyl Malonic Aciduria; Migraine, familial hemiplegic, 1; Episodic ataxia, type 2;NASH; Neurofibromatosis type 1; Neurofibromatosis type 2; Optic atrophy type 1; Propionic acidemia; Retinitis pigmentosa 18; Sotos syndrome 1; Beckwith-Wiedemann syndrome; Tay-Sachs disease; and Wagner syndrome 1.